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Abstract in English 
 
Background 
The current opioid epidemic is a major cause of suffering and overdose deaths globally. It can 
interact with patients’ general well-being and causes fatigue. Opioid agonist therapy (OAT) is 
a well-documented effective treatment for patients with severe opioid dependence. It protects 
against opioid overdose deaths and harms from injecting opioids. Over the past decade, 
reports from several countries indicate a high prevalence of other potentially addictive 
substances, involving benzodiazepines, z-hypnotics, gabapentinoids, centrally acting 
stimulants, and opioids, used alongside dispensed OAT opioids. Although potentially 
addictive substances may increase the risk of fatal and non-fatal overdoses, they can also be 
essential in treating underlying mental and physical disorders. No studies have evaluated the 
extent of all potentially addictive substances for the OAT population in Norway and Sweden 
and how they affect patients’ self-reported feeling of fatigue.    
 
Methods 
This thesis consists of four papers. Papers I-II evaluated the dispensation rates and dispensed 
doses of benzodiazepines or z-hypnotics, gabapentinoids, and medications used for attention 
deficit hyperactivity disorder (ADHD) for 10,371 OAT patients in Norway in 2013-2017 
using the Norwegian Prescription Database (NorPD). Paper III compared dispensation rates 
and dispensed doses of benzodiazepines, z-hypnotics, gabapentinoids, centrally acting 
substances, strong non-OAT opioids, weak non-OAT opioids among 7176 Norwegian OAT 
patients and 3591 Swedish OAT patients using data from the NorPD and the Swedish 
Prescribed Drug Register (SPDR) from 2015 to 2017. The aim of paper IV was three-folded; 
1) investigating the extent of some non-dispensed potentially addictive substances 
(benzodiazepines/z-hypnotics, stimulant substances (amphetamines and cocaine), and 
opioids), cannabis, and alcohol, 2) measuring fatigue using the nine-item Fatigue Severity 
Scale (FSS-9), and 3) evaluating how the non-dispensed potentially addictive substances, 
cannabis, and alcohol were associated with fatigue among substance use disorder (SUD) 
patients in Bergen and Stavanger, Norway. We defined frequent use of a non-dispensed 
substance, cannabis, or alcohol as those using a substance at least weekly during the past 12 
months. Patients who did not use substances/cannabis/alcohol or use them less than weekly 
during the past 12 months were categorized as having ‘no frequent use’ of these substances. 
To reduce confounding between substance use and fatigue, we adjusted for various 
sociodemographic and clinical factors. We included 954 FSS-9 measurements from 654 SUD 
patients, involving 82 % OAT patients, using the INTRO-HCV cohort data in 2016-2020.  
 
Results 
In papers I-III, 59 % of the Norwegian OAT patients and 55 % of the Swedish OAT patients 
were dispensed potentially addictive substances in 2017. In Norway, 46 % of the OAT 
patients were dispensed a benzodiazepine, 14 % a z-hypnotic, 12 % a weak non-OAT opioid, 
10 % a gabapentinoid, 6 % a strong non-OAT opioid, and 4 % a centrally acting stimulant. 
Among the Swedish OAT population, 26 % were dispensed a z-hypnotic, 19 % a 
gabapentinoid, 18 % a centrally acting stimulant, 15 % a benzodiazepine, 10 % a strong non-
OAT opioid, and 5 % a weak non-OAT opioid. Besides centrally acting stimulants, the mean 
daily dosages of the dispensed substances were within recommendations. The mean daily 
dosages of four out of five substances slightly exceeded the recommendations for centrally 
acting stimulants. Substantial similar results were seen for the period 2013-2016. In addition, 
being dispensed one benzodiazepine, z-hypnotic, gabapentinoid, non-OAT opioid, or centrally 
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acting stimulant increased the odds of being dispensed several potentially addictive 
substances.  
 
The use of non-dispensed potentially addictive substances, cannabis, and alcohol for SUD 
patients, mainly OAT patients, in Bergen and Stavanger was substantial. Fifty-two percents 
were frequent users of cannabis, 39 % benzodiazepines or z-hypnotics, 29 % stimulant 
substances, 26 % alcohol, and 16 % opioids.  
 
Sixty-seven percent of patients exceeded the threshold of severe fatigue (above 36 points). 
The mean FSS-9 sum score was 43 (standard deviation: 16) on a scale ranging from nine (no 
fatigue) to 63 points (worst fatigue). A considerable intra-individual variation in fatigue level 
from first to second fatigue measurement was found. Frequent use of benzodiazepines 
(adjusted mean difference of FSS-9 sum score: 5.7, 95 % CI: 3.0;8.4) or stimulants (-5.0, -
8.0;-2.9) were associated with changes in the FSS-9 sum score compared with less frequent or 
no use of these substances. Furthermore, females had more fatigue than males (4.1, 1.3;7.0), 
and having debt difficulties was associated with more fatigue than not having debt difficulties 
(2.9, 0.4;5.3). In addition, frequent use of benzodiazepines compared with less frequent or no 
use of these substances over time (-4.4, -8.2;-0.7), and liver fibrosis or cirrhosis compared 
with healthy liver over time (-5.5, -9.9;-1.0) were associated with slightly less fatigue per year 
from the first fatigue measurement.  
 
Conclusion 
There was extensive use of different dispensed and non-dispensed potentially addictive 
substances among OAT patients in Norway and Sweden. In addition, substantial fatigue 
symptoms were widespread. Considering the high prevalence of polysubstance use in the 
population, it has been paid relatively little attention to OAT research and national guidelines. 
Focusing on how polysubstance use can be handled in OAT and its impact on health 
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Sammendrag på norsk (abstract in Norwegian) 
 
Bakgrunn 
Den nåværende opioid epidemien er en vesentlig årsak til lidelse og overdosedødsfall globalt. 
Det kan påvirke pasienters generelle velvære og forårsake utmattelse (fatigue). 
Legemiddelassistert rehabilitering (LAR) er en veldokumentert behandlingsmetode for 
pasienter med alvorlig opioidavhengighet. Den beskytter mot opioidrelaterte overdosedødsfall 
og skader relatert til injiserende sprøytebruk. Over de siste tiårene har det imidlertid kommet 
reporter fra flere land som tyder på en høy forekomst av andre potensielt vanedannende 
stoffer som benzodiazepiner, z-hypnotika, gabapentinoider, sentralstimulerende legemidler og 
opioider som brukes sammen med de utleverte LAR-opioidene. Selv om de vanedannende 
legemidlene kan øke risikoen for dødelige og ikke-dødelige overdoser, kan de også være en 
essensielt del av behandlingen for underliggende psykiske og fysiske sykdommer. Ingen 
studier har tidligere evaluert omfanget av alle disse potentielt vanedannende stoffene for 
LAR-populasjonen i Norge og Sverige, ei heller om slik bruk påvirker pasienters’ 
selvrapporterte følelse av utmattelse.   
 
Metode 
Denne doktorgradsavhandlingen består av fire artikler. Artikkel I-II brukte Reseptregisteret i 
Norge til å evaluere forskrivningsraten og utskrevne doser av benzodiazepiner eller z-
hypnotika, gabapentinoider og ADHD-medisiner for 10 371 LAR-pasienter i Norge for 
perioden 2013-2017. Artikkel III brukte Reseptregisteret og Läkemedelsregisteret i Sverige til 
å sammenligne forskrivningsrater og utskrevne doser av benzodiazepiner, z-hypnotika, 
gabapentinoider, sentralstimulerende legemidler, sterke ikke-LAR opioider, og svake ikke-
LAR opioider blant 7176 norske LAR-pasienter og 3591 svenske LAR-pasienter fra 2015 til 
2017. Artikkel IV hadde tre formål: 1) å utforske omfanget av noen ikke-forskrevne potensielt 
vanedannende legemidler/rusmidler (benzodiazepiner/z-hypnotika, sentralstimulerende 
rusmidler (amfetaminer og kokain) og opioider), cannabis og alkohol, 2) å måle utmattelse 
ved å bruke Fatigue Severity Scale bestående av ni utmattelsesrelaterte påstander (FSS-9), og 
3) å vurdere hvordan de ikke-forskrevne potensielt vanedannende legemidlene/rusmidlene, 
cannabis og alkohol påvirker utmattelse blant rusavhengige pasienter i Bergen og Stavanger, 
Norge. Vi definerte hyppig bruk av et ikke-forskrevet potentielt vanedannende 
legemiddel/rusmiddel, cannabis og alkohol som det å bruke et slikt legemiddel/rusmiddel mer 
enn ukentlig i løpet av de siste 12 månedene. Pasienter som ikke hadde brukt 
legemiddelet/rusmiddelet eller hadde brukt dem sjeldnere enn ukentlig i løpet av de siste 12 
månedene ble kategorisert som det å «ikke ha et hyppig bruk» av legemiddelet/rusmiddelet. 
For å redusere effektforveksling mellom legemiddel/rusmiddel bruk og utmattelse, justerte vi 
for flere sosiodemografiske og kliniske faktorer. Vi inkluderte 954 FSS-9-målinger fra 654 




I artikkel I-III fant vi at 59 % av norske LAR-pasienter og 55 % av svenske LAR-pasienter 
fikk foreskrevet et potensielt vanedannende legemiddel i 2017. I Norge fikk 46 % av LAR-
pasientene foreskrevet et benzodiazepin, 14 % et z-hypnotikum, 12 % et svakt ikke-LAR 
opioid, 10 % et gabapentinoid, 6 % et sterkt ikke-LAR opioid og 4 % et sentralstimulerende 
legemiddel. Blant de svenske LAR-pasientene fikk 26 % foreskrevet et z-hypnotikum, 19 % 
et gabapentinoid, 18 % et sentralstimulerende legemiddel, 15 % et benzodiazepin, 10 % et 
sterkt ikke-LAR opioid og 5 % et svakt ikke-LAR opioid. Foruten de sentralstimulerende 
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legemidlene, var den gjennomsnittlige daglige dosen av de foreskrevne legemidlene innenfor 
anbefalingene. For fire av fem sentralstimulerende legemidler overskred imidlertid den 
gjennomsnittlige daglige dosen så vidt anbefalingene. Lignende funn var også funnet for 
perioden 2013-2016. I tillegg bemerket vi at det å få foreskrevet ett benzodiazepin, z-
hypnotika, gabapentinoid, ikke-LAR opioid eller sentralstimulerende legemiddel økte 
sannsynlighet (odds) for å få foreskrevet flere potensielt vanedannende legemidler.  
 
Bruken av ikke-foreskrevne potentielt vanedannende legemidler/rusmidler, cannabis og 
alkohol blant rusavhengige pasienter, hovedsakelig LAR-pasienter, i Bergen og Stavanger var 
betydelig. 52 % var hyppige brukere av cannabis, 39 % benzodiazepiner eller z-hypnotika, 29 
% sentralstimulerende rusmidler, 26 % alkohol og 16 % opioider.  
 
Sekstisyv prosent oversteg terskelen for alvorlig utmattelse (poengsum over 36). Den 
gjennomsnittlige FSS-9-sumskåren ble målt til 43 (standardavvik: 16) på en skala som går fra 
ni poeng (ingen utmattelse) til 63 poeng (verst tenkelig utmattelse). En betydelig 
intraindividuell variasjon i utmattelsesnivået fra den første til den andre FSS-9-målingen ble 
funnet. Hyppig bruk av benzodiazepiner (justert gjennomsnittlig forskjell i FSS-9-sumskår: 
5,7, 95 % konfidensintervall: 3,0;8,4) eller sentralstimulerende rusmidler (-5,0, -8,0; -2,9) var 
assosiert med endringer i FSS-9 sumskåren sammenlignet med mindre hyppig eller ingen 
bruk av disse legemidlene/rusmidlene. Dessuten var kvinner mer utmattet enn menn (4,1, 
1,3;7,0), og det å ha gjeldsproblemer var assosiert med mer utmattelse enn det å ikke ha 
gjeldsproblemer (2,9, 0,4;5,3). I tillegg var hyppig og vedvarende bruk av benzodiazepiner 
sammenlignet med mindre hyppig eller ingen bruk av disse stoffene og vedvarende 
leverfibrose eller skrumplever sammenlignet med det å ha en frisk lever assosiert med mindre 
utmattelse per år regnet fra den første utmattelsesmålingen.  
 
Konklusjon 
Det var et omfattende bruk av ulike foreskrevne og ikke-foreskrevne potensielt vanedannende 
legemidler/rusmidler blant LAR-pasienter i Norge og Sverige. I tillegg var det utbredt med 
betydelige utmattelsessymptomer. Tatt i betraktning den hyppige bruken av slike 
legemidler/rusmidler i denne populasjonen, har det fått lite oppmerksomhet i LAR forskning 
og i nasjonale retningslinjer. Å fokusere på hvordan bruk av flere rusmidler kan håndteres i 
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The global opioid crisis and its impact on overdose deaths 
 
Substance use disorder (SUD) is a chronic disease affecting more than 35 million people 
worldwide [2]. In 2017, it was estimated that 585,000 people died, and more than 42 million 
years of “healthy" life were lost due to substance use [2]. While hepatitis C virus (HCV) 
infection is the most prevalent reason for deaths among people with SUDs, opioid dependence 
itself is the primary reason for the “healthy life” years are lost in the SUD population. During 
the last decades, deaths attributed to opioid use have been increasing and problematic, causing 
a global high public health burden and suffering from patients with SUDs [3]. Between 2013 
and 2017, a 14-fold increase of non-medical use of the opioid tramadol was seized in Central, 
West and North African countries, while expanding use of fentanyl and its analogs have 
accelerated the opioid manufacture during the same period in the U.S. and Canada [2, 4, 5]. In 
Europe, heroin has dominated as the primary opioid of use among the illegal opioid market 
during the last decade [6].  
 
Globally, opioid use is an important contributor to overdose deaths among patients with SUDs 
[2]. The sharp increase in global opioid use has led to more than 49,800 opioid overdose 
deaths in the U.S. in 2019, an increase of 7 % from the previous year and a two-fold increase 
in opioid-related deaths from 2013 to 2019 [7]. One out of three of these deaths involved 
prescribed opioids [5]. In Europe, including the 28 European Union (EU) member states plus 
Norway and Turkey, 9461 people lost their lives due to overdose deaths in 2017, representing 
a stable situation compared with the 9397 deaths reported in 2016 [6, 8]. Nearly 80 % of these 
deaths involved opioids, often in combination with other substances [8]. In European 
countries, it is estimated that 1.3 million people are high-risk users of opioids, defined as 
those injecting opioids, with 77 % of these residing in the five most populous EU countries 
(Germany, Spain, France, Italy, and the U.K.) [6]. In 2017, opioid use dominated among those 
entering specialized substance treatment, representing 35 % of all first-time entrants [8]. 
Effective treatment approaches mainly aimed at high-risk opioid users are therefore essential 
for a global reduction in overdose deaths among the SUD population. 
 
Opioid agonist therapy as a treatment approach 
 
Opioid agonist therapy (OAT) is a well-known and essential treatment approach for some 
patients with opioid dependence (Figure 1) [9, 10]. In observational studies mainly, the OAT 
is shown to reduce illicit opioid use [9, 10], all-cause and opioid-related mortality, [11, 12] 
and risk behavior [13], and improve mental health [14, 15]. The OAT is granted to patients 
with opioid dependence who meet the opiate dependence syndrome criteria defined by the 
International Classification of Diseases and Health problems, version 10 (ICD-10) (Text box 
1) [16] or the criteria for opioid use disorder according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) (Text box 2) [17]. Other additional criteria are applied 
in some countries [18]. In contrast to the ICD-10, the DSM-5 subdivides drug use disorder 
into three categories: mild, moderate, or severe, where patients with moderate or severe 
opioid use disorder are intended for OAT. In the upcoming ICD-11 (Text box 3) [19], ICD-
10’s ‘opioid dependence syndrome’ will be replaced with opioid dependence with fewer 
criteria for dependence. However, how this will change the inclusion criteria for OAT remains 












































In Europe, nearly half of high-risk opioid users (approximately 662,000 opioid users) are 
estimated to have access to OAT, with considerable variations between countries from around 
85 % in France down to less than 10 % in Romania [8, 20]. Lack of national guidelines and 
scarcity of health care resources are reported to restrict the OAT distribution [21]. In addition, 
excessive regulations on who can prescribe OAT medications to substance users and strict 





Text box 1: 
Dependence syndrome according to the International Classification of Diseases and Health problems, version 10 
Dependence is usually made only if three or more of the following have been present together at some time during the 
previous year: 
1) A strong desire or sense of compulsion to take the substance; 
2) Difficulties in controlling substance-taking behavior in terms of its onset, termination, or levels of use; 
3) A physiological withdrawal state when substance use has ceased or have been reduced, as evidenced by: the 
characteristic withdrawal syndrome for the substance; or use of the same (or closely related) substance with the 
intention of relieving or avoiding withdrawal symptoms; 
4) Evidence of tolerance, such that increased doses of the psychoactive substance are required in order to achieve 
effects originally produced by lower doses (clear examples of this are found in alcohol- and opiate-dependent 
individuals who may take daily doses sufficient to incapacitate or kill nontolerant users); 
5) Progressive neglect of alternative pleasures or interests because of psychoactive substance use, increased 
amount of time necessary to obtain or take the substance or to recover from its effects; 
6) Persisting with substance use despite clear evidence of overtly harmful consequences, such as harm to the liver 
through excessive drinking, depressive mood states consequent to periods of heavy substance use, or drug-
related impairment of cognitive functioning; efforts should be made to determine that the user was actually, or 
could be expected to be, aware of the nature and extent of the harm. 





Figure 1: The figure displays the division of commonly used terms in Addiction Medicine 
and their relations to demand for care; “Substance use disorder”, “Opioid dependence”, 






































Buprenorphine and methadone are the two most widely used opioids in OAT [22]. Both are 
long-acting opioids with a duration of approximately 24 hours [23-25]. Overall, methadone is 
the most commonly prescribed opioid in OAT among European countries, received by over 
60 % of the OAT patients [22]. The remaining patients are prescribed buprenorphine-based 
medications, including buprenorphine-naloxone and depot-formulations of buprenorphine. 
Slow-releasing morphine, levomethadone, and heroin are more rarely prescribed by a 
calculated 2 % of the OAT population [22]. Methadone and buprenorphine are usually equal 
in suppressing illegal opioid use and treatment retention [10]. However, patients receiving 
methadone have a higher risk of overdose deaths than patients using buprenorphine as an 
OAT opioid, which are probably related to the methadone’s pharmacological properties as a 
full opioid agonist [26]. Unlike buprenorphine, methadone, by its properties, contributes to a 
high risk of sedation and overdose if doses are increased and used concomitantly with other 
opioids. In contrast, buprenorphine is a partial opioid agonist with a partial displacement of 
other opioids, which usually may protect against opioid overdoses caused by other opioids 
[27]. Although OAT opioids may lead to overdose itself, they can also induce overdoses if 
Text box 2: 
Opioid use disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)  
A problematic pattern of use leading to clinically significant impairment or distress is manifested by two or more of the 
following within a 12-month period: 
 
1) Opioids are often taken in larger amounts or over a longer period than was intended. 
2) A persistent desire or unsuccessful efforts to cut down or control opioid use. 
3) A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its 
effects. 
4) Craving or a strong desire or urge to use opioids. 
5) Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or home. 
6) Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or 
exacerbated by its effects. 
7) Important social, occupational, or recreational activities are given up or reduced because of opioid use. 
8) Recurrent opioid use in situations in which it is physically hazardous. 
9) Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem 




Mild: Two or three criteria. Moderate: four to five criteria. Severe: six or more criteria.  
 
American Psychiatric Association, 2013.  
Text box 3: 
Opioid dependence according to the International Classification of Diseases and Health problems, version 11 
Opioid dependence is a disorder of regulation of opioid use arising from repeated or continuous use of opioids. The 
characteristic feature is a strong internal drive to use opioids, which is manifested by impaired ability to control use, 
increasing priority given to use over other activities and persistence of use despite harm or negative consequences. These 
experiences are often accompanied by a subjective sensation of urge or craving to use opioids. Physiological features of 
dependence may also be present, including tolerance to the effects of opioids, withdrawal symptoms following cessation 
or reduction in use of opioids, or repeated use of opioids or pharmacologically similar substances to prevent or alleviate 
withdrawal symptoms.  
 
The features of dependence are usually evident over a period of at least 12 months but the diagnosis may be made if 
opioid use is continuous (daily or almost daily) for at least 1 month. 
 
World Health Organization, 2021. 
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used in parallel with other competing sedative substances – such as benzodiazepines, z-
hypnotics, and gabapentinoids [28-32].  
 























Sweden has treated patients with severe opioid dependence with methadone since the mid-
1960s, initially as a pilot scheme for selected patients [33]. During the past four decades, 
receiving OAT has been made increasingly available. In 2010, patients were offered 
multidisciplinary teams consisting of professionals from the social services, health 
professionals in primary care, and consultants in psychiatry or addiction medicine to take care 
of the patients’ rehabilitation. In 2015, when the current national recommendations for OAT 
were released, patients suffering from opioid dependence caused by other opioids than street 
heroin were granted OAT [34]. Compared with many other countries, the Swedish OAT is 
more strictly regulated, especially concerning the additional use of non-dispensed potential 
addictive substances [35]. Patients with polysubstance use undergoing OAT can be referred to 
other opioid treatment programs, while those with polysubstance use seeking OAT can be 
rejected. According to the Swedish Drug Report 2019, 4468 patients received OAT in Sweden 
in 2017 [35].  
 
Norway implemented OAT in 1998, initially for a few hundred patients with a long-term 
severe opioid dependence [36]. In 2018, the number of OAT patients had increased to nearly 
11,000 patients nationwide. Of those, approximately 700 patients enter or reenter and leave 
OAT yearly, substantially unchanged for the last decade. In 2010, the Norwegian OAT’s first 
and current national guidelines were released to ensure uniform medical practice for OAT 
across the country [37]. Following these guidelines, polysubstance use was no longer an 
absolute criterion for terminating OAT, giving more patients with opioid dependence access 
to OAT. The Norwegian OAT is organized differently across the country ranging from nurses 
and general practitioners in primary care to specialized outpatient clinics led by consultants in 
Figure 2: The timeline displays some essential milestones in OAT in Sweden and Norway. 
OAT: Opioid agonist therapy. 
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Addiction Medicine. However, granting OAT is usually independently assessed by 
specialized health care [37]. 
 
Defining potentially addictive substances and their relationship to OAT opioids 
 
By an additional use of potentially addictive substances in OAT, we mean classes of 
substances categorized as benzodiazepines, z-hypnotics, gabapentinoids, opioids, and 
centrally acting stimulants used alongside the OAT opioids. 
 
Benzodiazepines are a collective group name of potentially addictive substances with 
sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant effects used in a short-term 
period [38]. They are among the most distributed substances on the illegal market and are 
chronically used among several SUD patients [31]. Long-term use of benzodiazepines is 
controversial because of concern about physical and mental dependence, rebound effects, and 
development of tolerance. Combination therapy, including benzodiazepines and OAT opioids, 
enhances sedative effects, putting patients at particular risk of overdose and overdose death 
[28, 29]. In addition, benzodiazepines usually cause long-term withdrawals when abruptly 
reduced and ceased [39]. 
 
Z-hypnotics are similar to benzodiazepine and are used to sleep therapy [40]. In long-term 
use, physical and mental dependences, rebound withdrawal effects, and tolerance is observed. 
The tolerance is assumed to be somehow slower to develop than with benzodiazepines in the 
general population [41], while withdrawals resemble those seen during benzodiazepine 
withdrawal. Z-hypnotics are sedative agents causing an enhancing effect to OAT opioids, and 
co-use is controversial [28, 29, 42].  
 
Gabapentinoids, including pregabalin and gabapentin, also having similarities to 
benzodiazepines, are medically indicated for epilepsy, neuropathy, and anxiety disorders in 
Europe [43, 44]. During the last decade, both have been reported in observational studies and 
case reports to cause physical withdrawal, tolerance, and rebound effects [32, 45-47]. The 
synergistic effects of co-using opioids and gabapentinoids are substantially highlighted, with a 
risk of overdoses. Pregabalin is under surveillance for abuse potential by the European 
Medicines Agency for concern about dependence [48]. From June 2018 (Norway) and July 
2018 (Sweden), pregabalin was classified as a substance with a potential dependence by the 
Norwegian Medicine Agencies and the Swedish Medical Products Agency leading to 
restrictions in dispensing [49, 50].  
 
Opioids are opioid analgesic substances that have effects similar to those of morphine. They 
are primarily medically indicated for pain relief. For patients in OAT with severe opioid 
dependence, the additional use of opioids may indicate suboptimal OAT opioid dose and 
physical accident requiring pain relief [51, 52]. Long-term use can cause tolerance, physical 
dependence, and withdrawals when abruptly reduced in doses and ceased [53]. Otherwise, 
euphoria, sedation, and respiratory depression are potential side effects when overdosed [54].  
 
Centrally acting stimulants include methylphenidate, lisdexamphetamine, dexamphetamine, 
and racemic amphetamine. They are primarily medically indicated substances for attention 
deficit hyperactivity disorders (ADHD) or hyperkinetic disorders [55]. Higher doses produce 
euphoria, vigor, decreased appetite, and alertness [56, 57]. In contrast, therapeutic doses may 
contribute to the successful suppression of ADHD symptoms [55]. Among OAT patients with 
comorbid ADHD, co-use of centrally acting stimulants and OAT opioids is usually 
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recommended if taken as prescribed [58]. In Norway, prescribing OAT opioids and centrally 
acting stimulants in OAT is regulated by national guidelines that require abstinence of illegal 
substances from at least three months before prescribing centrally acting stimulants [59]. 
Otherwise, amphetamines and cocaine are the most widely consumed centrally acting 
stimulant substances for illegal use [8], with some geographic differences. While cocaine 
dominates in European countries, amphetamines (including methamphetamine) are the most 
consumed illegal stimulants in the Northern European countries, the Czech Republic, and 
Slovakia [8, 22, 60, 61]. 
 
Dispensing potentially addictive substances to OAT patients 
 
When investigating potentially addictive substances among OAT patients, it is important to 
keep in mind the distinction between dispensed and non-dispensed potentially addictive 
substances. While the non-dispensed use addresses illegal or non-medical use, the dispensed 
potentially addictive substances are dispensed for a medical purpose – such as treating the 
short-term sleeping disorder with z-hypnotics and severe acute somatic pain with opioid 
analgesics. Being dispensed potentially addictive substances are usually accepted as an 
additional treatment in OAT. A survey of comorbidities in the OAT population in general 
hospitals in Europe demonstrates a high but varying prevalence of several mental disorders 
[62]. Depression ranges from 34 % to 60 %, anxiety disorders from 3 % to 41 %, psychotic 
disorders from 20 to 39 %, ADHD from 5 % to 30 %, and personality disorder 20 %. These 
diseases may contribute to dispensing potentially addictive substances as a first-hand 
substance or an adjuvant substance to other medical therapy. For example, centrally acting 
stimulants are usually used as agents for curbing ADHD symptoms, and benzodiazepines are 
medically indicated for short-term therapy for insomnia and anxiety. In addition, 
benzodiazepines and gabapentinoids may be essential for patients with substance dependences 
undergoing detoxifications, while opioids may be needed for acute pain. Otherwise, in some 
cases, potentially addictive substances can be dispensed on off-label indications to recover 
mental or physical diseases, protect against injecting behavior, diminish contact with dealers, 
reduce criminality, and prevent withdrawals, so that non-dispensed substance use is 
assumingly less likely [63]. Despite this, combining potentially addictive substances with 
OAT opioids can cause fatal or non-fatal overdoses if taken outside the therapeutic aims, used 
as a currency in illegal markets, and used alongside non-dispensed potentially addictive 
substances. Several observational studies investigating dispensed potentially addictive 
substances for OAT patients have found evidence for an increased risk of all-cause deaths 
when being co-dispensed OAT opioids and potentially addictive substances compared with 
being dispensed OAT opioids in monotherapy [28, 29, 52]. However, these studies can be 
confounded for causality because they did not consider whether patients who were co-
dispensed substances had underlying comorbidities and risk behavior, increasing the risk of 
death. 
 
The use of non-dispensed potentially addictive substances among OAT patients 
 
The use of non-dispensed potentially addictive substances is usually related to 
benzodiazepines, including z-hypnotics, stimulant substances (amphetamine, 
methamphetamine, and cocaine), and opioids [8]. The use of these substances for OAT 
patients is controversial, leading to varying regulations between and within countries in 
handling [22]. In some countries, patients with non-dispensed potentially addictive substance 
use, involving opioids and other substances, are excluded from OAT [22, 64], while others 
allow co-use based on an individual assessment of justifiability [22, 31, 37]. During the past 
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years, non-dispensed potentially addictive substances have been commonly [22, 31, 65-67], 
representing now 60 % of patients seeking medical treatment for opioid dependence in some 
countries [22]. In 2016, based on those entering specialized opioid treatment programs, the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) estimated that 12 % 
misused benzodiazepines, 40 % amphetamines and cocaine, and 4 % ‘other substances’ [31]. 
“Misuse” was by the review defined as use without a prescription from a medical practitioner 
or, if prescribed, when used outside accepted medical practice or guidelines. However, the 
data regarding non-dispensed potentially addictive substance use among patients with opioid 
dependence are not fully investigated, and it lacks information of the extent of use from 
several countries worldwide. 
 
The impact of non-dispensed potentially addictive substance use on fatigue among SUD 
patients 
 
Fatigue is a subjective health complaint defined as a persistent and overwhelming feeling of 
exhaustion and lack of energy [68]. Its impact on individuals can vary considerably from an 
impeccable symptom to a symptom and chronic syndrome affecting job, daily activities, and 
social life with increased risk of depression and suicide [69-74]. Fatigue is also a common 
symptom in the general population [74-78], while severe fatigue, impairing daily functioning, 
is more often seen among patients with chronic diseases – such as those with HCV infection 
[79-81], Parkinson’s disease [82, 83], multiple sclerosis [84-86], or stroke [87-89]. Fatigue 
has, however, never been investigated thoroughly for SUD patients, despite several potential 
risk factors concerning; unstable housing situation [90], financial risks [91], unemployment 
[92, 93], extensive use of substances, and underlying mental disorders with committing 
suicide attempts [69-74, 94-96]. Substances leading to intoxications and withdrawals may 
cause mortality [97, 98] and cognitive impairment in several domains – such as deficits in 
cognitive flexibility [99-101], working memory [102], attention, and impulse control [103]. 
This might potentially impact fatigue. Surveying the extent of fatigue and how the chaotic life 
situation patterns, including use of non-dispensed potentially addictive substances, is 
associated with fatigue will be of particular interest to improve the knowledge of the SUD 
patients and how the non-dispensed potentially addictive substance use impacts them. 
 
How study the use of dispensed and non-dispensed potentially addictive substances among 
OAT patients? 
 
There are many ways to investigate the dispensed use of potentially addictive substances 
among patients in OAT. One way can be to collecting national data of all patients on OAT, 
which often are laborious and expensive. Another way can be to use national register data. 
Over the last two-three decades, the Scandinavian countries have developed nationwide 
prescription registers with information of practically all dispensed medicines delivered from 
national pharmacies [104, 105]. These data are suitable to identify OAT patients and all their 
dispensed medicines. 
 
Furthermore, little is known about the non-dispensed substance use and fatigue for SUD 
patients. However, in Norway, the annual health assessment on all the Norwegian OAT 
patients gives some information on non-dispensed benzodiazepine and amphetamines used 
the last four weeks before the assessment [36]. However, detailed information on substance 
use and its usage pattern lacks. Therefore, creating a new data cohort surveying more detailed 
information on non-dispensed potentially addictive substances and fatigue is required for 




Rationale for the studies 
 
As shown in the introduction, little is known about the extent and doses of dispensed 
potentially addictive substances in the OAT populations. Differences in OAT regulations may 
contribute to variations in dispensing substances between and within countries. In Norway 
and Sweden, the OAT is differently regulated regarding potentially addictive substances. 
While Sweden referred OAT patients with repeated non-dispensed potentially addictive 
substance use to other treatment approaches, this repeated use is not an exclusion criterion for 
receiving OAT in Norway. However, how these inter-country differences impact 
dispensations of dispensed potentially addictive substances are uncertain. Before these 
studies, we lacked knowledge of dispensed potentially addictive substances in OAT in 
Norway and Sweden. In addition, little is known about the differences and similarities in 
dispensing potentially addictive substances between the countries’ OAT programs. 
Considering this, we have presented data on dispensation rates and dispensed doses of the 
potentially addictive substances in Norway in papers I and II. In paper III, we have compared 
dispensation rates and dispensed doses of these substances between Norway and Sweden.  
 
Furthermore, little attention has been paid to the use of non-dispensed potentially addictive 
substances. In European countries, the prevalence varies considerably, and we lack 
knowledge of the extent of these substances for the OAT populations. Creating a regional 
OAT cohort (INTRO-HCV cohort) in Bergen and Stavanger, Norway, we collected 
information on non-dispensed potentially addictive substance use among almost all SUD 
patients, mainly OAT patients, in the two cities. Using these data, we have estimated the 
prevalence of non-dispensed potentially addictive substances in the population from 2016 to 
2020 in paper IV. 
 
Finally, fatigue is a symptom that is associated with patients’ well-being. As far as we know, 
no previous studies have investigated fatigue and its relationship to long-term use of non-
dispensed potentially addictive substances in a SUD population. Nevertheless, one can 
assume that the co-use of these substances and other sociodemographic and clinical factors – 
such as housing situation, debt difficulties, HCV infection, and educational level, may be 
associated with the level of fatigue in a SUD population. Using the INTRO-HCV cohort, we 
have investigated the extent and changes in fatigue and how the non-dispensed potentially 
addictive substance use is associated with fatigue, adjusted for the various clinical and 
















Aims of the thesis  
 
This thesis’s overall objectives were to assess the use of dispensed and non-dispensed 
potentially addictive substances and investigate the associations between non-dispensed 
potentially addictive substances and fatigue among OAT patients. 
 
1) To describe the dispensation rates and dosages of dispensed potentially addictive 
substances among OAT patients in Norway (papers I and II) 
 
2) To describe differences in the dispensation rates and dosages of dispensed potentially 
addictive substances among OAT patients in Norway and Sweden (paper III) 
 
3) To investigate the extent of non-dispensed potentially addictive substance use among 
SUD patients, mainly OAT patients, in Bergen and Stavanger, Norway (paper IV) 
 
4) To examine the extent of fatigue symptoms and investigate the associations between 
non-dispensed potentially addictive substances and fatigue adjusted for various 
sociodemographic and clinical factors among SUD patients, mainly OAT patients, in 




































The data in this thesis are from three different data sources; two nationwide registers from two 
different countries (Norway: The Norwegian Prescription Database (NorPD), Sweden: The 
Swedish Prescribed Drug Register (SPDR)) [104, 105], and cohort data from the INTRO-
HCV study [1]. 
 
The Norwegian Prescription Database 
 
Since January 1, 2004, the NorPD has collected information about all dispensed medicines 
from Norwegian pharmacies [104, 106]. The pharmacies are obliged by law to register all 
dispensed substance information electronically and send the information to NorPD monthly. 
Substances administrated at hospitals, nursing homes, and outpatient clinics are not registered 
in the NorPD. The NorPD receives information individually identified by an 11-digit person 
identifier, which are encrypted by a unique identification key number before data reach the 
researchers. The NorPD contains all information about dispensed substances, including the 
Anatomical Therapeutic Chemical (ATC) classification system codes, defined daily doses 
(DDD), date of dispensing, and reimbursement codes. In addition, information on patients 
(gender, the month and year of birth, and the month and year of death) and prescribers 
(encrypted prescriber identifier, gender, the year of birth, profession, and specialty) are 
reported. According to the current World Health Organization (WHO)’s standards [107, 108], 
the ATC codes and DDD are used. The NorPD is administrated and regulated by the 
Norwegian Institute of Public Health. There is estimated that about 90 % of the OAT patients 
are identified using the NorPD [109]. 
 
The Swedish Prescribed Drug Register 
 
The Swedish Prescribed Drug Register has collected information about all dispensed 
substances from the Swedish pharmacies since July 1, 2005 [105]. Like the NorPD, 
substances dispensed at hospitals, nursing homes, and outpatient clinics are not captured using 
this data source. All information delivered from SPDR to researchers are encrypted using 
patient identification key numbers. The SPDR contains information of dispensed substances 
using the ATC codes and DDD according to the current WHO’s standards [107, 108], 
information of patients (gender, the current age at the dispensation date), prescribers 
(profession and specialty), prescribing date, and dispensing date. The Swedish National Board 
of Health and Welfare has estimated that almost 60 % of the OAT patients are captured using 
the SPDR [33, 34]. Compared with the NorPD’s identification rate of 90 %, this relatively 
lower patient identification rate is assumingly due to a higher rate of dispensed OAT opioids 
from outpatient clinics in primary care or specialized care being not linked to the register. 
 
Anatomical Therapeutic Chemical classification system 
 
The Anatomical Therapeutic Chemical classification system is a global classification system 
governed by the WHO Collaborating Centre for Drug Statistics Methodology [107]. The ATC 
system classifies the most therapeutic substances for human use worldwide if “being 
substances with market authorization in at least one country (…)” (the relevant part of the 
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definition is included). The ATC classification system operates a hieratic structure of five 





















The ATC codes represent a crucial role in identifying patients who have received OAT 
opioids and their dispensations of potentially addictive substances in the NorPD and SPDR. In 
paper I-III using the ATC system, we defined dispensed substances/substance groups as 
follow: 
 
Benzodiazepines: Benzodiazepines are the substances categorized under the ATC code groups 
“N05BA” (“benzodiazepine derivatives”), “N05CD” (“Benzodiazepine derivatives”), and 
“N03AE01” (clonazepam). Of those, the following have marked authorizations in Norway or 
Sweden: alprazolam (ATC code: N05BA12), clonazepam (N03AE01), diazepam (N05BA01), 
flunitrazepam (N05CD03), midazolam (N05CD08), nitrazepam (N05CD02), lorazepam 
(N05BA06) (Sweden only), and oxazepam (N05BA04). 
 
Z-hypnotics: Zopiclone (N05CF01) and zolpidem (N05CF02).   
 
Gabapentinoids: Gabapentin (N03AX12) and pregabalin (N03AX16). 
 
OAT opioids: Buprenorphine (N07BC01), methadone (N07BC02), levomethadone 
(N07BC05), and buprenorphine-naloxone (N07BC51). These substances are mainly 
dispensed in Norway and Sweden. Other countries may dispensed other OAT opioids.   
 
Non-OAT opioids: All opioid categorize under the 3th ATC code level “N02A”, including all 
dispensed opioid analgesics and opioid analgesics combined with non-opioid analgesics or 
antispasmodics (e.g.: codeine plus paracetamol). The most commonly dispensed non-OAT 
opioids are: morphine (N02AA01), oxycodone (N02AA05), ketobemidone (N02AB01), 
fentanyl (N02AB03), and buprenorphine (N02AE01). 
 
Non-OAT opioids (paper I): “Weak non-OAT opioids” are defined as codeine (N02AJ06), 
tramadol (N02AJ13, N02AX02) and tapentadol (N02AX06). Other opioids (N02A) are 
Figure 3: The figure displays the hieratic structure of the ATC classification system 
exemplified using ATC code of methadone (ATC code: N07BC02). ATC: Anatomical 
Therapeutic Chemical. 
N  07  B  C  02
1st level: Anatomical main group (N = the nervous System)
2nd level: Therapeutic subgroup (07 = other nervous system drugs)
3rd level: Pharmacological subgroup (B = drugs used in addictive disorders)
4th level: Chemical subgroup (C = drugs used in opioid dependence)
5th level: Chemical substance (02 = methadone)
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classified as “strong non-OAT opioids”. The term “weak” refers to opioids with lower 
equipotency relative to other opioids.  
 
Non-OAT opioids (paper III): “Weak non-OAT opioids” are defined as codeine (N02AJ06, 
N02AJ08, N02AJ09), tramadol (N02AJ13, N02AJ14, N02AX02) and tapentadol (N02AX06). 
Other opioids (N02A) are classified as “strong non-OAT opioids”.  
 
Centrally acting stimulants: Racemic amphetamine (N06BA01), dexamphetamine 
(N06BA02), methylphenidate (N06BA04), and lisdexamphetamine (N06BA12). 
 
ADHD medications: All substances defined as “Centrally acting stimulants” plus atomoxetine 
(N06BA09). 
 


































ATC code Substance name 
1 DDD is equal to 
(in mg): 
Benzodiazepines 
N03AE01 Clonazepam 8 
N05BA01 Diazepam 10 
N05BA04 Oxazepam 50 
N05BA06 Lorazepam 2.5 
N05BA12 Alprazolam 1 
N05CD02 Nitrazepam 5 
N05CD03 Flunitrazepam 1 
N05CD08 Midazolam 15 
Z-hypnotics 
N05CF01 Zopiclone 7.5 
N05CF02 Zolpidem 10 
Gabapentinoids 
N03AX12 Gabapentin 300 
N03AX16 Pregabalin 1800 
ADHD medications 
N06BA01 Racemic amphetamine 15 
N06BA02 Dexamphetamine 15 
N06BA04 Methylphenidate 30 
N06BA09 Atomoxetine 80 
N06BA12 Lisdexamphetamine 30 
OAT opioids 
N07BC01 Buprenorphine 8 
N07BC02 Methadone 25 
N07BC05 Levomethadone 15 




The defined daily dose is a measurement of the quantity of the dispensed substances. The 
DDDs are mainly used in research to quantify dispensed substances’ consumption and study 
differences in substance dispensations. The basic definition is “the assumed average 
maintenance dose per day for a drug used for its main indication in adults [110].” Due to a 
substance having various medical indications, the DDD does not necessarily reflect the 
recommended dose of a medical indication. The NorPD and SPDR quantify all dispensed 
substances using the DDDs. In paper I-III, we recalculated all dispensed DDD per substance 
into milligrams using the table above (Table 1), according to the WHO’s standards per 
October 2018 [110]. 
  
INTRO-HCV cohort data 
 
The INTRO-HCV cohort data are data collected from SUD patients in Bergen and Stavanger, 
Norway. Patients are recruited from the OAT outpatient clinics in the two cities and two 
municipality clinics in Bergen. The data collection has been ongoing since May 2016, and up 
to June 2020, approximately 750 patients with SUDs are included. Of those, 82 % receive 
OAT at baseline. The clinics work in multidisciplinary teams consisting of physicians 
specialized in Addiction Medicine, psychologists, nurses, and social workers. The patients 
included are offered an annual health assessment, including a survey of sociodemographic and 
clinical conditions, self-reported substance use, self-reported physical and mental health, 
clinical examination, elastography, and complete blood counts. If any health issues are 
revealed during the health assessment, patients are medically and psychosocially followed up 
by the multidisciplinary teams. The teams work closely with physicians specialized in family 
medicine or other clinical consultants in the hospital. The data are collected using electronic 
data collection software Checkware® under research nurses’ supervision.  
 
Study design and specific aims of the papers 
 
Paper I is a prospective observational study that overall investigated dispensations of 
benzodiazepines, z-hypnotics, and gabapentinoids among the Norwegian patients who were 
dispensed OAT opioids per calendar year for the study period 2013-2017. In addition, we 
examined how discontinuing OAT opioids were associated with changes in the dosages of 
dispensed benzodiazepines or z-hypnotics, and gabapentinoids.  
 
Paper II is a prospective observational study that examined the dispensations of ADHD 
medications among the Norwegian patients who were dispensed an OAT opioid per calendar 
year during the study period 2015-2017. In addition, we examined whether the dosage of an 
ADHD medication was changed substantially per calendar year among those who received 
both an OAT opioid and ADHD medication yearly throughout the study period. Furthermore, 
we evaluated how this continuity in dispensed OAT opioids and ADHD medication 
throughout the study period were associated with being dispensed a benzodiazepine, z-
hypnotic, opioid (other than OAT opioids), and gabapentinoid in 2017.  
 
Table 1: The table displays the relationship between Defined Daily Doses (DDD) and 
milligrams among potentially addictive substances, according to the WHOs standards per 
October 2018. ATC: Anatomical Therapeutical Chemical Classification; OAT: Opioid 




Paper III is a prospective observational study that investigated dispensations of 
benzodiazepines, z-hypnotics, gabapentinoids, weak non-OAT opioids, strong non-OAT 
opioids, and centrally acting stimulants among patients who were dispensed OAT opioid per 
calendar year in the period 2015-2017 in Sweden and Norway.  
 
Paper IV is a prospective cohort study that studied the use of non-dispensed potentially 
addictive substances (benzodiazepines or z-hypnotics, stimulant substances (amphetamines 
and cocaine), and opioids), alcohol, and cannabis among SUD patients, mainly OAT patients, 
who were measured fatigue. Furthermore, we investigated the extent of self-reported fatigue 
in the population, and how the use of non-dispensed substances, alcohol, and cannabis 
influenced fatigue, adjusted for sociodemographic and clinical factors in 2016–2020 in 
Bergen and Stavanger, Norway. 
 




Paper I. All patients above 18 years of age who were dispensed an OAT opioid in the study 
period from 2013 to 2017 were included. Furthermore, the OAT opioid methadone has two 
medical indications in Norway: OAT and pain. While the methadone tablet formulation is 
approved for pain only, the mixture formulation has only the OAT as the medical indication 
 
Table 2 Paper 1 Paper 2 Paper 3 Paper 4 









% of coverage (estimated) 90 % 90 % 90 % Norway 
60 % Sweden 
70 % 
Inclusion criteria Being dispensed an OAT opioid 
from the Norwegian pharmacies 
 
Above 18 years of age during the 




mean ≥ 1 DDD 






Above 18 years 
of age and below 





in the outpatient 




















Study period 2013-2017 2015-2017 2015-2017 2016-2020 
Table 2:  The table displays the data sources, country/region, estimated coverage, 




[37]. Considering this, we excluded the cases who not had any dispensations of methadone 
mixture from January 1, 2004, to December 31, 2017. In addition, we used reimbursement 
codes for palliative care (ICD-10: -90; the International Classification of Primary Care, 
Version 2 (ICPC-2): -90) to exclude patients who were dispensed methadone tablets on these 
codes during the study period. Unlike methadone, the OAT opioids buprenorphine, 
buprenorphine-naloxone, and levomethadone dispensations have the OAT as their only 
medical indication. These dispensations were fully included in our analysis.  
 
In addition, we defined patients who discontinued OAT as all those who were dispensed the 
last dispensation of an OAT opioid in the inclusion period from January 1, 2017, to 
September 30, 2017, and then no dispensation until the end of the collected NorPD data on 
March 31, 2018.  
 
Paper II. The inclusion criteria were similar to paper I, except the study period, which was 
changed to 2015-2017 due to minimal changes in dispensation rates and doses from one year 
to another observed in paper I. Moreover, patients who were co-dispensed at least one ADHD 
medication and OAT opioid yearly in the study period 2015-2017 were defined based on 
those who fulfilled the inclusion criteria. 
 
Paper III. All Norwegian and Swedish patients above 18 years of age who were dispensed 
more than mean one DDD of an OAT opioid daily per calendar year during the study period 
2015-2017 were included. Due to the OAT opioid methadone could be administered as tablets 
and injection liquids for non-OAT patients with pain in both countries, we only included the 
methadone dispensations administrated as a mixture for this paper. Furthermore, to be safer in 
keeping out patients who received methadone for other medical indications than OAT, we 
used the total amount of dispensed OAT opioid DDD per day to measure whether patients 
were likely to be OAT patients. 
 
Paper IV. All patients who received OAT in the OAT outpatient clinics in Bergen or 
Stavanger, Norway, or received health care for SUD in two municipality clinics in Bergen and 
measured fatigue at least once using the nine-item Fatigue Severity Scale (FSS-9) were 
included.  
 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Substance definitions for papers I-III 
 
 
Calculating mean daily dosages: we calculated the mean daily dosages of dispensed 
potentially addictive substance per calendar year by summarizing the total amount of 
dispensed DDDs of the substance (e.g. clonazepam) per year. The total amount of DDDs was 
converted to milligrams according to Table 1. Furthermore, for benzodiazepines and z-
hypnotics in paper I, we summarized the total amount of dispensed substances by converting 
the total amount of each substance to diazepam equivalents using the equations below 
according to [111, 112] (Text box 5). 
 
 
Due to uncertainty regarding equipotency between different benzodiazepines and z-hypnotics 
relative to diazepam, we created the three equations above based on the lowest, mean, and 
highest stated equipotency dosages of benzodiazepines. Using these equations, we ran 
Text box 4: Essential definitions in the register-based studies 
 
Dispensation: A dispensation is defined as when patients received a medicine from a pharmacy.  
 
Dispensation rate: Dispensation rate was defined as patients who were dispensed at least one 
dispensation of a potentially addictive substance (e.g. clonazepam) or substance group (e.g. 
benzodiazepines) divided on the number of patients who were dispensed an OAT opioid per 
calendar year.  
 
Text box 5: Equations to convert benzodiazepines and z-hypnotics with different equipotency 
into diazepam equivalents: 
𝐷𝑖𝑎𝑧𝑒𝑝𝑎𝑚 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 𝑙𝑜𝑤𝑒𝑠𝑡
= 𝑑𝑖𝑎𝑧𝑒𝑝𝑎𝑚 + 𝑜𝑥𝑎𝑧𝑒𝑝𝑎𝑚 ×
1
5
+ 𝑎𝑙𝑝𝑟𝑎𝑧𝑜𝑙𝑎𝑚 × 10 + 𝑐𝑙𝑜𝑛𝑎𝑧𝑒𝑝𝑎𝑚 × 10

























= 𝑑𝑖𝑎𝑧𝑒𝑝𝑎𝑚 + 𝑜𝑥𝑎𝑧𝑒𝑝𝑎𝑚 ×
1
3
+ 𝑎𝑙𝑝𝑟𝑎𝑧𝑜𝑙𝑎𝑚 × 20 + 𝑐𝑙𝑜𝑛𝑎𝑧𝑒𝑝𝑎𝑚 × 20






sensitivity analyses calculating the uncertainty in the dispensed dosage of benzodiazepines 
and z-hypnotics.  
 
In contrast to paper II, we summarized the total amount of dispensed benzodiazepines and z-
hypnotics in two separate equations based on the mean equipotency dosage of the substance 
groups in paper III. The two equations were created to identify potential differences in 
dosages of the benzodiazepines and z-hypnotics between Norway and Sweden and were 
according to [111, 112] (Text box 6).  
 
 
Finally, the total amount of milligrams of the dispensed potentially addictive substances were 
divided by 365.25 days to estimate the mean daily dosage per calendar year. 
 
Specific definitions for papers I and II 
 
Categorizing the number of dispensations: The number of dispensations was defined per 
substance (e.g., oxazepam) or substance group (e.g., ‘benzodiazepine or z-hypnotic’). The 
number of dispensations for each potentially addictive substance group was categorized into 
three groups: 0, 1-2, and ≥ 3 dispensations per calendar year. The number of dispensations of 
OAT opioids was divided into five groups: 1-6, 7-12, 13-51, ≥ 52 dispensations per calendar 
year. 
 
Categorizing the dispensed mean daily dosages: The mean daily dosages of diazepam 
equivalents were categorized into five groups: 0, ≤ 20, > 20 - ≤ 40, and > 40. Furthermore, 
pregabalin was categorized into the following three groups (mean mg per day): > 0 - ≤ 300, > 
300 - ≤ 600, and > 600, and gabapentin into these three groups (mean mg per day): > 0 - ≤ 
900, > 900 - ≤ 3600, and > 3600. 
  
Type of dispensed OAT opioid: we defined the type of dispensed OAT opioid as the last type 
of OAT opioid dispensed per calendar year (buprenorphine-based or methadone-based). 
 
Discontinuing OAT: For patients who discontinued OAT, we defined three equal periods 
from 180 days before to 90 days after the discontinuation date. The three periods were: 1) 180 
to 90 days prior to the date for the last dispensation, 2) the last 90 days prior to the 
discontinuation date, and 3) the 90 days after the date for discontinuation. We calculated the 
mean daily dosage of dispensed ‘benzodiazepines and z-hypnotics’, pregabalin, and 
gabapentin for each period. 
 
Specific definition for paper III 
 
Text box 6: Equipotency equations to convert benzodiazepines to diazepam equivalents and 
z-hypnotics to zopiclone equivalents 
𝐷𝑖𝑎𝑧𝑒𝑝𝑎𝑚 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 𝑚𝑒𝑎𝑛












+ 𝑛𝑖𝑡𝑟𝑎𝑧𝑒𝑝𝑎𝑚 + 𝑙𝑜𝑟𝑎𝑧𝑒𝑝𝑎𝑚 × 4 






The type of dispensed OAT opioid: We defined the type of dispensed OAT opioid 
(buprenorphine-based or methadone-based) as the OAT opioid that was mostly dispensed per 
calendar year, calculated in DDDs per year. 
 
Specific definitions for paper IV 
 
Measuring fatigue: We used the FSS-9 to measure the fatigue during the last week, including 
items considering: mental and physical functioning, motivation, carrying out duties, and 
interference with work, family, or social life. The FSS-9 was a nine-item questionnaire 
consisting of a Likert scale per item ranging from one point to seven points, generating a sum 
score between nine and 63 points. We defined baseline as the first annual health assessment, 
including FSS-9 measurement, when the health assessments were listed chronologically.  
 
Non-dispensed potentially addictive substances: We defined non-dispensed substances as 
being dispensed a substance in the following substance groups: opioids (including heroin), 
stimulants (amphetamines and cocaine), and benzodiazepines (including z-hypnotics). 
 
Sociodemographic and clinical factors: From the INTRO-HCV cohort, we used information 
from the annual health assessment concerning; non-dispensed potentially addictive substance 
use plus alcohol and cannabis, injecting substance use, being on OAT (including OAT dosage 
ratio), educational level, housing situation, debt difficulties, and liver stiffness (measured by 
transient elastography). In addition, we obtained blood sample results per annual health 
assessment concerning; C-reactive protein, estimated glomerular filtration rate, hemoglobin, 
current infectious diseases (hepatitis B virus infection, HCV infection, and human 
immunodeficiency virus (HIV)), and Aspartate transferase and thrombocytes to calculate the 
Aspartate transferase to platelets ratio index score (APRI).  
 
Dealing with non-dispensed potentially addictive substances, plus alcohol and cannabis: We 
classified non-dispensed potentially addictive substances plus alcohol and cannabis in two 
groups per substance/substance group: frequent users and non-frequent users. A frequent user 
was defined as using a substance/substance group at least weekly during the past 12 months. 
Patients using alcohol, cannabis, or non-dispensed potentially addictive substances less than 
weekly were classified as a ‘no frequent user.” We presented the prevalence of frequent users 
and non-frequent users as percentages of the SUD population per substance/substance group 
(benzodiazepines, opioids (including heroin), stimulants (cocaine and amphetamines), 
cannabis, and alcohol). 
 
Dealing with no non-dispensed potentially addictive substance factors: We defined ‘injecting 
substance use’ as having injected at any time during the past 12 months according to the 
health assessment. Being on OAT was defined according to whether patients were currently 
enrolled in OAT at baseline. The OAT dosage ratio was calculated by dividing the received 
OAT opioid dosage by the expected OAT opioid dosage. The expected dosage was defined as 
the mean dosage of the lowest and highest recommended dosages according to WHO’s 
guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence 
(18 mg buprenorphine or 18/4.5 mg buprenorphine-naloxone, 90 mg methadone, or 45 mg 
levomethadone) [25]. Being infected with hepatitis B virus, HIV, or HCV were defined as 
detecting positive hepatitis B virus surface antigen, HIV antigen/antibodies, or positive HCV 
polymerase chain reaction at the first annual health assessment. If positive HCV polymerase 
chain reaction, we used the Helmert contrast in order to classify patients into two groups – 
transmitted and non-transmitted – and further into two subgroups: whether patients have a 
21 
 
low viral load (< 800 000 IU/ml) or high viral load (≥ 800 000 IU/ml). We classified the 
educational levels in five groups: ‘not completed primary school,’ ‘completed primary school 
(nine years),’ ‘completed high school (12 years),’ ‘three or fewer years of college or 
university’ or ‘more than three years of college or university. Moreover, patients were 
classified into two groups based on the housing situation the last 30 days prior to the health 
assessment; “unstable” and “stable.” “Unstable housing situation” represented patients who 
had lived on the street, in a homeless shelter, or with family and friends during the last 30 
days. Others who had a more permanent residence were classified as having a stable housing 
situation. Debt difficulties were defined as striving to pay off legal or illegal debt due to a 




Table 4 Paper I Paper II Paper III Paper IV 
Statistical analysis 
Frequency tables x x x x 
One-sample t-test  x    
Paired t-test x x   
Sensitivity analysis x   x 
Binary logistic regression x x   
Expectation-maximization 
imputation 
   x 
Longitudinal analysis x x  x 
Mixed model regression    x 
Outcome measures     
Dispensation rates x x x  
Mean daily dosages x x x  
Crude odds ratio (cOR) x x   
Adjusted odds ratio (aOR) x x   
Fixed effects: estimate 
(baseline) (mixed model) 
   x 
Fixed effects: slope (time 
trend) (mixed model) 
   x 










Papers I and II. The one-sample t-tests were used to calculate mean daily dosages of dispensed 
benzodiazepines or z-hypnotics, and gabapentinoids with 95 % confidence intervals. 
Furthermore, we used the paired sample t-test to compare the differences in the mean daily 
dosages of benzodiazepines or z-hypnotics (in diazepam equivalents), gabapentinoids 
(pregabalin or gabapentin), and ADHD medications in defined periods for patients who 
discontinued OAT and those who were co-dispensed ADHD medications and OAT opioids. 
Furthermore, we created binary logistic regression models per calendar year with being 




dispensed at least one benzodiazepine or z-hypnotic, gabapentinoid, and ADHD medication, 
respectively, as the dependent variables. The independent and categorical variables were age 
groups (≤ 25, 26-35, 36-45, 46-55, and ≥ 56 years), gender, the number of dispensed OAT 
opioids, the type of dispensed OAT, and being dispensed at least one non-OAT opioids. In 
addition, being dispensed a gabapentinoid was used as an independent and categorical variable 
when being dispensed a ‘benzodiazepine or z-hypnotic’ was defined as a dependent variable, 
and vice versa. We presented the odds ratio (OR) for the analyses. The level of statistical 
significance was set to p < 0.05.  
 
Paper III. We performed descriptive statistics (means, medians, percentiles, and percentages) 
of dispensation rates and dispensed dosages of potentially addictive substances 
(benzodiazepines, z-hypnotics, gabapentinoids, ADHD medications, strong non-OAT opioids, 
and weak non-OAT opioids) per calendar year per country in the study period. 
 
Paper IV. We used a linear mixed model to investigate whether the sociodemographic and 
clinical factors affected the FSS-9 sum score at baseline and to which extend they impacted 
changes in the sum score from baseline to the following health assessments. We presented the 
statistical analyses in a three-step procedure. First, we dealt with missing data using 
Expectation-Maximization imputation of the sociodemographic and clinical factors. This 
imputation method is a common and recommended method to input data before running linear 
mixed model analyses [113]. When running the imputation, the missing values were dealt 
with as “missing at random.” Overall, a total of 2.6 % of the factor variables were replaced 
with estimated values by imputation. Second, using linear mixed models, we analyzed the 
factor variables separately as outcome variables as a function of the time (time from baseline). 
We investigated whether the factor variables changed significantly from baseline to the 
following health assessments by these analyses. Clinically substantial changes in these 
outcome variables over time have been handled as time-varying exposure variables in a linear 
mixed model analysis with the FSS-9 sum score as an outcome variable. However, we did not 
identify any clinically significant changes in the factor variables. Thus, the factors’ 
(predictors’) baseline level were handled as stable predictors in the model. Third, we created a 
linear mixed model using the FSS-9 sum score as an outcome variable and the 
sociodemographic and clinical factors at baseline as stable, independent predictor variables. 
The interactions between these factors and time were added to the model to explore whether 
predictors changed the FSS-9 sum score (outcome variable) over time. We specified a random 
intercept fixed slope regression model. Restricted maximum likelihood was set as an 
estimator. The full information maximum likelihood ensured that all available FSS-9 sum 
score measurements were used. Additionally, we ran similar analysis models by including 
OAT patients using methadone or buprenorphine, respectively, at baseline. In all analyses, the 
level of statistical significance was set to p < 0.05. Due to the risk of type I errors caused by 
the above 40 predictors in the models, we performed a sensitivity analysis by adding 
Bonferroni corrected p-values for adjusting. 
 
Ethics approval and consent to participate 
 
Paper I and II. The Regional Committee for Medical and Health Research Ethics (REC), 
REC vest, Norway, has approved the use of registry data for the study (approval number 
2018/939/REK Vest, June 19, 2018). No informed consent from included patients was 




Paper III. The Regional Committee for Medical and Health Research Ethics West, Norway, 
and the Swedish Ethical Review Authority in Stockholm, Sweden, have both approved the 
use of the Norwegian and Swedish registry data for the study (Norway: reference number 
2018/939/REK Vest, June 19, 2018; Sweden: reference number 2018/2080-31/1, 14 
November 2018 and reference number 2019-04791, November 22, 2019). The Regional 
Committee for Medical and Health Research Ethics West, Norway, is appointed by the 
Norwegian Ministry of Education and Research, and the Swedish Ethical Review Authority is 
under the Swedish Ministry of Education. No informed consent from the patients was 
necessary. 
 
Paper IV. The INTRO-HCV study is reviewed and approved by the Regional Ethical 
Committee for Health Research West, Norway (REK Vest 2017/51). All patients provided 








































Aim 1: To describe the dispensation rates and dosages of dispensed potentially addictive 
substances among OAT patients in Norway (papers I and II) 
 
Paper I. In 2017, the dispensation rate of being dispensed a ‘benzodiazepine and z-hypnotic’ 
was 50 % per calendar year throughout the study period. Twenty-nine percent were dispensed 
oxazepam, which was the most dispensed benzodiazepine in 2017. The mean daily dosage 
was 21 mg (standard deviation (SD): 38 mg) diazepam equivalents in 2013 and 17 mg (SD: 
25 mg) in 2017. In 2017, being dispensed at least one benzodiazepine or z-hypnotic was 
associated with females compared with males (aOR: 1.2, 95 % confidence interval (CI): 
1.1;1.3), age above 56 years compared with age below 25 years (1.2, 1.1;1.3), using 
methadone as OAT opioid compared with using buprenorphine (1.3, 1.2;1.4), and being 
dispensed a non-OAT opioid (3.0, 2.6;3.5) or gabapentinoid (2.5, 2.1;3.0) compared with not 
being dispensed these substances. Substantial similar results were seen in 2013-2016. 
 
Gabapentinoids were dispensed to 9 % of the patients in 2013 and 11 % of the patients in 
2017. Pregabalin was twice as frequently dispensed as gabapentin per year. For 2017, the 
mean daily dosage of pregabalin was 386 mg (SD: 454 mg), and for gabapentin, 1047 mg 
(1450 mg). The mean dosages of gabapentinoids were nearly unchanged during the study 
period. Being dispensed a gabapentinoid was associated with being dispensed a non-OAT 
opioid (3.0, 2.5;3.5) and ‘benzodiazepine or z-hypnotic’ (2.0, 2.1;3.0) compared with not 
being dispensed these substances.  
 
A total of 693 patients discontinued OAT during the study period. Of those, 156 patients were 
dispensed benzodiazepines or z-hypnotics for the defined 90-days’ periods. We did not 
identify any changes in the dispensed dosages of benzodiazepines and z-hypnotics, 
pregabalin, or gabapentin at baseline compared to the following 90 days after the 
discontinuation date. 
 
Paper II. The dispensation rates of being dispensed an ADHD medication were 3.5 % in 2015 
and 4.6 % in 2017. In 2017, above half of the patients with co-dispensed ADHD medication 
and an OAT opioid received short- and intermediate-acting methylphenidate (55 %), followed 
by lisdexamphetamine (24 %). Similarly, we found that being dispensed buprenorphine rather 
than methadone as OAT opioid (1.6, 1.3;2.1), being dispensed a non-OAT opioid compared 
with not dispensed these opioid substances (1.5, 1.1;1.9), and being below 25 years of age 
rather than being above 56 years of age (0.3, 0.1;0.6) were associated with being dispensed 
ADHD medication. Similar results were substantially seen for 2015 and 2016.  
 
We identified 142 patients who were co-dispensed ADHD medication and OAT opioids 
throughout the period from 2015 to 2017. Of those using methylphenidate, we found an 
increase in the dispensed mean daily dosages from 63 mg (SD: 43 mg) in 2015 to 76 mg (39 
mg) in 2017 (p = 0.01). For lisdexamphetamine, we showed a non-significant increase of 64 
mg during the three years (p = 0.10). Notably, except atomoxetine, the mean daily dosages for 
all ADHD medications exceeded the recommendations, according to the European Medicines 
Agency, the Norwegian Medicines Agency, and the Norwegian Medicines Handbook [114-
118]. Moreover, 85 out of 142 patients receiving co-dispensed ADHD medication and an 
OAT opioid throughout the study period also were dispensed other potentially addictive 





Aim 2: To describe differences in the dispensation rates and dosages of dispensed potentially 
addictive substances among OAT patients in Norway and Sweden (paper III) 
 
The proportion of patients who were dispensed at least a substance from one of the substance 
groups (benzodiazepines, z-hypnotics, gabapentinoids, non-OAT opioids, or centrally acting 
stimulants) was almost equal between the countries (in 2017: 59 % (Norway) and 55 % 
(Sweden) (Figure 14). However, there were some substantial inter-country differences in the 
dispensed substance groups. Most notably, 44 % of the Norwegian patients were dispensed 
benzodiazepines compared with 14 % among the Swedish OAT patients in 2017. 
Furthermore, 14 % of the Norwegian OAT patients compared with 26 % of the Swedish OAT 
patients were dispensed z-hypnotics, whereas gabapentinoids were dispensed to 10 % of the 
OAT patients in Norway and 19 % of the OAT patients in Sweden. Interestingly, the centrally 
acting stimulants were dispensed to 4 % in Norway and 18 % in Sweden. Similar results were 












In 2017, the mean daily dosages of dispensed benzodiazepines were 17 mg (SD: 25 mg) 
diazepam equivalents in Norway, with a corresponding 16 mg (22 mg) in Sweden. Moreover, 
the mean dosage of dispensed z-hypnotics was 8 mg (9 mg (Norway), 7 mg (Sweden)) 
zopiclone equivalents in both countries. For pregabalin, gabapentin, and lisdexamphetamine, 
the mean daily dosages were higher in Norway than in Sweden (pregabalin: 402 mg (431 mg) 
(Norway) versus 345 mg (260 mg) (Sweden), gabapentin: 1021 mg (1524 mg) versus 772 mg 








≥ 1 addictive 
drug





























Figure 4: The figure displays the proportion of OAT patients who were dispensed at least 
one potentially addictive substance (benzodiazepine, z-hypnotic, gabapentinoid, strong 
non-OAT opioid, weak non-OAT opioid, or centrally acting stimulant) in Norway and 
Sweden in 2017. Weak non-OAT opioids were defined as all substances containing 
codeine, tramadol, or tapentadol, while strong non-OAT opioids defined all other opioids. 




daily dosage of dispensed methylphenidate was higher in Sweden compared with Norway 
(methylphenidate: 80 mg (63 mg) vs 57 mg (40 mg)).  
 
Among patients who were co-dispensed OAT opioids and centrally acting stimulants, 34 % in 
Norway and 31 % in Sweden also dispensed at least one of the other potentially addictive 
substances (benzodiazepines, z-hypnotics, gabapentinoids, and non-OAT opioids) in 2017. 
Furthermore, a quarter was dispensed OAT opioids, centrally acting stimulants, and two of 
the other potentially addictive substances. In 2017, the most commonly dispensed 
combination of three substances was OAT opioid, centrally acting stimulants, and 
‘benzodiazepines or z-hypnotics.’ 
 
Aim 3: To investigate the extent of non-dispensed potentially addictive substance use among 
SUD patients, mainly OAT patients, in Bergen and Stavanger, Norway (paper IV) 
 
Of 654 SUD patients who were recruited, approximately one-third completed two or more 
annual health assessments. Of those included, 82 % received OAT at baseline. At baseline, 
the self-reported prevalence of frequent users of non-dispensed potentially addictive 
substances plus alcohol and cannabis, the past 12 months was: cannabis 52 %, 
benzodiazepines or z-hypnotics 39 %, stimulants 29 %, alcohol 26 %, and opioids 16 %. 
Furthermore, patients who have ever used substances during the past 12 months had the 
following prevalence at baseline: cannabis 78 %, alcohol 72 %, benzodiazepines or z-
hypnotics 71 %, stimulants 64 %, and opioids 49 % (data not shown in the paper). Using the 
linear mixed model, we found that the frequent users’ substance prevalence was not clinically 
significantly changed from baseline to the following health assessments. 
 
Aim 4: To examine the extent of fatigue symptoms and investigate the associations between 
non-dispensed potentially addictive substances and fatigue adjusted for various 
sociodemographic and clinical factors among SUD patients, mainly OAT patients, in Bergen 
and Stavanger, Norway (paper IV) 
 
The FSS-9 sum score was 43 (SD: 16) at baseline, representing a mean score for the FSS-9 
items of 4.8 (SD: 1.8). Females had a higher score than males (adjusted mean difference of 
FSS-9 sum score: 4.1, 95 % CI: 1.3;7.0), and frequent use of benzodiazepines (5.7, 3.0;8.4) or 
stimulants (-5.0, -8.0;-2.0) compared with less frequent or no use of these substances were 
associated with changes in the FSS-9 sum score at baseline. In addition, patients with debt 
difficulties were barely associated with more fatigued than those with no debt difficulties (2.9, 
0.4;5.3). 
 
Substantial intra-individual changes in the FSS-9 sum score from baseline to the following 
health assessment were observed (Figure 5). Furthermore, patients with frequent use of 
benzodiazepines compared with those with less frequent or no use (-4.4, -8.2;-0.7), and 
patients with liver fibrosis or cirrhosis measured by transient elastography compared with 
those with healthy liver (-5.5, -9.9;-1.0) over time were associated with less fatigue per year. 














For patients receiving methadone as an OAT opioid, females had more fatigue than males 
(7.3, 2.5;12.2), and patients with frequent use of benzodiazepines compared with those with 
less frequent or no use were associated with higher FSS-9 sum scores (6.0, 1.6;10.5) at 
baseline. Furthermore, patients with debt difficulties had higher FSS-9 sum score than those 
with no debt difficulties (4.9, 0.7;9.1). A high versus low hepatitis C viral load was also 
associated with more fatigue at baseline (31.5, 1.5;61.5). Furthermore, patients with frequent 
benzodiazepine use compared with those with less frequent or no use (-6.8, -12.5;-1.1) were 
associated with a decreasing FSS-9 sum score from baseline to the following health 
assessment. In addition, patients with liver fibrosis or cirrhosis compared with those with 
healthy liver (-6.2, -11.7;-0.7) and patients with high versus low viral hepatitis C load (-44.6,-
81.7;-7.5) were also associated with a decreasing FSS-9 sum score per year from baseline.  
 
For patients receiving a buprenorphine-based OAT opioid, frequent alcohol use compared 
with less frequent or no use was associated with a higher fatigue score at baseline (4.8, 
0.2;9.3). In contrast, frequent stimulant use compared with less frequent or no use was 
associated with a lower fatigue score at baseline (-5.0, -9.9;-0.1). In addition, patients with 
frequent benzodiazepine use compared with those with less frequent or no use (-8.0, -14.1;-
Figure 5: The figure displays the FSS-9 sum scores at the first health assessment 
(baseline) and the second health assessment when the health assessments are listed 
chronologically per patient. The darkest line represents the FSS-9 sum scores at baseline, 
while the grey spikes mark the changes in the FSS-9 score between baseline and the 
second health assessment if patients completed two or more health assessments. The 
spikes’ endpoints (furthest from the darkest line) demonstrates the FSS-9 sum score at the 
second health assessment. FSS-9: Nine-item Fatigue Severity Scale.  
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1.8), and patients with liver fibrosis or cirrhosis compared with those with a healthy liver 




















































The discussion section begins with a methodological discussion of the papers, followed by a 
summary and a clinical discussion of the main findings.  
 
Methodological discussion of the papers 
 
The measurement errors are usually classified as either random or systematic errors [119]. 
Random errors cause an unknown and unpredictable condition on one measurement, while 
systematic errors always affect all measurements with the same amount or by the same 
proportion. The random errors are considerably reduced and tended towards zero with high 
precision when using national register databases with thousands of participants. For the 
INTRO-HCV cohort, the risk of random errors affecting the results is somewhat higher than 
the national register data due to a smaller study sample and self-reported data concerning 
fatigue questionnaire or sociodemographic and clinical conditions. 
 
Systematic errors (bias) patterns affect all study’s measurements independent of its sample 
size [119]. These errors skew the results towards a specific direction from the true values, 
affecting the study’s validity. The validity is expressed by internal validity and external 
validity. The internal validity expresses how well the results fit the included patients in the 
study, while the external validity shows the results’ generalizability to other populations. Key 
violations of internal validity are confounding, selection bias, and information bias, which 




Selection bias expresses the selection of individuals, groups, or data for analysis, not ensuring 
the population’s representativeness that was intended to be analyzed. In paper I-III using the 
NorPD and SPDR, we received practically all information about dispensed substances in the 
two countries, eliminating the risk of recall biases entirely. Furthermore, we identified 
patients who received OAT opioids from pharmacies. These patients were dispensed at least 
one OAT opioid (paper I-II) or at least one DDD per day (paper III) per calendar year from 
the pharmacies during the study period. These inclusion criteria could introduce selection 
bias. Approximately 10 % of the Norwegian OAT patients and 40 % of the Swedish OAT 
patients received OAT opioids from other health services than pharmacies, which were not 
linked to the databases’ dispensations [34, 109]. These patients were assumed to receive the 
OAT opioids from specialized addiction outpatient clinics and were missed in our studies. 
One could assume that these patients were more frequently followed up in the outpatient 
clinics by health professionals who work daily with patients with substance dependences. 
Close follow-ups by professionals with expertise in addiction medicine could limit potentially 
addictive substances dispensing compared with patients receiving OAT medications by 
pharmacies, contributing to an overestimation of dispensation rates and dosages in papers I-
III.  
 
Moreover, methadone has two medical indications in Norway and Sweden: OAT [120, 121] 
and pain [122, 123]. In papers I and II, we excluded patients receiving methadone due to pain 
by identifying those who only are dispensed methadone tablets (usually for palliative care) 
without any dispensation of methadone mixture from January 1, 2004, to December 31, 2017. 
According to the national OAT guidelines, methadone mixture is the first-hand choice when 
choosing methadone as an OAT opioid in Norway, indicating that all OAT patients who used 
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methadone have at any time received methadone mixture. This gave us a reasonable 
opportunity to exclude those only receiving methadone tablets. In addition, to ensure 
including most OAT patients and not palliative care patients receiving OAT opioids, we also 
used reimbursement codes for palliative care to exclude non-OAT patients during the study 
period. Nevertheless, non-OAT patients with pain who were dispensed methadone mixture as 
a pain killer on other medical indications than palliative care or were switched from mixture 
to tablets formulation could still be categorized as OAT patients using these criteria. Thus, we 
could not be entirely sure that patients using methadone on other medical indications than 
OAT were not classified as OAT patients.  
 
Furthermore, in paper III, we dealt with the inclusion criteria using the mean defined daily 
dosages. We included patients who exceeded the threshold on one mean DDD of dispensed 
OAT opioids per day during a calendar year, independent of which OAT opioid dispensed, 
corresponding to a mean daily dosage of at least 8 mg buprenorphine/buprenorphine-
naloxone, 25 mg methadone, or 15 mg levomethadone [108]. According to the World Health 
Organization’s standard, the recommended mean dosage of OAT opioids was 18 mg 
buprenorphine and 90 mg methadone [25], a substantially higher dosage than the present 
study’s threshold value. However, patients received OAT opioids on other medical indication, 
e.g., for palliative care or acute medical conditions, rarely reach a dispensed mean dosage per 
calendar year above the defined threshold. Nevertheless, with this in mind, we tried to balance 
the criteria by not including too many patients with pain as an indication (if too low cut-off 
value) and being aware of excluded OAT patients using a low-dosage OAT opioid (if too high 
cut-off value). Still, one could assume that our results were less generalizable to patients using 
a low dosage of an OAT opioid than those using a dosage above the threshold. We have 

























Figure 6: The figure displays a graph of the expected distribution of patients who were 
dispensed OAT opioids for OAT and other medical indications. We assumed that OAT 
patients are more likely to be dispensed OAT opioids in doses above mean one DDD daily 
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Another source for bias is that the NorPD and SPDR did not receive information about 
dispensed substances from hospitals, prisons, and outpatient clinics underlying hospitals. This 
could limit these papers’ internal validity, considering that SUD patients, including OAT 
patients, are occasionally incarcerated [124, 125], followed up in OAT outpatients clinics, or 
hospitalized [126-129]. 
 
We reached the majority of OAT patients in Bergen and Stavanger by the inclusion criteria in 
paper IV [1]. However, only a third of patients in the INTRO-HCV cohort completed two or 
more health assessments within the study period. One could assume that those with the most 
interest in being followed up met for health assessments, while patients with delayed follow-
up or drop-outs could present findings that were not captured by our results. The reasons for 
delayed follow-up and drop-outs could be multifactorial, involving substance intoxication, 
substance withdrawals, severe anxiety, hospitalizations, moving from the OAT outpatient 
clinics to pharmacies, etc. For these cases, a substantial change in the sociodemographic and 
clinical conditions not capturing could contribute to selection bias affecting the longitudinal 
fatigue analyses’ results. Another bias was patient and system delays and capacity challenges 
in the outpatient clinics that could postpone the health assessments. During the year 2020, 
reorganizations of the OAT medication delivery model due to the COVID-19 pandemic 
delayed some health assessments. In this period, the OAT opioids were provided to patients 
by home deliveries rather than consultations in the OAT outpatient clinics. These delivery 
changes reduced the capacity to conduct the annual health assessments and recruit patients to 
the INTRO-HCV cohort. However, when comparing patients with two or more health 
assessments with those with one or more health assessments at baseline, substantial changes 
in sociodemographic and clinical factors, including substance use, were not found.  
 
Moreover, we expected missing values in analysis variables in paper IV when collecting data 
of patients with a historically high risk of loss-to-follow-ups. Interestingly, the predictors 
were rarely affected by missing values, representing only 2.6 % of the variables. We handled 
missing values using the Expectation-Maximization imputation to optimize the data set before 
running linear mixed models. The Expectation-Maximization algorithm for imputing data is 
iteratively performing maximum likelihood estimation in latent variables [130, 131]. The 
method is recommended to estimate missing values for a linear mixed model [113]. By using 
the Expectation-Maximization imputation, we introduced bias by replacing missing values 
with estimated values. However, these imputed values represented a relatively small number 
of the total predictor values in the data set and were calculated using a recommended imputed 
method for mixed models. Nevertheless, to be transparent about this bias’s impact, we could 
present the linear mixed model analysis with and without imputed data and adjust and 
unadjusted/crude estimates of the models’ predictors in the paper. Furthermore, we simplified 
the linear mixed models in paper IV by not running the analysis with time-varying predictor 
variables. This could theoretically introduce bias if they did not capture changes in predictors 
between the annual health assessments. However, we ran separate analyses with the predictors 
as the outcome variable and time between the annual health assessments as the independent 
variable in the linear mixed models. When running these analyses, we did not find any 
clinically significant changes in the predictor variables from baseline to the following health 







Information bias is a systematic difference between the truths and results that were presented. 
The differences may be related to data collection, recall, recording, and handling data in the 
study. Using the NorPD and SPDR, the bias in handling data, including dealing with missing 
values, was practically eliminated. On the other hand, the NorPD and SPDR have a few 
sociodemographic and clinical variables, giving us limited options to adjust for all relevant 
factors. Unlike the SPDR, the NorPD contains information on month and year of death, and 
reimbursement codes for chronic diseases, making us able to exclude patients who were not 
likely to receive OAT in papers I and II. Moreover, the two data sources only receive 
information on dispensed substances, which prevented us from knowing whether substances 
were taken as prescribed. The substances could be given to other patients, or for some cases, 
sold on the illicit market in order to get income [132, 133]. Furthermore, the papers could not 
accurately identify whether patients co-used potentially addictive substances and OAT 
opioids concomitantly. Patients could be classified as co-users of substances for a calendar 
year, although OAT opioid dispensations were terminated when the other potentially 
addictive substances were dispensed. 
 
Furthermore, the paper IV variables were collected by drawing blood samples, measuring 
liver stiffness by transient elastography, and self-reporting sociodemographic and substance 
use variables. Transient elastography can introduce systematic measurement errors for obese 
patients and those who have eaten during the hours before the measurement. Furthermore, 
self-reporting itself, e.g., reporting substance use for the past 12 months, could introduce 
recall bias [134]. Short and long-term benzodiazepine and z-hypnotic use, representing 40 % 
of the study sample, could impair cognition by reducing nonverbal memory and not recalling 
specific details of new information [135]. Considering this, we could improve the validity 
between self-reporting and laboratory variables, e.g., by verifying self-reported substance use 
with observed urine samples. However, drawing observed urine samples could create a barrier 
to recruiting and following up, giving us probably fewer patients included. Moreover, self-
reporting could also introduce socially-desirability bias related to sensitive topics, such as 
non-dispensed substance use and debt difficulties [136-138]. This bias could lead to that the 
patients report as regards what is socially acceptable to respond. Consequently, debt 
difficulties and non-dispensed substance use could be underreported, especially for OAT 
patients where non-dispensed substance use could contribute to stricter follow-ups and more 
frequently observed OAT opioid intakes. To partly avoid the risk of socially desirable 
reporting bias, we handled some of the information confidentially for clinicians and ensured 
that research nurses were not involved in OAT-related decisions. However, we could not 
entirely exclude this bias when using self-reported data.  
 
Moreover, we measured liver stiffness using the gold standard, transient elastography. The 
measurements were performed using measuring equipment facilitated for patients with body 
mass index below 30.0 kg/m2. A proportion of 16.2 % of patients exceeded this threshold 
(data not shown in the paper), introducing a systematic measuring error for these liver 
stiffness measurements. This could impact the association between fatigue and liver stiffness. 
 
The nine-item Fatigue Severity Scale is a well-known self-reporting questionnaire to measure 
fatigue in the general population and patients with chronic diseases [74, 75, 79, 83, 84, 86, 
89]. However, the questionnaire items’ comprehension regarding item wording, item format, 
item context, and scale ratings could impact how the items were answered, introducing 
information bias [139]. For patients with SUDs, we addressed some common challenges. 
First, overlapping items made it challenging for patients to understand the nuances between 
the items thoroughly, which significantly impacted patients who were intoxicated by 
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substances or gone through substance withdrawals. Second, in some formulations, the patients 
were tempted to respond to the items with what made general sense rather than personally 
impacting them. For example, item seven, “Fatigue interferes with carrying out certain duties 
and responsibilities patients with SUDs,” which, in some cases, were responded as “of course, 
getting tired interferes with duties and responsibilities.” These patients tended to respond with 
a high rather than low score on the items. Third, most SUD patients included were 
unemployed, which were not considered in one item (item nine), concerning their daily 
functioning on the job. This item could perform answers not fully capture the purpose of the 
item. Fourth, scale rating could impact how patients respond to an item. Scales including 
negative numbers (-5 to +5) have shown to not obtain a similar answer than a corresponding 
scale with only positive numbers (0 to 10), considering that the difference between the highest 
and lowest values in the two scales was equal [140]. How this influences the FSS-9 sum score 
was not evaluated but could impact the responses on the FSS-9. Fifth, in a previous study, the 
FSS-9 was translated to Norwegian from the US-English version with a naïve Norwegian 
speaking translator and a qualified naïve US-English translator [74]. However, a high-quality 
translation lacked, according to Wild, D. et al. [141]. Nevertheless, we have recently validated 




Confounding is a variable that influences both the outcome and exposure variables, resulting 
in a spurious association [119]. In the pharmacoepidemiological studies involving the NorPD 
and SPDR (paper I-III), the exposure variable is often a dispensed substance linked to the 
outcome variable by a medical indication. This introduces the risk of “confounding by 
indication” [143]. For OAT patients with a consistently high prevalence of mental diseases 
and polysubstance use, the potential for confounding between the exposure and outcome in 
studies is likely. Using only the NorPD and SPDR, we could not sufficiently differentiate 
between the medical indications for dispensing potentially addictive substances. For example, 
being dispensed benzodiazepines could be dispensed for approved short-term medical 
indications, such as jet-lag, panic attacks, sleeping disorders, agents to curb status epilepticus, 
and short-term treatment of alcohol withdrawal. However, in several cases, the number of 
dispensations indicated long-term use of some substances. Although long-term use of 
benzodiazepines is discouraged, in some cases, it may help treat chronic mental disorders or 
replace non-dispensed benzodiazepine use with dispensed benzodiazepine use for patients 
undergoing detoxification. Furthermore, we also found a strong association between being 
dispensed a gabapentinoid and a benzodiazepine or z-hypnotic, which could be co-dispensed 
for withdrawal treatment, anxiety disorder, or neuropathic pain. These examples illustrate a 
spectrum of potential underlying causes (confounders) for dispensing, which could not be 
addressed using information from the NorPD and SPDR. Considering this, we were unable to 
conclude with causality in paper I-III, and the presented indications for dispensing and their 
associations should therefore be interpreted in caution. The figure below illustrates some 








































Fatigue is a subjective health complaint that is considerably affected by various medical and 
psychosocial factors. We dealt with confounding by surveying sociodemographic and clinical 
factors, including non-dispensed potentially addictive substances in the annual health 
assessments that we thought influenced the patients’ fatigue level. We illustrate the potential 













Figure 7: The figure displays a biomedical model on potential medical disorders/conditions 
(confounders) that may explain the associations between SUD patients and dispensed substances. 























































The results pointed out a higher fatigue level in the SUD population than a general Norwegian 
population, and being on the level for other severe chronic diseases – such as HCV infection 
[79-81], Parkinson’s disease [82, 83], multiple sclerosis [84-86], or stroke onset [87-89]. 
Despite adjusting for the sociodemographic and clinical variables, the fatigue level and its 
predictors were unlikely to fully cover all causes of the populations’ high fatigue level. Most 
notably, the frequent use of benzodiazepines increased the fatigue sum score by five points, 
and the frequent use of stimulants decreased the score by five points compared with those 
with less frequent or no use of these substances. Other underlying factors could, therefore, 
explain more of the fatigue level presented. For example, using benzodiazepines frequently 
could be confounded by depression (mental disorder), giving them higher fatigue level, while 
criminality and violence related to difficulties in repaying illegal substance debt, broken 
relationship to family and friends, and poor living condition could usually increase the fatigue 
level in some cases (Figure 9). Other underlying medical and psychosocial aspects – such as 
intoxication, withdrawal, and physical diseases – could also confound the FSS-9 score at the 
Figure 8: The figure displays direct acyclic graphs of potential relationship between 


























moment when surveying fatigue. However, adjusting for these complex individual events was 
challenging. Thus, the selection of variables in models without concern for causal 
interferences could give higher risks of inappropriate conclusions without transparently 
showing potential short-comings. Paper IV has presented this transparently in contrast to 
















Assessing type I and type II errors 
 
Avoiding false associations and differences between exposure and outcome is of interest in all 
research. To handle this, we differentiate between type I errors revolving around false positive 
values (rejection of a true null hypothesis) and type II errors expressing false negative values 
of tests (rejection of a false null hypothesis) [144]. Type I and II errors can be dealt with in 
different ways; reduce alpha if many tests, ensure adequate sample size and statistical power, 
assess the precision of confidence intervals etc. Although the potential factors affecting type I 
and II errors in this dissertation have been partly discussed in the previous sections, we point 
out some crucial errors in the following paragraphs.  
 
Despite high power with large populations in paper I-III, type II errors could be introduced. 
The current inclusion criteria of being dispensed an OAT opioid (paper I-II) or achieving the 
threshold of mean one DDD per day of dispensed OAT opioids per calendar year (paper III) 
to be included, could include patients who not were OAT patients. These non-OAT patients 
could introduce type II errors by having a different prevalence of disorders and dispensing 
patterns of dispensed potentially addictive substances than OAT patients. For example, a third 
of the SUD population had comorbid SUDs and ADHD, which was substantially higher than 
expected for the general population and non-OAT patients dispensing methadone for pain. 
This could introduce type II errors by impacting the dispensation rates of ADHD medication 
in the study sample and reducing the generalizability and transferability to other SUD 
populations.  
 
In paper IV, the linear mixed model analyses were more prone to type I errors. With 20-21 
predictors used for baseline and time trend assessments, we estimated the risk of one estimate 
distributed outside a 2.5-97.5 % distribution when drawn from a random sample (type I error) 
to be 87 %. Considering this, we introduced Bonferroni corrected p-values as a conservative 
method to handle the risk of error, leading to the number of significant predictors declined 
from six to two: frequent use of benzodiazepines or stimulants compared with less frequent or 
no use of these substances.  
Figure 9: The figure displays potential confounder (threats and violence) between 












Furthermore, in paper IV, the predictors of being infected with the HIV or hepatitis B virus 
infections presented wide confidence intervals in the linear mixed model analyses. This 
corresponded to a low prevalence of these diseases in the SUD population, reducing the 
analysis’s statistical power, and gave us potential false-negative associations (type II errors). 
However, previous studies investigating fatigue in these populations have shown an 
association between these diseases and fatigue [145-147]. The similar potential false-negative 
association with fatigue could also be the case for severe kidney diseases measured by 
estimated glomerulus filtration rates, considering that few patients had severe disease 
associated with substantial fatigue symptoms in this study [148-150]. The longitudinal 
analyses (slope estimates) could also introduce type II errors because only a third had more 
than one measuring point for fatigue. Loss of patients reduced the statistical power, which 




Bradford Hill suggested nine criteria to evaluate whether the associations were causal in 
epidemiological studies [151]. The criteria are the strength (effect size), consistency, 
specificity of the association, temporality (i.e., the causal predictor preceding the outcome), 
biological gradient (dose-response relationship), plausibility, coherence with current 
knowledge, and experiment and analogous examples. In the following, we discuss our results 
according to the criteria illustrated by examples from the papers.   
 
Paper I-III. Using the NorPD and SPDR, the strength was reached by including a high 
proportion of OAT patients, giving us high precision and statistical power for most analyses. 
However, a weakness could be the cases in some subgroup analyses, e.g., patients who were 
dispensed an ADHD medication where the number of patients did not count more than 349 in 
2017 (paper II). The consistency criterion was sufficiently met in all the analyses. This could 
be illustrated by the fact that the predictors for being dispensed a potentially addictive 
substance were maintained from one calendar year to another. For example, being dispensed a 
gabapentinoid or being female rather than male reached unchanged odds for being dispensed a 
benzodiazepine per calendar year throughout the study period 2013-2017. Similar consistency 
was also found in other analyses. 
 
Furthermore, it was more challenging to evaluate the specificity of the associations. A broad 
specter of underlying medical diseases/conditions for being dispensed a potentially addictive 
substance could impact the predictors’ associations with being dispensed a potentially 
addictive substance. For example, some OAT patients were well-functioning by living a life 
with family and work with no other substance dependences than opioids. In these cases, 
benzodiazepine could be dispensed for short-term sleeping disorders for a few days or weeks 
according to the preapproved medical indication. Other OAT patients were polysubstance 
users living on the street with broken family and friend relationships with several 
hospitalizations due to intoxications where long-term use was more likely. The fact that we 
lacked information on comorbidities to study participants and the indication for dispensing 
could make the results less specific. Furthermore, the temporality was weakened. We did not 
consider whether some predictors (e.g., being dispensed a potentially addictive substance) had 
preceded before or after the outcome. For example, being dispensed a gabapentinoid 
(exposure) could be dispensed after patients were dispensed a benzodiazepine or z-hypnotic 




The dose-response relationship criterion evaluates whether a greater exposure leads to a 
greater/lower incidence of the effect. A potential age gradient was found regarding patients 
above 56 years of age who had an increased odds of being dispensed a benzodiazepine or z-
hypnotic compared with those below 25 years of age (paper I). Similarly, a potential age 
gradient was also found for patients above 56 years of age who had a reduced odds for being 
dispensed an ADHD medication compared with those were below 25 years of age. Other 
predictors were not created for evaluating dose-response relationships. Moreover, due to other 
studies investigating the underlying reasons for dispensed potentially addictive substances 
were lacked in the literature, the plausibility evaluation was also challenging. However, our 
results were substantially in line with what was clinically expected. For example, we found 
that being dispensed one potentially addictive substance, e.g., benzodiazepines, increased the 
odds of being dispensed one of the remaining potentially addictive substances, e.g., 
gabapentinoids or non-OAT opioids, according to paper I. This finding could be explained by 
patients’ comorbidities, e.g., anxiety disorders and substance withdrawals, making more 
substance dispensations medically indicated [62]. Additionally, patients using methadone as 
an OAT opioid were associated with being dispensed a benzodiazepine or z-hypnotic, or a 
gabapentinoid, contrary to what were shown for those using buprenorphine. One potential 
plausible cause of this was that patients on methadone could be more comorbid than patients 
on buprenorphine, so that dispensing on benzodiazepines, z-hypnotics, or gabapentinoids was 
more likely.  
 
Furthermore, although little is known about the associations with potentially addictive 
substances in the SUD population, the results were substantially coherent with existing 
clinical knowledge. On the aspect of analogy, two studies evaluating mortality in the OAT 
population in the U.K. and Sweden showed that the dispensation rates of benzodiazepines and 
gabapentinoids were in line with our results [28, 29]. However, the studies did not evaluate 
the same associations for being dispensed a potentially addictive substance, which gave us not 
analogous examples of similarities to the existing SUD patient literature in line with our 
identified associations.    
 
Paper IV. The OAT cohort also met some of the Bradford Hill criteria. Although the study’s 
strengths were insufficient to conclude with causal associations, the study’s large sample of 
SUD patients gave us sufficient statistical power to point out some associations between 
predictors and fatigue. Moreover, the consistency criterion was partly fulfilled, although 
substantial intra-observer reliability between the FSS-9 measurements was found. The 
consistency could be shown by the fact that the comparable predictors went in the same 
direction in the analyses. For example, the non-significant predictors ‘having debt difficulties’ 
and ‘being females rather than males’ went in the same direction as the significant predictor 
‘the frequent use of non-dispensed benzodiazepines compared with less frequent or no use,’ 
consistent with what was expected clinically. In addition, the non-significant ‘frequent use of 
non-dispensed benzodiazepines compared with less frequent or no use’ reduced fatigue over 
time (time trend, slope), which was expected since persistent benzodiazepine use could lead 
to less fatigue induced by increasing substance tolerance.  
 
The specificity criterion was partly met by including a specter of sociodemographic and 
clinical predictors describing the SUD population. Although several predictors impacted 
fatigue, they did not thoroughly explain the high fatigue score in the population compared 
with the general population. For example, the frequent use of benzodiazepines only increased 
the fatigue score by five points. This could indicate that other underlying factors than those 
were assessed impact fatigue in this study. Moreover, we could not be sure that the exposure 
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variables preceded the fatigue level (temporality). Although most predictor variables were 
substantially stable over time, some predictors could be affected by being collected either 
after the FSS-9 measurement. For example, predictors involving blood samples could be 
drawn after the outcome had occurred. This could be in conflict with the temporality criterion 
to some degree. Moreover, the dose-response relationship was found for persistent liver 
fibrosis or cirrhosis compared with a healthy liver, contributing to less fatigue. Other dose-
response relationships between the fatigue level and the predictors (age, liver stiffness 
(transient elastography and APRI), hemoglobin, estimated glomerulus filtration rate, and C-
reactive protein), were not found in the SUD population.  
 
Moreover, since fatigue has not been studied well in the SUD population, the plausibility and 
coherence evaluations were challenging. Although our study’s results were partly in line with 
what was clinically expected, further research was needed to assess the plausibility before 
transferring to other SUD populations. For example, contrary to other studies [79-81, 145, 
152], we did not estimate more fatigue among patients infected with HCV and HIV 
infections. Unstable housing situations or injecting substance use did not affect fatigue, 
although clinical experience suggest that this may be the case. Furthermore, analogous 
examples of fatigue measurements for the SUD population do not exist as far as we know. 
However, similar studies evaluating fatigue among patients with chronic diseases have shown 
a high fatigue level compared with the general population [74, 81-86, 89], corresponding to 
our SUD population’s result. 
 
External validity and transferability  
 
Exploring the extent of dispensing potentially addictive substances in a national OAT 
population is most relevant for health professionals and national health governments working 
with OAT patients. Before generalizing our results to other OAT populations, it is important 
to interpret the results according to regulations and organizations of the OAT in Norway and 
Sweden. It is also important to underline that paper III included only patients receiving more 
than one mean DDD daily of an OAT opioid per calendar year. This made our results less 
transferable to OAT patients who were dispensed the lowest dosages of OAT opioids. 
Furthermore, changes in dispensing rates have occurred from 2013-2017 to 2021. For 
example, the stricter dispensation practice of pregabalin introduced in June/July 2018 by the 
Norwegian Medicine Agencies and the Swedish Medical Products Agency has probably 
reduced the dispensation rate for pregabalin during the last three years. One can also assume 
that the dispensation rates of lisdexamphetamine have increased from 2017 to 2021, 
considering facilitation in the pre-approved reimbursement of lisdexamphetamine introduced 
in October 2018. 
 
As far as we know, research on fatigue for SUD patients, mainly OAT patients, has not earlier 
been studied. However, it is essential to keep in mind that 18 % of the SUD patients in the 
OAT cohort do not receive OAT as the treatment approach. These patients were included 
because they received low-threshold primary health care frequently for substance-related 
harms, thus representing many of the same health conditions as OAT patients. This can 
increase the generalizability of our results to other SUD populations and those with similar 
comorbidities in high-cost countries with cultural and health system similarities with Norway. 
Moreover, this study was also mainly aimed at patients who were marginalized with extensive 
substance use. This can make the study less transferable to OAT and SUD patients with high 
daily functioning, those with only one mild to moderate substance dependence, or patients 




Neutrality and interests  
 
Concerning neutrality, all papers in this thesis have strengths. Using national register data, we 
analyzed data having high completeness and precision compared with data collected by self-
reporting. Data were collected with low cost and no use of clinical health professional 
resources and were automatically collected from the pharmacies in Norway and Sweden. For 
the INTRO-HCV cohort, all data were collected by research nurses employed by our research 
group. The researchers were not involved in patient consultations when collecting data. We 
could not altogether remove the chance for research nurses had affected the participants’ 
answers during the health assessments. However, the data collection information was 
presented as neutral as possible from the researchers with no interest in influencing the results 
in a particular direction. 
 
Concerning interests, all authors and research nurses in these studies were employed and 
funded by governmental funding, including the University of Bergen, Haukeland University 
Hospital, the Norwegian Institute of Public Health, the University of Oslo, and/or the 
Research Council of Norway. No authors had any conflicting interests, including financial 
interests by receiving salary and remunerations from organizations or the pharmaceutical 
industry related to these studies. The funders were independent of the studies and were not 
involved in data collecting, analyzing, and publishing.  
 
Proper reporting of data is essential. According to the Strengthening The Reporting of 
Observational Studies in Epidemiology (STROBE) checklist [153], we addressed the reported 
data for all the published papers to ensure accuracy and completeness of reporting the 




Collecting large data of all dispensations of substances from Norwegian and Swedish patients 
who were dispensed OAT opioids and the INTRO-HCV cohort have some ethical 
considerations. First, the data were stored on a protected research server with access only for 
pre-approved users involved in the research project. The researchers were approved by the 
Regional Ethic Committee, REC Vest, before getting access to the data. Second, data from 
register research are exempted from obtaining informed consent from patients. Data were 
therefore delivered anonymously with identification keys for each patient. There were not at 
any time possible to expose the identity of the included patients. However, using local 
geographical knowledge of the individuals based on region, gender, birth year, dispensed 
substances, etc., one can theoretically be able to identify patients. However, it is improbable 
that this could happen. Third, all included patients in the INTRO-HCV cohort had obtained 
informed consent for using the collected data on research before being enrolled in the study. 
The collected data were personally identifiable and were stored on a protected research server 
with user-controlled accesses. Fourth, all HCV-infected participants included in the INTRO-
HCV cohort were offered HCV treatment with direct-acting antiviral agents. These 
participants were followed up closely regarding HCV treatment adherence and potential 
treatment complications. However, the harm of participating in the INTRO-HCV cohort could 
be the time spent conducting an annual health assessment. Some participants spent several 
consultations before completing. Overall, data, including tables and figures with variables 




Clinical discussion of the results  
 
Extensive use of potentially addictive substances among patients in OAT 
 
Nearly three out of five Norwegian and Swedish patients were dispensed a potentially 
addictive substance per calendar year during 2015-2017. In Norway, 46 % were dispensed a 
benzodiazepine and 14 % a z-hypnotic in 2017, of which 42 % (absolute value) received three 
or more dispensations of either a benzodiazepine or z-hypnotic during the same calendar year. 
In Sweden, 15 % were dispensed a benzodiazepine and 26 % a z-hypnotic in 2017. Being 
dispensed a benzodiazepine or z-hypnotic was associated with females rather than males, 
using methadone compared with buprenorphine as OAT opioids, and being dispensed a 
gabapentinoid or non-OAT opioid in Norway in 2017. The amount of dispensed 
benzodiazepines tended to be slightly reduced during 2015-2017 in both countries. The 
proportion of patients who were dispensed a gabapentinoid increased slightly by 2 % from 
2015 to 2017 in Norway and by 1 % in Sweden. Further, the dispensation rate of pregabalin 
was worryingly twice as high as for gabapentin. Moreover, the dispensation rate of weak 
opioids was twice as high as for the strong opioids in Norway in 2017, which was the 
opposite of what was seen between strong and weak opioids in Sweden. Furthermore, we 
found a slight increase in dispensation rates of centrally acting stimulants from 3 % (2015) to 
4 % (2017) in Norway and from 17 % (2015) to 18 % (2017) in Sweden, and for four out of 
five ADHD medications, the mean dosage exceeded the recommendations [114-118]. In 
Norway, being dispensed an ADHD medication was associated with patients below 25 years 
of age compared with those above 56 years of age, being dispensed buprenorphine rather than 
methadone as an OAT opioid, and being dispensed non-OAT opioids. Moreover, in Bergen 
and Stavanger, 39 % of SUD patients reported frequent use of non-dispensed benzodiazepines 
or z-hypnotics during the past 12 months prior to the first health assessment. A similar 
proportion for cannabis use was 52 %, stimulant use 29 %, alcohol use 26 %, and opioids use 
16 %. In these two cities, the FSS-9 sum score was 43 (SD: 16) at baseline. The sum score 
was higher for females than males, those with frequent use of benzodiazepines compared with 
those with less frequent or no use of these substances, and patients having debt difficulties 
compared with not having these difficulties at baseline. In addition, patients with frequent use 
of stimulant substances were associated with lower FSS-9 sum scores than those with less 
frequent or no use. Furthermore, patients with frequent use of benzodiazepines compared with 
those with less frequent or no use over time and patients with liver fibrosis or cirrhosis 
measured by transient elastography compared with those with healthy liver over time were 
associated with lower the FSS-9 sum score per year from baseline. These trend effects were 
less likely to be clinically significant. Group differences in fatigue between patients using 
buprenorphine and methadone as OAT opioids in sociodemographic and clinical factors were 
also identified.  
 
The Norwegian and Swedish dispensation rates of benzodiazepines and z-hypnotics were 
substantially in line with European and North-American countries’ rates, although some inter-
country differences existed between countries [28, 29, 154-156]. When comparing the 
dispensation rates for benzodiazepines and z-hypnotics among OAT patients in Sweden in 
2005-2015 with our findings for 2015-2017, the rates seemed to decrease [28]. In contrast, the 
Norwegian dispensation rates of benzodiazepines and z-hypnotics increased compared with 
the dispensation rates in 2005 [154]. This could correspond to the change in criteria to 
granting OAT in 2010, making it possible for patients with polysubstance use to receive OAT 
[37]. Furthermore, comparing the use of non-dispensed benzodiazepines and z-hypnotics in 
Bergen and Stavanger, Norway, with other European countries, the prevalence was also 
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substantially equal [31]. The EMCDDA examining the non-dispensed benzodiazepine use 
among high-risk opioid users admitted to treatment facilities in some European countries 
detected that the prevalence of benzodiazepine use varied considerably from one country to 
another, with a range from 70 % in Germany down to 45 % in France [31], with a tendency 
towards an increased use with the length of stay in OAT [157]. When including all SUD 
patients using benzodiazepines in Bergen and Stavanger, they ranked between the prevalence 
of benzodiazepine use in France and Germany but just below France when we only assessed 
the prevalence of frequent users of the substances. However, compared with all other 
European countries, France has the highest coverage of OAT among opioid dependence 
(approximately 80 %), alluding to more polysubstance users using non-dispensed 
benzodiazepines compared with the SUD patients in Bergen and Stavanger [22]. This could 
explain the lower prevalence in Bergen and Stavanger compared with France. However, our 
findings only represented non-dispensed benzodiazepine and z-hypnotic use from two cities 
in Norway, and intra-country variations in non-dispensed benzodiazepine use were therefore 
likely.  
 
Not surprisingly, we found a substantially higher proportion of patients who used non-
dispensed benzodiazepines or z-hypnotics (71 %) than those dispensed these substances 
(2017: 50 %) in Norway. When considering the annual national self-reporting survey pointing 
out that half of the Norwegian OAT patients consumed benzodiazepines the four weeks prior 
to the survey [36], our results regarding non-dispensed benzodiazepine or z-hypnotic use were 
expected. Nevertheless, benzodiazepines are discouraged in Norway according to national 
guidelines, signifying that most Norwegian OAT patients did not fulfill the criterion in 
guidelines [37]. In Sweden, the use of non-dispensed potentially addictive substances is 
uncertain; however, dispensed potentially addictive substances reached almost equal rates in 
Sweden as in Norway in 2015-2017, indicating that non-dispensed substance use among 
Swedish OAT patients also is likely. 
 
The mean dosages of dispensed benzodiazepines and z-hypnotics were considerably lower 
during the period 2013-2017 compared with the dispensed mean dosages of these substances 
in 2005 in Norway and an Australian cross-sectional study examining benzodiazepine 
dosages among OAT patients [154, 158]. The current Norwegian OAT guidelines 
discouraging benzodiazepine use could play an important role in reducing the dispensed 
dosages [37]. In Sweden, there does not exist comparable data of dispensed mean dosages 
before publishing this study; however, both countries presented similar trends towards 
decreasing mean daily dosages of dispensed benzodiazepines during the study period. 
Nevertheless, the decreasing mean daily dosage of dispensed benzodiazepines could also 
cause increased use of non-dispensed substances for patients with substance dependence. 
Considering that 71 % of SUD patients in Bergen and Stavanger reported non-dispensed 
benzodiazepines use, often high-potency benzodiazepines – such as clonazepam, diazepam, 
alprazolam – likely, the total mean dosage per patient was considerably above the mean daily 
dosages estimated using the NorPD and SPDR. This could affect the consumed dosage trends 
of non-dispensed and dispensed benzodiazepine use in the population without being obtained 
in our studies.   
 
The use of dispensed gabapentinoid was slightly increased in Norway and Sweden in 2015-
2017, corresponding to other countries’ prevalence and trends [29, 159]. Interestingly, 22 % 
of the Swedish OAT patients were dispensed a gabapentinoid in 2005-2012, indicating a 
slight reduction in dispensation rate compared with our finding on 19 % in 2017 [28]. For the 
non-dispensed gabapentinoid use, no data were collected in Norway and Sweden; however, 
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other countries showed a diverging prevalence from 18 % to 37 % in different SUD 
populations during the past years [66, 160, 161]. Globally, several worries regarding 
gabapentinoid misuse and dependence have been reported among SUD patients, which for 
2012-2016 had led to 634 published reports of gabapentinoids’ side effects [162]. Some 
reports indicated that opioid dependent patients particularly preferred gabapentinoids due to 
their sedative and euphoric effects when taken alongside opioids [28, 32, 45, 159]. A 
systematic review of gabapentinoid misuse found that gabapentinoids often were sold and 
bought on the illegal substance market [32], exemplified by 70 % of 30 U.K. heroin users 
who reported gabapentinoid use [163]. Interviews concerning gabapentinoid misuse presented 
that they often were co-administrated with other sedative substances to enhance their effects, 
being a barrier to access of other substances, synergism with other substances, or to self-treat 
withdrawal or pain [46, 164-167]. From June 1, 2018, the Norwegian Medicines Agency 
decided to put pregabalin under stricter dispensing regulation [49], and Sweden introduced 
similar regulation on July 24, 2018 [50]. Both regulations can reduce pregabalin’s 
dispensation rate among SUD patients in the future, even though it might lead to more non-
dispensed gabapentinoid use. Considering these worries, dispensing gabapentinoid itself and 
its co-dispensing involving other potentially addictive substances among SUD patients should 
be thoroughly and individually assessed before dispensing, especially among OAT patients 
with a particular risk of fatal and non-fatal overdose when combining. Further monitoring of 
dispensed and non-dispensed gabapentinoid use is needed to understand its benefit and harms, 
in particular the impact on dependence and misuse.    
 
Moreover, a slight increase in OAT patients who were dispensed ADHD medications in 
Norway and Sweden in 2015-2017 was found, corresponding to a slight increase from 
Norway’s prevalence in 2008-2010 [168]. In addition, the dispensation rate of ADHD was 
almost four-fold higher in Sweden than in Norway. In both countries, the dispensation rates 
were higher than those in general Northern countries [169, 170], but still considerably lower 
than the estimated ADHD prevalence for SUD patients in the Northern countries [171]. This 
difference between dispensation rates and the prevalence of ADHD could demonstrate some 
differences in handling ADHD medications between countries. First, there are differences in 
national guidelines for dealing with dispensed ADHD medications in OAT. Besides SUD 
patients initiating ADHD medication in hospitals, the Norwegian guidelines for ADHD 
require at least three months abstinence of non-dispensed potentially addictive substances 
prior to ADHD medication were initiated for SUD patients who are followed up at outpatient 
clinics [59]. This criterion for ADHD medication is not noted in the national 
recommendations for ADHD treatment in Sweden, which could explain a higher dispensation 
rate of ADHD medication in Sweden than in Norway [172]. Otherwise, the three-month 
criterion was also not mentioned in a consensus report involving experts’ advice from several 
European countries [58]. However, the experts did not reach any consensus about whether 
patients should abstain or reduce/recover their substance use before starting dispensing 
centrally acting stimulants. Second, the criteria for granting OAT are stricter in Sweden than 
Norway, e.g., by having a higher threshold for accepting non-dispensed substances. 
Considering this, one can also assume that the differences in dispensation rates were 
addressed more polysubstance users in OAT in Norway than Sweden, so dispensed ADHD 
medication was less justifiable in the former country.  
 
The mean daily dosage for four out of five dispensed ADHD medications exceeded 
recommendations [114-118]. Some evidence suggests that SUD patients who received ADHD 
medication should be dispensed dosages equal to or higher than the recommendations [173, 
174]. Although high-dosage ADHD medication itself did not show more effect on patients’ 
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ADHD symptoms, they may increase the adherence to the treatment among SUD patients. 
However, a Norwegian study found that half of the OAT patients with comorbid ADHD 
initiating ADHD medication discontinued it during two years [175]. The reasons were 
relapsing to non-dispensed substance use, poor perceived effect, substance craving, adverse 
effects, and failure to meet the driver’s license regulation. For OAT patients with ADHD 
using non-dispensed substances in doses that considerably exceed the dispensed ADHD 
medication dosages, one could also assume that the substance was terminated because it did 
not meet the patient’s expectations.    
 
Moreover, nearly 30 % of the SUD patients in Bergen and Stavanger self-reported at least 
weekly use of non-dispensed amphetamines or cocaine over the past 12 months. This was 
twice as high as reported in the annual national self-reported assessments in Norway [36, 
109]. On the other hand, the result was lower than reported among 60 OAT patients in 
Finland but within the range of stimulant use in some U.S. regions [66, 176]. The higher 
availability of non-dispensed stimulant substances in the Bergen and Stavanger than 
nationwide may be one of several substantial reasons for this finding. However, it does not 
seem that patients with ADHD are more likely to use non-dispensed stimulants than those 
without ADHD [177], giving less evidence for the fact that low dispensation rate of ADHD 
medication nationwide can address a high use of non-dispensed stimulant substances. 
However, patients with non-dispensed stimulant substance use are often comorbid, and 
depression, psychosis, suicide attempts, worsening psychosocial functioning, and 
hospitalizations are frequently reported [178-181]. Therefore, addressing reasons for the high 
prevalence of non-dispensed stimulant use is of interest for further research. 
 
The dispensation rate of weak non-OAT opioids was twice the rate for strong non-OAT 
opioids in Norway, opposed to Sweden’s picture. In Norway, the total dispensation rate of 
weak and strong opioids was 12 % in 2005, representing a slight increase in the proportion of 
OAT patients dispensed non-OAT opioids [51]. The introduction of the Norwegian guidelines 
for OAT in 2010 represented a shift in OAT by not excluding patients with non-dispensed 
substance use. This encompasses patients with polysubstance use preserving more complex 
medical and psychosocial health challenges than those with solely opioid dependence. This 
could address some of the increase in the dispensed non-OAT opioid use from 2015 to 2017. 
On the other hand, we were surprised that weak non-OAT opioids were dispensed to OAT 
patients, in particular, above the dispensation rate for strong non-OAT opioids in Norway. 
When considering the equipotency between opioids, the weak non-OAT opioids have a lower 
opioid-acting effect per tablet, with recommended daily dosages far below dosages needed to 
curb pain for patients who received OAT opioids. For example, patients with acute moderate 
to severe pain usually need 20 % more of their daily OAT opioids to curb pain. For patients 
with a daily dosage of 90 mg methadone, 20 % are equal to approximately 20 mg methadone, 
converting into short- or intermediate-acting opioids as morphine is equal to almost 80 mg 
morphine per day [182]. For weak non-OAT opioids, 80 mg morphine represents 480 mg 
codeine (1.0 mg codeine is almost equal to 0.2 mg morphine) or 800 mg tramadol (1.0 mg 
tramadol is almost equal to 0.1 mg morphine) daily, which are far above the recommendations 
for tramadol or codeine (weak non-OAT opioids) [183, 184]. This example illustrated that 
dispensing weak non-OAT opioids for OAT patients using OAT opioids in recommended 
dosage does not usually meet the dosages needed for great analgesic effects for most patients 
with high opioid tolerance using OAT opioids daily. Still, we wondered why the dispensation 
rate of weak non-OAT opioids was higher than the rate for strong OAT opioids in Norway. 
This could indicate that OAT patients were suboptimal pain treatment and the opioid 




Sixteen percent of SUD patients, mainly OAT patients, used non-dispensed opioids at least 
weekly during the past 12 months. Compared with national self-reported data, the use of non-
dispensed opioids in Bergen and Stavanger was higher than nationwide, stable for the past 
years [36]. Our finding of non-dispensed opioid use was also higher than detected among the 
Finnish OAT patients [66]. Although we did not fully understand why they used non-
dispensed opioids when undergoing OAT, one could assume that suboptimal pain treatment 
or too low OAT opioid dosage could address the use in some cases. Nevertheless, these 
results were uncertain and will need more attention in research before concluding with causal 
relationships. 
 
Patient characteristics associated with dispensed potentially addictive substances 
 
Being dispensed a ‘benzodiazepine or z-hypnotic’ or gabapentinoid was associated with 
females rather than males in Norway, corresponding to results also were seen in the general 
population [185-188]. In addition, we found a strong association between being dispensed a 
benzodiazepine or z-hypnotic and using methadone rather than buprenorphine as an OAT 
opioid. Unlike males, females have a higher prevalence of anxiety disorders and sleeping 
disorders, and they more often seek medical and psychosocial treatment for health challenges 
[189-191]. This could address the higher dispensation rates of ‘benzodiazepine or z-hypnotic’ 
and gabapentinoids among females than males. Furthermore, methadone is a second-hand 
substance in OAT used in many cases who were insufficiently medicated with buprenorphine-
based therapy. Methadone’s full opioid agonistic properties could be feasible for OAT 
patients suffering from underlying painful diseases and patients with severe opioid 
dependence who were inadequately treated by buprenorphine. Thus, one could assume that 
patients using methadone were more comorbid than those on buprenorphine, attributing to 
more dispensed benzodiazepine or z-hypnotic than those using buprenorphine-based 
medication. 
 
The Norwegian OAT patients who were dispensed benzodiazepine or z-hypnotic showed an 
association with being dispensed a gabapentinoid, and vice versa. A similar dispensing pattern 
was also observed in other countries [29, 192]. Although co-users’ underlying reasons are not 
thoroughly understood, the overlapping medical indications for benzodiazepine and 
gabapentinoid dispensing could play an important role in addressing these associations [193]. 
Benzodiazepines and gabapentinoids are both medically indicated for epilepsy and anxiety 
disorder, and gabapentinoids for neuropathic pain [43, 44]. Among SUD patients, the 
prevalence of anxiety disorder is substantially higher than the general population [62], 
contributing to the co-use of benzodiazepines and gabapentinoids could be dispensed in 
several cases. Although co-use may indicate a higher risk of non-fatal and fatal overdose 
death [28, 29], co-dispensing of benzodiazepines/z-hypnotics and gabapentinoids could 
exceptionally be the way to reach a higher functioning level with complex co-occurring 
diseases, e.g., by reducing criminality, treating underlying diseases, and stopping non-
dispensed potentially addictive substance use and injecting substances in some of these cases 
[63]. 
 
The odds of being dispensed an ADHD medication were lower for patients above 56 years of 
age than those below 25 years of age, corresponding to the general population’s findings [170, 
194]. Additionally, being dispensed a ADHD medication was associated with patients who 
were dispensed buprenorphine rather than methadone as an OAT opioid and those who were 
dispensed non-OAT opioids compared with those who were not dispensed non-OAT opioids 
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in 2017. Little is known about why buprenorphine rather than methadone was associated with 
being dispensed ADHD medication; however, previous studies showed that patients on 
methadone were less likely to have ADHD symptoms and had greater dependence severity 
than those on buprenorphine [195-197]. In addition, some other characteristics of patients on 
methadone could contribute to lower ADHD medication rates than those using buprenorphine. 
First, methadone is the second-hand OAT opioid in Norway, probably used on patients having 
more severe opioid dependence and other substance dependence [37]. This could make the 
methadone cases less available to be treated with ADHD medication. Second, sedation is 
more likely for patients using full opioid agonist as methadone than those receiving the partial 
opioid agonist buprenorphine [198], potentially reducing the efficacy, acceptability, and 
tolerability of ADHD medications [58]. Third, according to paper I, more patients on 
methadone were co-dispensed benzodiazepines and z-hypnotics, potentially enabling 
prescribers to withhold the ADHD medication dispensations.  
 
Fatigue among SUD patients 
 
Paper IV is, as far as we know, the first study evaluating fatigue quantitatively for patients 
receiving SUD worldwide. The overall finding was that SUD patients had substantially higher 
fatigue levels than the general population [74], with seven out of 10 patients who presented 
severe fatigue symptoms, defined as at least 40 points on the FSS-9 sum score. Although it 
was considerable intra-individual variations in fatigue over time, the SUD patients’ fatigue 
level at baseline was in line with other chronic diseases evaluated – such as post-stroke 
fatigue [199], myasthenia gravis [200], and HCV infection [80, 152, 201].  
 
Non-dispensed potentially addictive substance impact on fatigue among SUD patients  
 
The frequent use of non-dispensed benzodiazepines was associated with more fatigued than 
less frequent or no use of these substances at baseline, while the fatigue level was associated 
with a slight decrease per year when the frequent use of benzodiazepines was maintained 
from the baseline. We were not surprised that the frequent benzodiazepine use was associated 
with more fatigued; however, the underlying reasons for this are uncertain in this population. 
A report of high-risk opioid users showed that benzodiazepine and opioid users have poorer 
physical and psychological health, more hospitalizations, lower quality of life, and more 
disability than those only using opioids without benzodiazepines [31]. In addition, they are 
significantly more vulnerable to overdose, overdose deaths, and mental disorders – such as 
depression, anxiety disorders, personality disorders, and psychosis [62]. These underlying 
comorbidities and their treatments could also increase fatigue. Thus confound the association 
between patients with frequent use of non-dispensed benzodiazepines and those with less 
frequent or no use of these substances, e.g., by being depressed [72, 202] or using 
antipsychotic agents with sedative properties [203]. However, the frequent use of 
benzodiazepines over time was associated with decreasing fatigue levels, which could be 
related to changes in mental health or higher tolerance to benzodiazepines over time, giving a 
reduced sedative effect. 
 
Moreover, the frequent use of non-dispensed stimulant substances was associated with less 
fatigue than those with less frequent or no use at baseline. This fatigue level was unchanged 
per year from baseline. Lower levels of fatigue for stimulant users could be related to 
stimulant substances’ toxicological properties, including invigorating, euphoria, suppressing 
appetite, and lack of lethargy [56, 57]. However, frequent use of these substances is also well-
documented to facilitate a wide range of harms in health associated with increased fatigue 
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[178, 179]. Reviews examining the health challenges of methamphetamine use indicated a 
higher risk of psychosis, violence, suicidality, depression, criminality, and injecting substance 
use [204, 205]. Considering this, one can assume that the reduced fatigue level could be 
related to stimulant intoxication, suppressing underlying comorbidities associated with higher 
fatigue levels. This could also partly address the considerable intra-individual changes in 
fatigue level presented in Figure 5.  
 
Non-dispensed potentially addictive substance impact on fatigue among OAT patients 
 
The type of OAT opioid used could affect which non-dispensed potentially addictive 
substances, including alcohol and cannabis, were associated with fatigue changes among 
OAT patients. The frequent use of non-dispensed benzodiazepine, which is taken alongside 
methadone, enhances these substances’ sedative properties, probably making patients more 
fatigued than those with less frequent or no non-dispensed benzodiazepine use [31]. 
Compared with patients on methadone, we were surprised that the buprenorphine patients 
with frequent use of non-dispensed benzodiazepines were not associated with more fatigued 
than those on buprenorphine with less frequent or no use of non-dispensed benzodiazepines. 
The reasons are uncertain, although more differences in underlying comorbidities among 
patients with frequent use of benzodiazepines than those with less frequent or no use of 
benzodiazepines could have played a role. As shown earlier in this thesis, patients on 
methadone are likely to suffer from more comorbidities than patients with buprenorphine 
[195-197]. This could also have contributed to using a higher dose of non-dispensed 
benzodiazepines cause more fatigued among patients on methadone than those on 
buprenorphine. However, little is known about why frequent alcohol use was associated with 
less fatigue, and frequent stimulant use was associated with more fatigued than less frequent 
or no use of these substances among patients with buprenorphine. Why not similar findings 
were found for patients using methadone as an OAT opioid is not understood and needs 
further research before drawing causal relationships. The results and their potential reasons 
should, therefore, be interpreted in caution.  
 
No other studies have evaluated fatigue in the OAT population and how the non-dispensed 
potentially addictive substances were associated with fatigue in this population. For these 
OAT patients often having a chaotic life situation, fatigue and its changes could be widely 
affected by individual confounding factors; being affected by substances, going through 
substance withdrawals, quarreling with family and friends, and exposing to treats and 
violence from other substance users, etc. The large intra-individual variations in the FSS-9 
sum score found could support this suggestion. However, one can assume that improving 
medical and psychosocial conditions – such as treating HCV infection, reducing substance 
use, treating underlying mental disorders, and protecting against injecting substance use – will 














This thesis has shown that nearly three out of five OAT patients were dispensed at least one 
potentially addictive substance in Norway and Sweden in 2015-2017, with some inter-country 
differences between substances. Besides four out of five ADHD medications, all mean daily 
dosages of potentially addictive substances assessed were estimated within recommendations. 
The considerable extent of dispensed potentially addictive substances in the OAT population 
compared with the general population could be understood with the high prevalence of mental 
and physical comorbidities in the OAT population. Furthermore, we presented that more than 
half of SUD patients in Bergen and Stavanger used non-dispensed potentially addictive 
substances, including alcohol, more than weekly during the past 12 months before the first 
health assessment. Moreover, the SUD patients in the two cities were more fatigued than the 
general population and on the level with other chronic diseases. The sociodemographic and 
clinical factor associated with the most increase in fatigue was the frequent use of 
benzodiazepines compared with less frequent or no use of these substances. 
 
The dispensation rates of potentially addictive substances varied between Norway and 
Sweden. This could be related to substantial inter-country differences in the organization of 
OAT. In 2010, when Norway introduced the first and current OAT guidelines, non-dispensed 
substance use itself was not a criterion to be excluded from the OAT. In contrast, Sweden has 
a lower threshold to transfer patients to other treatment if OAT patients use non-dispensed 
substance use. This could lead to different OAT populations, with a higher prevalence of 
polysubstance users in Norway than in Sweden, with more dispensed potentially addictive 
substance use in Norway.  
 
Non-dispensed potentially addictive substances were prevalent among OAT patients in 
Bergen and Stavanger, Norway, illustrating by nearly three out of four OAT patients had used 
non-dispensed benzodiazepine during the past 12 months. Not surprisingly, self-reported use 
of non-dispensed substances was substantially higher than the rates of dispensed potentially 
addictive substances in Norway and Sweden. However, the prevalence of non-dispensed 
substances corresponded to the prevalence of non-dispensed substances in other European 
countries. 
 
Moreover, SUD patients in Bergen and Stavanger had high fatigue levels, with significant 
intra-individual changes between the annual health assessments. The underlying factors for 
being fatigued and the intra-individual fluctuations in fatigue were associated with some 
included sociodemographic and clinical factors. However, other factors beyond those 














Consideration for future research 
 
Limited attention has been paid to research on patients with polysubstance dependences in 
OAT, their comorbidities, and the overdose death risk. We lack knowledge on how these 
patients can be reached with OAT and how we best tackle their polysubstance dependences 
when receiving OAT opioids. Polysubstance dependence is also a substantial problem when it 
comes to ADHD medications. Unfortunately, little is known about how ADHD medication 
improves ADHD symptoms among patients with polysubstance dependences with comorbid 
ADHD.  Furthermore, besides OAT, we lack knowledge about how we best protect against 
overdoses and reduce the risk of injecting substance use for patients with non-dispensed 
substance dependences. Can dispensing stimulants and benzodiazepines for dependences for 
these substances recover patients from criminality and diminish contact with dealers so that 
overdoses and injecting substance use are less likely? Finally, more knowledge of subjective 
health complaints – such as fatigue, quality of life, and psychological distress, can be essential 
to evaluate SUD populations, compare SUD populations to other chronic disease populations, 
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- Page 1: Paragraph 2: “In 2017, opioid use dominated those entering specialized
substance treatment, representing 35 % of all first-time entrants” should be replaced
with “In 2017, opioid use dominated among those entering specialized substance
treatment, representing 35 % of all first-time entrants”.
- Page 1: Paragraph 3: “However, whether this change will affect the criteria for
granting OAT is still unknown” should be rewritten to “How this will change the
inclusion criteria for OAT remains unknown”.
- Page 2: Figure 1 legend: “The figure displays the division of commonly used terms in
Addiction Medicine and how these realte to demand for care; “Substance use disorder”,
“Opioid dependence”, and “Opioid agonist therapy” should say “The figure displays the
division of commonly used terms in Addiction Medicine and their relations to demand
for care: “Substance use disorders”, “Opioid dependence”, and “Opioid agonist
therapy”.
- Page 11: Non-OAT opioids: “e.x.: codeine plus paracetamol” should be rewritten to
“e.g.: codeine plus paracetamol.”
- Page 19: “Discontinuing OAT”: “For patients who discontinued OAT, we defined three equal
periods from 180 days prior to the discontinuation date to 90 days” should be rewritten to “For
patients who discontinued OAT, we defined three equal periods from 180 days before to 90
days after the discontinuation date.”
- Page 37: Paragraph 4: “Other OAT patients were polysubstance users living on the street with
broken family and friend relationships with several hospitalizations due to intoxications where
the risk of long-term use was more likely” should be edited to “Other OAT patients were
polysubstance users living on the street with broken family and friend relationships with
several hospitalizations due to intoxications where long-term use was more likely”.
- Page 39: Paragraph 1: “The other predictors measuring dose-response relationships: age, liver
stiffness (transient elastographyand APRI), hemoglobin, estimated glomerulus filtration rate,
and C-reactive protein, a dose-response relationship was not seen in the SUD population”
should be rewritten to “Other dose-response relationships between the fatigue level and the
predictors (age, liver stiffness (transient elastographyand APRI), hemoglobin, estimated
glomerulus filtration rate, and C-reactive protein) were not found in the SUD population.”
- Page 39: paragraph 2: “Unstable housing situations or injecting substance use not affected
fatigue, although they could do se based on clinical experience” should be rewritten to
“Unstable housing situations or injecting substance use did not affect fatigue, although clincial
experience suggest that this may be the case.”
- Page 40: paragrah 4: “The Regional Ethic Committee, REC Vest, approved the users before
data became available” should be rewritten to “The researchers were approved by the
Regional Ethic Committee, REC Vest, before getting access to the data.”
- Page 42, paragraph 3: “In Sweden, there not exists comparable data of dispensed mean
dosages prior to this study (…)” should be rewritten to “In Sweden, there does not exist
comparable data of dispensed mean dosages before publishing this study (…)”
- Page 57: Reference 143: The paper has been published and should be referred as: “Vold JH,
Gjestad R, Aas CF, Meland E, Johansson KA, Fadnes LT: Validation of a three-item
Fatigue Severity Scale for patients with substance use disorder: a cohort study from
Norway for the period 2016-2020. Health Qual Life Outcomes 2021, 19(1):69.”
Paper II 
- Page 4: Statistical analyses: Chi-square test was not used and should be removed.
Paper IV 
- Page 11: Reference 25 refers to a wrong paper. The correct paper should be: “World
Health Organization: Guidelines for the Psychosocially Assisted Pharmacological
Treatment of Opioid Dependence. 2009. [Available from:
https://www.who.int/publications/i/item/9789241547543].
Paper I 
Vold JH, Skurtveit S, Aas C, Chalabianloo F, Kloster PS, Johansson KA, Fadnes LT: 
Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving 
opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. BMC 
health services research 2020, 20(1):352. 

RESEARCH ARTICLE Open Access
Dispensations of benzodiazepines, z-
hypnotics, and gabapentinoids to patients
receiving opioid agonist therapy; a
prospective cohort study in Norway from
2013 to 2017
Jørn Henrik Vold1,2*, Svetlana Skurtveit3,4, Christer Aas1,2, Fatemeh Chalabianloo1,2, Pia Synnøve Kloster1,
Kjell Arne Johansson1,2 and Lars Thore Fadnes1,2
Abstract
Background: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist
therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the
dispensation rates of these potentially addictive drugs, and whether the number and the mean daily doses of
dispensed OAT opioids and discontinuing OAT, are associated with being dispensed benzodiazepines, z-hypnotics
and gabapentinoids among patients on OAT in Norway in the period 2013 to 2017.
Methods: Information about all dispensed opioids, benzodiazepines, z-hypnotics and gabapentinoids were
recorded from the Norwegian Prescription Database (NorPD). A total of 10,371 OAT patients were included in the
study period. The dispensation rates were defined as the number of patients who were dispensed at least one of
the potentially addictive drugs divided among the number of patients who have dispensed an OAT opioid per
calendar year. Mean daily doses were calculated, and for benzodiazepines and z-hypnotics, stated in diazepam
equivalents. The association between dispensed potentially addictive drugs, and the number and the type of
dispensed OAT opioids were calculated by using logistic regression models.
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Results: Half of the OAT patients received at least one dispensation of a benzodiazepine or z-hypnotic, and 11%
were dispensed at least a gabapentinoid in 2017. For dispensed benzodiazepines or z-hypnotics, the mean daily
dose was reduced from 21mg (95% confidence interval (CI): 20–23) diazepam equivalents in 2013 to 17 mg (95%
CI: 16–17) in 2017. The mean daily dose of pregabalin increased from 365 mg (95% CI: 309–421) in 2013 to 386 mg
(95% CI: 349–423) in 2017. Being dispensed a gabapentinoid (adjusted odds ratio (aOR) = 2.5, 95% CI: 2.1–3.0) or a
non-OAT opioid (aOR = 3.0, 95% CI: 2.6–3.5) was associated with being dispensed a benzodiazepine or z-hypnotic.
Discontinuing OAT did not affect the number of dispensations and the doses of potentially addictive drugs.
Conclusion: The dispensation rates of potentially addictive drugs are high in the OAT population. Treatment
indications, as well as requirements for prescription authority, need to be debated and made explicit. Randomized
controlled trials evaluating the benefits and risks of such co-prescription are required.
Keywords: Opioid substitution treatment, Benzodiazepines, Zopiclone, Zolpidem, Pregabalin, Gabapentin, Opioids,
Drug prescriptions
Background
Dispensations of benzodiazepines, z-hypnotics, and
gabapentinoids to patients on opioid agonist therapy
(OAT) have pros and cons. These drugs may increase
the mortality among patients on OAT and are associated
with criminality, psychosocial problems, and injecting
drug use [1, 2]. The use of several potentially addictive
drugs is particularly challenging in an OAT program
aimed at reducing mortality and injecting drug use and
achieve rehabilitation among marginalized and comorbid
patients with opioid addiction [3–8]. However, dispensa-
tions of benzodiazepines among highly comorbid patients
with polydrug use may decrease the mortality if such dis-
pensations make patients abstinent of illegal drugs, and
they are followed up strictly by health professionals [2].
The proportion of OAT patients who were dispensed
benzodiazepines or z-hypnotics varies across countries.
In the United Kingdom, the proportion of OAT patients
who were dispensed benzodiazepines and z-hypnotics
was 42 and 20%, respectively, between 1998 and 2014
[9]. In Sweden, 32% of OAT patients were dispensed a
benzodiazepine, and 41% received a z-hypnotic in the
period from 2005 to 2012 [1]. Further, the proportion of
Norwegian OAT patients who were dispensed benzodi-
azepine was 40% in 2005. Regulations of OAT are a typ-
ical reason for differences in the proportion of patients
who are dispensed, potentially addictive drugs between
countries [10]. In some countries, OAT has been a subject
for strict regulation, implying that OAT is stopped if used
potentially addictive drugs concomitantly [11–13]. Others,
e.g., Norway, such discontinuation of OAT in case of
benzodiazepine, and z-hypnotic use has become less com-
mon compared to during the early 2000s [14, 15].
The knowledge of gabapentinoid use among patients
on OAT is lacking. However, for the last couple of years,
gabapentinoids, particularly pregabalin, are consumed
significantly more often among patients with opioid ad-
diction compared to patients with other drug addictions
[16]. Withdrawal symptoms are described if dose reduc-
tion or discontinuation [17–20], while using high-dosed
gabapentinoids may cause euphoric effects, sedation, hal-
lucinations, dissociation, conspicuous behavior, and the
reinforced effect of OAT opioids [8, 16]. Dispensing
gabapentinoids among patients with opioid addiction
not necessarily indicated misuse or addiction. However,
it is worrying if adverse side effects occur when combin-
ing with highly potent opioids with OAT opioids [16].
In Norway, opioid agonist therapy has been applied in-
creasingly as an available treatment approach for opioid
addiction [15]. In 2017, about 7500 patients received
OAT opioids, and the majority received their OAT opi-
oids at least once per week from pharmacies. A decreas-
ing proportion of patients discontinued OAT during the
past few years, and in 2017, 681 patients, including those
who died, left the treatment [15]. Although, little is
known about dispensations of benzodiazepines and z-
hypnotics and gabapentinoids among patients on OAT.
Thus, this observational study aims to investigate the
dispensation rates and doses of these potentially addict-
ive drugs among patients who were dispensed at least
one OAT opioids in Norway in the period 2013 to 2017
and those who discontinued OAT. This study has three
objectives:
(1) To define dispensation rates and mean daily dose of
benzodiazepines, z-hypnotics, and gabapentinoids
per calendar year.
(2) To assess the association between OAT opioids in
terms of the number of dispensations and mean
daily dose of OAT opioids, and whether patients
are dispensed a benzodiazepine, z- hypnotic, or
gabapentinoid, or not per calendar year.
(3) To evaluate whether discontinuations of OAT affect
the number of dispensations and the mean daily
dose of dispensed benzodiazepines and z-hypnotics,
or gabapentinoids.
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Methods
Data source
All data were register data and were drawn from the
Norwegian Prescription Database (NorPD) (www.norpd.
no). From January 1, 2004, all pharmacies in Norway are
obliged by law to submit all the dispensed drugs data
electronically to the Norwegian Institute of Public
Health. NorPD contains information of all dispensed
drugs, including reimbursements, dispensed from phar-
macies in Norway, except for dispensations dispensed
during hospitalizations or at outpatient clinics. Anatom-
ical Therapeutic Chemical (ATC) classification system
was employed according to the determination by the
World Health Organization (WHO) collaborating centre
for drug statistics per October 2018 [21]. NorPD data
were collected from January 1, 2013, to March 31, 2018,
in this study. The STROBE checklist was applied in the
preparation of the study (Additional file 1).
Study population
All patients above 18 years of age who received at least
one dispensation of an OAT opioid, including methadone,
levomethadone, buprenorphine, and buprenorphine-
naloxone, from January 1, 2013, to December 31, 2017,
were included. The patients using methadone tablets to
achieve pain relief in palliative care were excluded by iden-
tifying those who only were dispensed methadone tablets
without any dispensations of other OAT opioids or
methadone mixture in the period from January 1, 2004, to
December 31, 2017. Discontinuing OAT was defined as
all patients who had the last dispensation of an OAT opi-
oid in the inclusion period from January 1, 2017, to Sep-
tember 30, 2017, and then, no dispensations until the end
of the collected NorPD data on March 31, 2018.
Analysis strategy and statistical analyses
Definitions of opioids, benzodiazepines, z-hypnotics,
gabapentinoids, age, the number of dispensations, mean
daily doses, and the type of dispensed OAT opioid
Opioid agonist therapy opioids, non-OAT opioids, and
gabapentinoids, including gabapentin and pregabalin, were
defined according to their ATC codes (Additional file 2).
Benzodiazepines and z-hypnotics were defined as all benzo-
diazepines and z-hypnotics that have or have had marketing
authorizations in Norway during the study period, including
alprazolam, clonazepam, diazepam, flunitrazepam, nitraze-
pam, oxazepam, zolpidem, and zopiclone. Dispensations of
benzodiazepines and z-hypnotics were pooled.
All included OAT patients were categorized into age
groups per calendar year. The age groups were ≤ 25, 26–
35, 36–45, 46–55, and ≥ 56. The number of dispensa-
tions was defined as all dispensations of a drug per cal-
endar year. Further, the type of OAT opioid was defined
as the last type of opioid that was dispensed per year.
The mean daily doses of benzodiazepines, z-hypnotics,
and gabapentinoids per year were calculated by using
daily defined doses (DDD) stated in NorPD defined by
the WHOs standards [21]. For benzodiazepines and z-
hypnotics, dispensed DDDs of each benzodiazepine or z-
hypnotic were summarized per year and converted to
milligrams. For each benzodiazepine or z-hypnotic, the
doses per year (in milligrams) were converted to diazepam
equivalents, according to a benzodiazepine and z-hypnotic
equipotency table stated in the Norwegian national guide-
lines for addictive drugs (Additional file 3) and WHOs
standards [21, 22]. The total doses of each benzodiazepine
or z-hypnotic were summarized (in diazepam equivalents)
and divided on 365.25 days to calculate the mean daily
doses per year. For gabapentinoids, the number of DDDs
of gabapentin and pregabalin, respectively, were summa-
rized per calendar year, and further, converted to milli-
grams by using WHOs standards [21]. The total
dispensed doses of pregabalin and gabapentin were di-
vided similarly on 365.25 days to calculate the mean daily
dose per year. For OAT opioids, the number of DDDs of
any defined OAT opioid were summarized and divided
this by the number of days between the date of the first
and the last dispensation per year. Due to this estimation,
all patients that only were dispensed one dispensation of
an OAT opioid per year were censored.
Moreover, patients were stratified into different cat-
egories according to the number of dispensations and
the mean daily doses of dispensed benzodiazepines and
z-hypnotics, gabapentinoids, and OAT opioids, respect-
ively. Benzodiazepines and z-hypnotics, and gabapenti-
noids had three dispensation groups: 0, 1–2, and ≥ 3
dispensations per calendar year, and the OAT opioids
were categorized into four groups: 1–6, 7–12, 13–51,
and ≥ 52 dispensations per calendar year. Benzodiaze-
pines and z-hypnotics were divided into three groups ac-
cording to the mean daily doses (in milligrams) were
dispensed: 0, ≤20, > 20 - ≤40, and > 40 diazepam equiva-
lents. The mean daily doses of pregabalin and gabapen-
tin were categorized into three groups. For pregabalin
(mg per day): > 0 - ≤300, > 300 - ≤600, and > 600, and
for gabapentin (mg per day): > 0 - ≤900, > 900 - ≤3600,
> 3600. OAT opioids were defined as the mean daily
DDDs, and the following three groups were used: 0- < 1,
1- < 2, and ≥ 2 mean DDDs per day. The ratio between
DDD and milligrams are presented in Additional file 3.
Analysis strategy according to the aims
Dispensation rates were defined as all OAT patients who
were dispensed one or more of the defined benzodiazepines
or z-hypnotics, or gabapentinoids, respectively, per calendar
year divided on all included OAT patients the same year.
Diazepam equivalents were used to adjust for equipo-
tency of benzodiazepines and z-hypnotics. Due to the
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absence of consistent international guidelines of equipo-
tency for these drugs, a sensitivity analysis was conducted
[22]. The lowest and highest stated equipotency for each
benzodiazepine and z-hypnotic, as well as a mean of them,
respectively, were used to create three equipotency equa-
tions to convert all dispensed doses per year of each benzo-
diazepine or z-hypnotic into diazepam equivalents. The
mean equivalent equation was as follow (in milligrams
(mg)):














The lowest and the highest equivalent equations are
presented in Additional file 4.
The number of dispensations of benzodiazepines and
z-hypnotics, gabapentinoids, and OAT opioids, respect-
ively, was plotted against the number of dispensations of
an OAT opioid per year. Furthermore, the mean daily
doses of dispensed benzodiazepines and z-hypnotics,
and gabapentinoids, respectively, were plotted against
mean daily DDD of OAT opioids per year.
The associations between being dispensed a benzodiazep-
ine or z-hypnotic, or a gabapentinoid, and age, gender, type
of OAT opioid, the number of dispensed OAT opioids, and
being dispensed a non-OAT opioid were assessed per cal-
endar year by using logistic regression models.
Dispensation rates and the mean daily doses of ben-
zodiazepines and z-hypnotics, and gabapentinoids were
evaluated for patients who discontinued OAT. For the
baseline, the dispensation rates and the mean daily
doses of dispensed benzodiazepines or z-hypnotics
(stated in diazepam equivalents), and gabapentinoids,
respectively, were calculated for the period 180 to 90
days before discontinuation date. Furthermore, the
dispensation rates and the mean daily doses of benzodi-
azepines or z-hypnotics, and gabapentinoids, during the
last 90 days before and the 90 days after discontinuation
date, respectively, were summarized separately and
Table 1 Baseline characteristics of patients on opioid agonist therapy in Norway
Baseline characteristics 2013 2014 2015 2016 2017
No. % No. % No. % No. % No. %
Patients 7709 7914 7958 7804 7709
Deaths 165 151 138 114 124
Patients, excl. deaths 7544 7763 7820 7690 7585
Age
- ≤ 25 211 3 185 2 171 2 135 2 120 2
- 26-35 1590 21 1570 20 1551 20 1403 18 1333 18
- 36-45 2724 36 2730 35 2605 33 2508 33 3292 32
- 46-55 2283 30 2449 32 2544 33 2540 33 2548 34
- ≥ 56 736 10 829 11 949 12 1104 14 1192 16
Mean (SD) 43 (10) 44 (10) 44 (10) 44 (10) 45 (10)
Gender
Men 5221 69 5390 69 5430 69 5354 70 5245 69
Women 2323 31 2373 31 2390 31 2336 30 2340 31
OAT opioidsa
Methadone, included levomethadone 3406 45 3264 42 3216 41 3066 40 2981 39
Buprenorphineb 4138 55 4499 58 4604 59 4624 60 4604 61
Potentially addictive drugs
Dispensed a benzodiazepine and z-hypnoticc 3747 50 3809 49 3714 47 3758 49 3762 50
Dispensed a gabapentinoid 708 9 662 9 717 9 762 10 845 11
NorPD Norwegian Prescription Database, OAT Opioid agonist therapy, SD Standard deviation
aThe last type of dispensed OAT opioid per year
bInclude buprenorphine-naloxone
cZ-hypnotic includes zolpiclone and zolpidem
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compared to dispensation rates and mean daily doses at
baseline.
Statistical analyses
Means, median, percentiles, percentage, 95% confidence
interval (CI), odds ratio (OR), and p-value are presented
when appropriate. The one-sample t-test was used to
calculate mean daily doses of dispensed benzodiazepines
or z-hypnotics, or gabapentinoids with 95% CI. The
paired sample t-test was used to compare the differences
in the mean daily dose of benzodiazepines or z-
hypnotics and gabapentinoids, respectively, per year
among OAT patients who discontinued OAT. Multivari-
able analyses for categorical variables were performed
per year by creating logistic regression models. For these
models, being dispensed a gabapentinoid, or a benzodi-
azepine or z-hypnotic were dependent variables, respect-
ively, per year. Age groups, gender, type of OAT opioid,
the number of dispensed OAT opioids, and being dis-
pensed a non-OAT opioid were independent variables
and defined categorically. In addition, being dispensed a
gabapentinoid was used as an independent and categor-
ical variable when being dispensed a benzodiazepine, or
a z-hypnotic was defined as a dependent variable, and
vice versa. The level of statistical significance was p <
0.05. All patients were excluded from the calendar year
they died. SPSS version 24 was used for all analyses.
Ethical considerations
The Regional Committee for Medical and Health Re-
search Ethics, REC vest, Norway, has approved the use
of registry data for the study (approval number 2018/
939/REK Vest, June 19, 2018). No informed consent
from included patients was necessary.
Results
Basic characteristics
A total of 10,371 patients were dispensed at least one
OAT opioid from pharmacies in Norway in the period
2013 to 2017 (Table 1). In 2017, 69% were men. The
mean age increased from 43 (standard deviation (SD):
10) years in 2013 to 45 (SD: 10) years in 2017. A total of
690 participants died during the study period.
Dispensation rates and mean daily doses of dispensed
benzodiazepines, z-hypnotics, and gabapentinoids
The proportion of patients who received at least one
dispensation of benzodiazepines or z-hypnotics was 50%
in 2017, and 42% received three or more such dispensa-
tions (Fig. 1). Similar findings were found yearly from
2013 to 2016. The dispensation rates of benzodiazepines
Fig. 1 The proportion of patients on OAT were dispensed a benzodiazepine or z-hypnotic, and a gabapentinoid. Legend: OAT = opioid agonist
therapy. The figures display the proportion of patients who were dispensed 1–2 or 3 or more dispensations of benzodiazepines or z-hypnotics
and gabapentinoids, respectively, of those who dispensed an OAT opioid per calendar year in the study period. Each figure a) to d) displays
patients on OAT categorized on the number of dispensations of OAT opioids per year: a) 1–6 dispensations, b) 7–12 dispensations, c) 13–51
dispensations, and d) 52 or more dispensations
Vold et al. BMC Health Services Research          (2020) 20:352 Page 5 of 12
and z-hypnotics declined from 21mg (95% CI: 20–23
mg) diazepam equivalents per day in 2013 to 17 mg
(95% CI: 16–17mg) diazepam equivalents per day in
2017 (Table 2a and Table 2b). A quarter of patients was
dispensed oxazepam, which was the most frequently dis-
pensed benzodiazepine per year throughout the study
period (Table 3). Zopiclone was the most frequently dis-
pensed z-hypnotic per patient per year.
Gabapentinoids were dispensed to 9 % of the patients
in 2013 and 11% of the patients in 2017. Pregabalin was
almost twice as frequently dispensed per patient as gaba-
pentin per year throughout the study period. The mean
daily doses of dispensed pregabalin increased with 1%
per year from 365mg (95% CI: 309–421 mg) in 2013 to
386 mg (95% CI: 349–423 mg) in 2017, and gabapentin
increased with 4% per year from 911mg (95% CI: 753–
1068 mg) to 1047mg (95% CI: 885–1209 mg) in the
same period.
The dispensation rates of benzodiazepines and z-
hypnotics, and gabapentinoids related to the number of
dispensations and mean daily DDD of dispensed OAT
opioids
The number of dispensations and the mean daily DDD
of OAT opioids was not associated with changes in dis-
pensation rates or the number of dispensations of ben-
zodiazepines and z-hypnotics or gabapentinoids per year
in the study period (Additional files 5, 6 and 7). However,
Table 2 The daily doses of dispensed potentially addictive drugs
a)
All indications 2013 2014 2015 2016 2017
Benzodiazepine and z-hypnotic dose per
patient (in diazepam equivalents)
mean (lowest-highest)
Mean (mg/day) 21 (17–29) 20 (16–27) 19 (15–25) 17 (14–23) 17 (14–22)
Median (mg/day) 10 (9–12) 10 (9–12) 10 (8–12) 10 (8–12) 10 (8–11)
25 percentile (mg/day) 3 (2–3) 2 (2–3) 3 (2–3) 3 (2–3) 3 (2–3)
75 percentile (mg/day) 23 (20–29) 22 (19–27) 21 (18–26) 21 (18–26) 20 (18–25)
All indications 2013 2014 2015 2016 2017
Pregabalin dose per patient Mean (mg/day) 365 365 371 381 386
Median (mg/day) 205 230 249 285 255
25 percentile (mg/day) 46 74 62 84 69
75 percentile (mg/day) 506 552 552 561 552
All indications 2013 2014 2015 2016 2017
Gabapentin dose per patient Mean (mg/day) 911 970 997 960 1047
Median (mg/day) 411 488 493 493 513
25 percentile (mg/day) 82 124 82 82 164
75 percentile (mg/day) 1228 1314 1383 1286 1430
b)
All indications 2013 2017
Mean dose (95 % CI) Mean dose (95% CI)
Diazepam equivalents per patient
Benzodiazepine and z-hypnotic dose per
patient (in diazepam equivalents)
Mean (mg/day) 21 (20–23)a 17 (16–17)b
Pregabalin dose per patient Mean (mg/day) 365 (309–421)c 386 (349–423)d
Gabapentin dose per patient Mean (mg/day) 911 (753–1068)e 1047 (885–1209)f
Df Degrees of freedom, Lowest Lowest equipotency dose, Highest Highest equipotency dose, and Mean =Min +Max divided by 2
aOne sample t-test, df = 3746, bone sample t-test, df = 3761, cone sample t-test, df = 486, done sample t-test, df = 590, eone sample t-test, df = 260, and fone sample
t-test, df = 309
The table a) displays the daily doses (mean, median, 25 percentile, and 75 percentile) of dispensed benzodiazepines or z-hypnotics (calculated in diazepam
equivalents), pregabalin and gabapentin per year among patients on OAT in Norway in period 2013 to 2017
The table b) displays the mean daily doses of dispensed benzodiazepines or z-hypnotics (calculated in diazepam equivalents), pregabalin and gabapentin in 2013
and 2017. The 95% confidence intervals were calculated by one-sample t-test analyses
For table a) and b), an equipotency table for benzodiazepines and z-hypnotics were used to make sensitivity analyses displaying the lowest equipotency dose and
the highest equipotency dose of the included benzodiazepines and z-hypnotics. The results were presented in parentheses. All dispensed benzodiazepines and z-
hypnotics were summarized per year
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being dispensed a benzodiazepine or z-hypnotic was asso-
ciated with aging 46–55 years or being above 56 years of
age rather than aging below 25 years, gender women,
using methadone rather than buprenorphine as OAT opi-
oid, or being dispensed at least one dispensation of non-
OAT opioids, or gabapentinoids in 2017 (Table 4, Add-
itional file 8). Further, being dispensed a gabapentinoid
was associated with being dispensed a benzodiazepine or
z-hypnotic or a non-OAT opioid. Similar results were
substantially found per year in the period 2013 to 2016.
Dispensation rates and mean daily doses of dispensed
benzodiazepines and z-hypnotics, and gabapentinoids
related to discontinuation of OAT
We identified 693 patients who discontinued OAT during
the inclusion period. Of those, 156 patients were dispensed
at least one dispensation of a benzodiazepine or z-hypnotic
in the period from 180 days before to 90 days after discon-
tinuation. The mean daily dose of dispensed benzodiazep-
ine and z-hypnotic was not changed compared to the mean
daily dose at baseline when patients discontinued OAT (Δ
mean daily dose (in mg): 0, 95% CI: − 3 – 3) (Fig. 2).
Furthermore, 42 patients were dispensed a benzodiazepine
or z-hypnotic only during the 90 days after discontinuation.
Of these patients, the mean daily dose of benzodiazepines or
z-hypnotics during the 90 days after discontinuation was
about half of the mean daily dose of these patients who were
dispensed benzodiazepines or z-hypnotics at baseline and
until 90 days after the discontinuation. Pregabalin and gaba-
pentin were prescribed to 50 and 23 patients, respectively,
during the 180 days before to 90 days after discontinuation
of OAT (Additional file 9). No changes in mean daily doses
of these drugs were found when comparing the mean daily
doses at baseline with the mean daily doses the first 90 days
after the discontinuation (pregabalin: Δ mean daily dose (in
mg): 50, 95% CI: − 47 – 149, gabapentin: Δ mean daily dose
(in mg): 190 mg, 95% CI: − 789 – 1168).
Discussion
In the period 2013 to 2017, a steady proportion of the
Norwegian OAT population received at least one pre-
scription of a benzodiazepine or z-hypnotic. Further-
more, the number of patients who were dispensed at
least one dispensation of a gabapentinoid increased
slightly in the study period. The mean daily dose of ben-
zodiazepines and z-hypnotics was declining, while the
mean daily dose of pregabalin and gabapentin were in-
creasing. The number of dispensations and the mean
daily DDD of OAT opioids did not affect the number of
dispensations of benzodiazepines and z-hypnotics, or
gabapentinoids. Being dispensed a benzodiazepine or
z-hypnotic was associated with aging 46–55 years or
being above 56 years of age rather than aging below
25 years, gender women, using methadone rather than
buprenorphine as OAT opioid or being dispensed at
least once a non-OAT opioid, or a gabapentinoid in
2017. Similar results were substantially found in the
period from 2013 to 2016. Oxazepam and zopiclone
were the most frequently dispensed benzodiazepine
and z-hypnotic, respectively, and pregabalin was pre-
scribed twice as often per patient per year as gaba-
pentin throughout the study period. Discontinuation
of OAT was not associated with changes in the dis-
pensation rates or the mean daily doses of benzodiaz-
epines or z-hypnotics, or gabapentinoids.
Our findings were in line with dispensation rates of ben-
zodiazepines, z-hypnotics, and gabapentinoids in the OAT
population in the United Kingdom in the period from
Table 3 The proportion of patients who were dispensed benzodiazepines, z-hypnotics, and gabapentinoids, respectively
Year 2013 2014 2015 2016 2017
Benzodiazepines or z-hypnotics No. %a No. %a No. %a No. %a No. %a
Oxazepam 2094 28 2091 27 2124 27 2183 28 2229 29
Diazepam 1216 16 1251 16 1222 16 1272 17 1289 17
Zopiclone 1026 14 964 12 932 12 936 12 863 11
Nitrazepam 757 10 759 10 747 10 737 10 701 9
Clonazepam 479 6 432 6 362 5 331 4 268 4
Zolpidem 351 5 359 5 333 4 315 4 327 4
Alprazolam 305 4 304 4 237 3 206 3 196 3
Flunitrazepam 41 1 38 0 37 0 32 0 36 0
Gabapentinoids No. %a No. %a No. %a No. %a No. %a
Pregabalin 487 6 449 6 491 6 523 7 591 8
Gabapentin 260 3 240 3 277 4 291 4 310 4
No. Number of patients, OAT Opioid agonist therapy
aPercent of all patients who were dispensed an OAT opioid
The table displays the proportion of all OAT patients who were dispensed different benzodiazepines, z-hypnotics, and gabapentinoids
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1998 to 2014 [9]. Further, the dispensation rates were
higher for being dispensed a benzodiazepine or a gabapen-
tinoid and lower for being dispensed a z-hypnotic com-
pared with the OAT population in Sweden in the period
2005 to 2013 [1]. In Norway, the proportion of OAT pa-
tients who were dispensed benzodiazepines or z-hypnotics
was at least as high as comparable descriptive analyses of
benzodiazepine dispensations in 2005 [23]. Moreover, the
proportion of the general Norwegian population was dis-
pensed a benzodiazepine or z-hypnotic decreased rela-
tively on 1.2% per year from 10.8% in 2015 to 10.4% in
2017, whereas pregabalin increased by 3.5% per year, and
gabapentin increased by 5.8% per year in the same period
[24]. The dispensation rates of all these potentially addict-
ive drugs were substantially higher in the OAT popula-
tion. For gabapentinoids, the dispensation rates were
increasing in both the OAT population and the general
Norwegian population in the study period.
The reasons for the increasing use of gabapentinoids
in the OAT population are lacking. In the past decade,
gabapentinoids, particularly pregabalin, were placed
under scrutiny due to the risk of addiction [16], and pre-
scribers have become aware of the risk of prescribing
these drugs to patients with a history of drug addiction
[1]. Although, it is remarkable that the dispensation rate
of gabapentinoids was increasing, and pregabalin was
dispensed twice as frequently as gabapentin. The reason
may be a high prevalence of psychiatric comorbidities
like anxiety in the OAT population [25–27]. Further
Table 4 Logistic regression analyses of variables associated with







cOR p-value aOR (95% CI) p-value
Age
- ≤ 25 1.0 (ref.) 1.0 (ref.)
- 26-35 1.0 .80 0.9 (0.6–1.4) .76
- 36-45 1.0 .85 1.0 (0.7–1.5) .94
- 46-55 1.6 .02 1.7 (1.1–2.5) .05
- ≥ 56 1.9 < .01 1.2 (1.1–1.3) .01
Gender
- Men 1.0 (ref.) 1.0 (ref.)
- Women 1.2 < .01 1.2 (1.1–1.3) < .01
The number of dispensations of OAT opioids
- ≥ 52 1.0 (ref.) 1.0 (ref.)
- 13-51 1.3 < .01 1.2 (1.1–1.5) .01
- 7-12 1.1 .27 1.0 (0.9–1.3) .73




1.0 (ref.) 1.0 (ref.)
- Methadone (incl.
Levomethadone)
1.4 < .01 1.3 (1.2–1.4) < .01
Dispensed a non-
OAT opioid
3.5 < .01 3.0 (2.6–3.5) < .01
Dispensed a gabapentinoid 3.0 < .01 2.5 (2.1–3.0) < .01
b)
2017 Dispensed a gabapentinoid
N = 845
cOR p-value aOR (95% CI) p-value
Age
- ≤ 25 1.0 (ref.) 1.0 (ref.)
- 26-35 1.1 .71 1.2 (0.6–2.2) .60
- 36-45 1.0 .90 1.1 (0.6–2.0) .79
- 46-55 1.0 .99 0.9 (0.5–1.7) .75
- ≥ 56 1.0 .95 0.8 (0.4–1.5) .45
Gender
- Men 1.0 (ref.) 1.0 (ref.)
- Women 1.3 < .01 1.1 (1.0–1.3) .16
The number of dispensations of OAT opioids
- ≥ 52 1.0 (ref.) 1.0 (ref.)
- 13-51 0.9 .62 0.9 (0.7–1.1) .31
- 7-12 1.0 .95 0.9 (0.7–1.3) .72
Table 4 Logistic regression analyses of variables associated with
being dispensed a benzodiazepine or z-hypnotic, and a
gabapentinoid (Continued)




1.0 (ref.) 1.0 (ref.)
- Methadone (incl.
Levomethadone)
1.1 .46 1.1 (0.9–1.3) .41
Dispensed a non-
OAT opioid




3.0 < .01 2.5 (2.1–3.0) <.01
cOR crude odds ratio, aOR adjusted odds ratio, CI Confidence interval, and OAT
Opioid agonist therapy
aThe last type of dispensed OAT opioid
Table a) and b) display unadjusted (crude) and adjusted odds ratio for all
independent variables of patients who were dispensed at least a
benzodiazepine or z-hypnotic, and a gabapentinoid, respectively, in 2017 in
Norway. a) Being dispensed at least a benzodiazepine or z-hypnotic was
defined as a dependent variable, and age, gender, ‘the number of
dispensations of OAT opioids,’ ‘OAT opioids,’ ‘dispensed a non-OAT opioid,’
and ‘dispensed a gabapentinoid’ were defined as categorical and independent
variables. b) Being dispensed a gabapentinoid was defined as a dependent
variable, and age, gender, ‘the number of dispensations of OAT opioids,’ ‘OAT
opioids,’ ‘dispensed a non-OAT opioid,’ and ‘dispensed a benzodiazepine or z-
hypnotic’ were defined as categorical and independent variables
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studies evaluating reasons for the increasing gabapenti-
noid use among patients on OAT is required.
Being dispensed a benzodiazepine or z-hypnotic was par-
ticularly associated with being dispensed non-OAT opioids,
and gabapentinoids, as well as methadone rather than
buprenorphine as the type of OAT opioid. Chronic non-
malignant pain like pain in muscles and skeleton is highly
prevalent in the OAT population using methadone as an
OAT opioid and affects up to 68% in some studies [28–31].
Having chronic non-malignant pain on OAT is strongly as-
sociated with using benzodiazepines [26, 27], and the pres-
ence of psychiatric comorbidities such as anxiety and
depression [31]. Even though the prevalence of chronic
non-malignant pain in the Norwegian OAT population is
uncertain, one can assume that chronic non-malignant pain
was an essential explanation for the association between
the dispensation of benzodiazepines and gabapentinoids
and using methadone on OAT in this study.
Overall, there is substantial evidence that OAT pro-
tects against overdose-related deaths and injecting
opioid use [32, 33]. Nevertheless, the mortality increases
significantly among patients on OAT if dispensed
benzodiazepines, z-hypnotics, or gabapentinoids [1, 2].
Therefore, the guidelines in several European countries
recommend careful dispensation of potentially addictive
drugs to these patients on OAT [34, 35]. However,
being dispensed of a potentially addictive drug is
not necessarily wrong, and the reasons for these
dispensations may be multifactorial. Physical and
mental comorbidities are highly prevalent among
patients on OAT, which predict and defend the
dispensations of potentially addictive drugs [25–27].
In a few marginalized cases with several addictions,
it is argued that dispensations of benzodiazepines
decrease mortality if low dosed benzodiazepines re-
place illegal drug consumption [2]. Nevertheless, it
should be a better awareness of whether such dis-
pensations are medically indicated on patients on
OAT taken our findings into consideration. Improv-
ing prescription routines among general physicians,
application of strict monitoring systems, and a close
co-operation with specialized addiction health care
center may be considered as some of the essential
approaches to strive for optimal conditions in cases
Fig. 2 Daily doses of benzodiazepines and z-hypnotics among patients who discontinued OAT. Legends: CI = Confidence interval, df = degrees of
freedom, lowest = lowest equipotency dose, highest = highest equipotency dose, and OAT = opioid agonist therapy. 1) Paired t-test, df = 155,
comparing mean daily dose ≥0 - ≤90 days to baseline related to discontinuation. 2) Paired t-test, df = 24, comparing mean daily dose ≥0 - ≤90
days to baseline related to discontinuation. 3) Paired t-test, df = 32, comparing mean daily dose ≥0 - ≤90 days to ≥90 - < 0 days related to
discontinuation. Displays the daily doses of dispensed benzodiazepines and z-hypnotics, in the following period related to the date of the last
dispensation of an OAT opioids: 1) 180–90 days before discontinuation (baseline), 2) 90–0 days before discontinuation, and 3) 0–90 days after
discontinuation. Discontinuation was defined as all patients on OAT who had the last dispensation of an OAT opioid in the period January 1,
2017, to September 30, 2017, and no dispensation until the end of March 31, 2018. The daily doses were stated in mean, median, 25 percentile,
and 75 percentile. An equipotency table for benzodiazepines and z-hypnotics were used to make sensitivity analyses, displaying the lowest
equipotency dose and the highest equipotency dose of the included benzodiazepines and z-hypnotics. The results were presented in
parentheses. All dispensed benzodiazepines and z-hypnotics were summarized per year
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on OAT where several potentially addictive drugs
are medically indicated.
Strengths and limitations
Using Norwegian registry data had some strengths.
Pharmacy records are viewed to be more valid than both
medical records and data collected from questionnaires
and interviews. Because practically all dispensed drugs
are registered in the database, completeness, and preci-
sion of all received information is high, and the potential
for information biases is low.
This study also had some limitations. The NorPD only
receives information about dispensed drugs, and we
cannot know whether the drugs have been consumed.
Second, due to that a minor part of reimbursed prescrip-
tions being received through the Norwegian Health
Economics Administration (HELFO), the medical indica-
tions for these dispensations are not available for the re-
searchers through NorPD. For example, clonazepam,
pregabalin, and gabapentin may be dispensed on the
medical indication of epilepsy, while oxazepam or diaze-
pam may be used preferably for detoxifications, or treat-
ment of short-term anxiety or sleeping disorder. Third,
the number of dispensations may be incomplete regis-
tered by the pharmacies. For OAT opioids, the self-
reporting survey of OAT showed that the mean number
of dispensation per patient was four times a week [15].
This finding may indicate that the number of dispensa-
tions is underestimated in our study. In order to adjust
for this uncertainty to some extent, the mean daily dose
calculated by summing the dispensed DDD, divided by
the number of days between the first and the last dis-
pensation were used. Fourth, slightly less than 10% of
OAT opioids are dispensed in addiction specialist out-
patient clinics, and those are not necessarily registered
in NorPD. Some of these outpatient clinics ordered
OAT opioids directly from pharmacies without linking
to a personal identification number. These patients were
lost in this study [15].
Conclusion
The dispensation rates of benzodiazepines, z-hypnotics,
and gabapentinoids to patients receiving OAT in
Norway are high. A high burden of disease among
patients on OAT may be an essential explanation.
Future policies need to debate the indications for
dispensations of benzodiazepines, z-hypnotics, and
gabapentinoids explicitly in guidelines on OAT as
well as make requirements for dispensation authority.
More randomized controlled trials evaluating the ben-
efits and risks of such co-dispensation with sufficient
power are required.
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Abstract
Background: It is estimated that up to a third of patients on opioid agonist therapy (OAT) have attention deficit
hyperactivity disorder (ADHD). Treatment by ADHD medication, including a centrally acting stimulant (CAS) or
atomoxetine is one of the essential approaches. This study evaluates the use of dispensed ADHD medications in
the Norwegian OAT population in the period from 2015 to 2017. Types and doses of ADHD medications, co-
dispensations of other potentially addictive drugs like benzodiazepines, z-hypnotics, gabapentinoids, and non-OAT
opioids, as well as direct-acting antivirals (DAA) against hepatitis C infection, are investigated.
Methods: Information about all dispensed ADHD medication, OAT opioids, and the defined potentially addictive
drugs were recorded from the Norwegian Prescription Database. Dispensation rates, the types, and the doses of
dispensed ADHD medications were estimated by summarizing the number of dispensations, and the dispensed
doses. Logistic regression analyses were employed to assess the associations between ADHD medication, and OAT
opioid use, and dispensations of other potentially addictive drugs and DAAs against hepatitis C infection.
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Results: A total of 9235 OAT patients were included. The proportion of patients who were dispensed ADHD
medication increased from 3.5 to 4.6% throughout the study period. The three most dispensed CAS were short-
and intermediate-acting methylphenidate (55%), lisdexamphetamine (24%), and dexamphetamine (17%) in 2017.
Buprenorphine, rather than methadone, as OAT opioid (adjusted odds ratio: 1.6, CI: 1.2–2.1) was associated with
being dispensed ADHD medication. Among patients who received CAS and OAT opioids each calendar year, the
dispensed doses of methylphenidate increased from 63mg/day in 2015 to 76 mg/day in 2017 (p = 0.01). Sixty
percent of patients receiving ADHD medications were also dispensed other addictive drugs concomitantly in 2017.
Similar results were found in 2015 and 2016.
Conclusion: Co-prescription of ADHD medications was low among patients on OAT in Norway, considering a high
prevalence of ADHD in this patient group. On the other hand, concurrent dispensations of multiple addictive drugs
were common in this population. Understanding the underlying reasons for such prescribing is essential, and
research on how to optimize ADHD medication of patients with ADHD receiving OAT is needed.
Keywords: Opioid substitution treatment, Centrally acting stimulants, Hyperkinetic disorder, Attention deficit
hyperactivity disorder, Substance-related disorders, Dispensed drugs, Register data
Background
The strong association between opioid addiction and at-
tention deficit hyperactivity disorder (ADHD) is well
known [1]. Studies indicate that up to a third of patients
receiving opioid agonist therapy (OAT) meet the criteria
for ADHD [1–5]. Both opioids used in OAT and cen-
trally acting stimulants (CAS) may have properties asso-
ciated with euphoria and addiction. Current treatment
guidelines and previous reviews, therefore, recommend
stable psychosocial surroundings and close follow-ups by
health professionals in case of prescription of these
high-potent drugs [6–10]. The use of other reinforcing,
potentially addictive drugs such as benzodiazepines, z-
hypnotics, non-OAT opioids, and gabapentinoids should
be considered carefully to prevent adverse interactions
and risk of new addictions [11, 12]. However, about 50%
of patients receiving OAT and ADHD medication, in-
cluding CAS and atomoxetine, concomitantly discon-
tinue ADHD medication during the first 2 years after
the start of the treatment [13]. Reasons for discontinu-
ation include illicit drug use, side effects, and lack of
psychosocial stability [13]. Long-term therapy of ADHD
medication seems to have the highest chance of ad-
equate adherence when combining psychosocial treat-
ment with ADHD medication and OAT in the absence
of other reinforcing, potentially addictive drugs [14, 15].
Little is known about the prevalence of co-existing
ADHD and the utilization and the dose of prescribed
ADHD medication among patients with ADHD on
OAT. Additional use of other potentially addictive drugs
makes ADHD assessment and treatment with ADHD
medications more challenging. Psychosocial factors and
medical conditions among these patients may also
complicate diagnosis and the co-therapy with ADHD
medication. Therefore, studies show substantial inter-
country differences in co-existing ADHD prevalence
(5–30%) [2, 16], and variations in utilization and the dose
of prescribed ADHD medication [7, 9, 10, 17, 18]. There
is evidence that CAS have an effect by suppressing ADHD
symptoms among patients with drug use disorders
and comorbid ADHD [18]. Some studies also point
towards that the high-dosed CAS increases patients’
retention to treatment, and prevents discontinuation
[19, 20]. However, individual assessment taking into
consideration medical and psychosocial conditions will
be of particular interest to ensure a proper prescrip-
tion of CAS to patients on OAT with comorbid
ADHD.
During the past years, the guidelines for ADHD world-
wide recommend prescribing ADHD medication to
patients on OAT with comorbid ADHD and those with
other drug use disorders if they are abstinent from any
illegal drugs [7, 9, 10, 17]. However, the evidence support-
ing this recommendation is weak. In Norway, prescribing
ADHD medication has been recommending for patients
with ADHD on the OAT program since 2014 [21]. A total
of 7500 Norwegian patients are given OAT [22], and, in
2016, about 15% self-reported the use of illegal and legal
CAS during the last 4 weeks. Although the proportion
that was dispensed ADHD medication, on medical indica-
tion is uncertain after the guidelines were revised. To be
able to improve the treatment of ADHD, it is essential to
know more about the current prescription rates of ADHD
medications and the prescription patterns of other poten-
tially addictive drugs among patients on OAT who were
dispensed an ADHD medication.
Thus, this observational study was aimed to define
dispensation rates of attention deficit hyperactivity
disorder (ADHD) medications and potentially addict-
ive drugs among patients on opioid agonist therapy
(OAT) in the period from 2015 to 2017 in Norway.
The aims were to:
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1. define the dispensation rates of ADHD medication
and the types of ADHD medication dispensed per
calendar year.
2. assess whether the dispensations of ADHD
medication per calendar year were associated with
dispensations of benzodiazepines, z-hypnotics,
gabapentinoids, non-OAT opioids, as well as
direct-acting antivirals (DAA) against hepatitis C
infection, types of OAT opioids, the number of
dispensed OAT opioids, gender, and age in the
study period.
3. define the mean daily doses of dispensed ADHD
medications, and the dispensation rates of
benzodiazepines, z-hypnotics, gabapentinoids, and
non-OAT opioids in 2017 among patients who were
dispensed ADHD medication in the calendar year
throughout the study period.
Methods
Data source
All data were register data and were drawn from the
Norwegian Prescription Database (NorPD). From January
1, 2004, all pharmacies are obliged to submit data for all
dispensed drugs electronically to NorPD underlying the
Norwegian Institute of Public Health (www.norpd.no).
The NorPD contains information on all drugs dispensed
from pharmacies, except for drugs administrated at hospi-
tals, nursing homes, and outpatient clinics [23]. The Ana-
tomical Therapeutic Chemical (ATC) classification system
was employed in accordance with the World Health
Organization (WHO) standards per October 2018 [24].
Study population
All patients above 18 years of age who received at least
one dispensation of OAT opioids per calendar year, in-
cluding methadone, levomethadone, buprenorphine,
and buprenorphine-naloxone from January 1, 2015, to
December 31, 2017, were included. In addition, some
patients in palliative care use methadone tablets to
achieve pain relief. These patients were excluded by
identifying those who only were dispensed methadone
tablets without any dispensations of other OAT opioids
or methadone mixture in the period from January 1,
2004, to December 31, 2017.
Analysis strategy and statistical analyses
Definitions of drugs, including ADHD medications and
opioid agonist therapy opioids, the number of
dispensations of OAT opioids, and diagnoses
Attention deficit hyperactivity disorder medications were
defined as all CAS that had marketing authorizations in
Norway in the period 2015 to 2017, including racemic
amphetamine, dexamphetamine, methylphenidate, and
lisdexamphetamine. In addition, we included the non-
stimulant atomoxetine, which is also authorized and rec-
ommended in the treatment of ADHD according to
guidelines and reviews [6–10, 18, 25]. For methylphenidate,
the dispensations were classified by whether the formula-
tion was ‘short- or intermediate-acting’ or ‘long-acting.’
Long-acting methylphenidate included depot formulations
(Concerta®, Delmosart®, Equasym Depot®, or Methyl-
phenidate Sandoz®), while short- or intermediate-acting
methylphenidate included all other formulations (capsules
or tablets). All included OAT opioids, ADHD medica-
tions, non-OAT opioids, benzodiazepines, z-hypnotics,
gabapentinoids, including gabapentin and pregabalin, and
DAAs were categorized according to their ATC codes
(Additional file 1). The type of OAT opioid that patients
were dispensed was defined as the last type of OAT opioid
that was dispensed per calendar year.
The number of dispensed OAT opioids was defined as
the number of dispensations of any OAT opioid per pa-
tient per calendar year. The number of dispensations
was stratified according to four categories: 1–6, 7–12,
13–51, and ≥ 52 dispensations per calendar year. Age
was defined according to the patient’s age in the calendar
year and categorized into five groups: ≤ 25, 26–35, 36–45,
46–55, and ≥ 56 years.
All reimbursable and non-reimbursable ADHD medi-
cation dispensations were included. The prescribing
physician needs to specify the medical condition that is
treated by the particular drug, using codes from the 10th
revision of International Classification of Diseases (ICD-
10) or International Classification of Primary Care 2
(ICPC-2) to get public drug expenses reimbursed in
Norway. The diagnostic codes of reimbursed drugs are
recorded in the NorPD. Only two medical indications
are approved for ADHD medication expense reimburse-
ments in Norway: Hyperkinetic disorder/ADHD (ICD-10:
F90 and ICPC-2: P81) or narcolepsy (ICD-10: G47 and
ICPC-2: P81). For narcolepsy, only CAS are reimbursed.
The information on diagnostic codes for non-reimbursable
dispensations are not collected in the NorPD.
Analysis strategy according to the aims
One-year’s dispensation rates of ADHD medication
during the study period were assessed by summing all
patients who received at least one dispensation of an
ADHD medication per the calendar year. Furthermore,
patients were divided into two groups “all medical indi-
cations” and “ADHD” for the years in the study period.
The group named “ADHD” only included patients who
were dispensed ADHD medications with reimbursement
codes for ADHD. The group named “all medical indica-
tions” included all patients who received dispensations
of ADHD medications, either they were reimbursed or
not. Less than five patients were dispensed CAS on the
reimbursement code for narcolepsy in the study period.
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The association with being dispensed ADHD medica-
tion, or not adjusted for age, gender, type of dispensed
OAT opioids, the number of dispensed OAT opioids,
being dispensed benzodiazepines, z-hypnotics, gabapen-
tinoids, or non-OAT opioids were calculated per calen-
dar year in the study period. Age and the number of
dispensed OAT opioids were categorized according to
the predefined categories or groups per year. All dis-
pensed ADHD medication, and potentially addictive
drugs were identified and categorized into four drug
groups: “benzodiazepines or z-hypnotics,” “gabapenti-
noids,” “non-OAT opioids,” and “ADHD medication”
per year. For each group, categorical variables were cre-
ated by whether patients were dispensed one or more of
the drugs in the drug groups or not. Dispensations of
DAA were also included due to the frequent use of illicit
stimulant drugs in the OAT population and the fact that
DAA against hepatitis C infection has made treatment
more applicable for these patients. Patients were defined
to be dispensed treatment with DAA if they had at least
one dispensation of DAA from 2011 and until the end of
2015, 2016, or 2017, respectively.
The mean daily dose of each ADHD medication and
the dispensation rates of benzodiazepines or z-hypnotics,
gabapentinoids, and non-OAT opioids in 2017, were cal-
culated among patients with at least one dispensation of
ADHD medication and OAT, respectively, for each cal-
endar year in the study period. These patients were as-
sumed to have achieved medical continuity in their
ADHD treatment and follow up treatment according to
national guidelines. The mean daily doses of ADHD
medication were calculated by summarizing the total
volume of defined daily doses (DDD) of each drug that
was dispensed for each patient per year [26]. Further,
the number of DDDs dispensed per patient was con-
verted to milligrams according to WHO’s standards
(Additional file 2). The mean daily dose for each ADHD
medication was calculated by dividing the total dose (in
milligram) of each drug per year by 365.25 days. The
drug groups of each potentially addictive drugs were
used to calculate dispensation rates. Each drug group
was defined as categorical variables according to whether
patients were dispensed at least one drug defined into
the drug group or not during 2017.
Statistical analyses
Means, medians, percentiles, percentages, 95% confidence
intervals (CI), odds ratios (OR), and p-values are presented
when appropriate. Multivariable analyses for categorical
variables were performed by binary logistic regression.
Being dispensed ADHD medication, as well as OAT at
least once, respectively, during a calendar year, were de-
fined as a dependent variable in the logistic regression
model. Independent variables were age, gender, ‘the
number of dispensations of OAT opioids,’ ‘benzodiaze-
pines or z-hypnotics,’ ‘gabapentinoids,’ ‘non-OAT opioids,’
and ‘DAA.’ All these variables were defined categorically.
The level of statistical significance was defined as p < 0.05.
The Chi-square test and paired sample t-test were used to
estimate differences in dispensed mean daily doses of
ADHD medication in 2015 compared to 2017 among pa-
tients with at least one dispensation of ADHD medication
and OAT, respectively, during a calendar year throughout
the study period. All patients were censored from the
calendar year they died. SPSS version 24 was used for all
analyses.
Ethical considerations
The Regional Committee for Medical and Health Re-
search Ethics, REC vest, Norway, has approved the use
of registry data for this study (approval number 2018/
939/REK Vest, June 19, 2018). No informed consent
from included patients was necessary. The STROBE




A total of 9235 patients received at least one OAT
opioid from pharmacies in Norway in the period 2015 to
2017. In 2017, 69% were male, and the mean age was 45
years (Table 1). A total of 376 participants died during
the study period.
One-year prevalence and the types of dispensed ADHD
medications
The proportions of OAT patients who received at least
one dispensation of an ADHD medication increased from
3.5% in 2015 to 4.6% in 2017. A vast majority of them, i.e.,
74% received buprenorphine or buprenorphine-naloxone,
whereas the remaining 26% were dispensed methadone or
levomethadone. In 2017, the most dispensed CAS was
short- and intermediate-acting methylphenidate (55%),
followed by lisdexamphetamine (24%), dexamphetamine
(17%), long-acting methylphenidate (9%), and racemic am-
phetamine (2%) (Table 2ab). The non-stimulant atomoxe-
tine was dispensed in 6% of these patients. These findings
were substantially similar to the results in 2015 and 2016.
Dispensations of potentially addictive drugs to patients
receiving OAT opioids and ADHD medication
concomitantly
In the period from 2015 to 2017, being dispensed ADHD
medications were associated with being dispensed bupre-
norphine rather than methadone as OAT opioid (2017:
adjusted odds ratio (aOR): 1.6, 95% confidence interval
(CI): 1.3–2.1) (Table 3). Further, in 2017, being dispensed
ADHD medications were associated with being dispensed
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a non-OAT opioid (aOR 1.5, 95% CI: 1.1–1.9) and a DAA
against hepatitis C infection (aOR 1.6, 95% CI: 1.2–2.2).
The odds ratio (OR) of being dispensed DAA increased
steadily during the study period. Being dispensed ADHD
medications were not statistically associated with be-
ing dispensed gabapentinoids, benzodiazepines, or z-
hypnotics per year in the study period.
Mean daily doses of dispensed ADHD medications and
dispensation rates of other potentially addictive drugs
We identified 142 patients who received at least one dis-
pensation of ADHD medication per calendar year
throughout the study period. We found a substantial in-
crease in the dispensed mean daily doses of methylphen-
idate from 63mg in 2015 to 76mg in 2017 (p = 0.01)
(Fig. 1). The mean doses of other dispensed ADHD
medications were not statistically significantly different
in 2017 compared to 2015. However, the mean daily
dose of lisdexamphetamine increased from 21mg in
2015 to 83mg in 2017. The mean doses of amphet-
amine, dexamphetamine, methylphenidate, and lisdex-
amphetamine were near the highest recommended doses
for each drug, according to the European Medicines
Agency (EMA) [27]. Furthermore, 85 of the 142 patients
(60%) who were dispensed an ADHD medication per
year throughout the study period also received at least
one dispensation of z-hypnotics or benzodiazepines,
gabapentinoids, or non-OAT opioids in 2017 (Fig. 2).
The most frequent combination of dispensed drugs was
‘OAT opioid, ADHD medication, and benzodiazepines,
or z-hypnotics.’ Seven patients received ‘OAT opioid,
ADHD medication, benzodiazepines, or z-hypnotics,
gabapentinoids, and non-OAT opioids.’
Discussion
In the period 2015 to 2017, the proportion of patients
receiving ADHD medication in the OAT population in-
creased from 3.5 to 4.6%. Short- and intermediate-acting
methylphenidate and lisdexamphetamine were the most
frequently dispensed CAS. Dispensation of buprenor-
phine rather than methadone as an OAT opioid was
associated with being dispensed ADHD medication. In
2017, being dispensed non-OAT opioids and DAA
against hepatitis C infection were associated with being
dispensed ADHD medication. For four out of five
ADHD medication, the mean doses were near the high-
est recommended doses. Furthermore, the dose of
methylphenidate increased significantly throughout the
study period. Eighty-five of 142 patients who were dis-
pensed ADHD medication each year throughout the
Table 1 Baseline characteristics
2015 2016 2017
Patients 7958 7804 7709
Deaths 138 114 124
Patients, excl. Deaths 7820 7690 7585
OAT OAT + AMb OAT OAT + AMb OAT OAT + AMb
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Dispensed ADHD medication – 274 (3.5) – 312 (4.1) – 349 (4.6)
Age
≤ 25 171 (2.2) 5 (1.8) 135 (1.8) 7 (2.2) 120 (1.6) 9 (2.6)
26–35 1551 (19.8) 81 (29.6) 1403 (18.2) 90 (28.8) 1333 (17.6) 84 (24.1)
36–45 2605 (33.3) 107 (39.1) 2508 (32.6) 118 (37.8) 2392 (31.5) 134 (38.4)
46–55 2544 (32.5) 69 (25.2) 2540 (33.0) 79 (25.3) 2548 (33.6) 97 (27.8)
≥ 56 949 (12.1) 12 (4.4) 1104 (14.4) 18 (5.8) 1192 (15.7) 25 (7.2)
Mean (SD) 43.9 (9.7) 41.0 (8.5) 44.5 (9.8) 40.8 (8.7) 45.0 (9.9) 41.8 (9.0)
Gender
Male 5430 (69.4) 193 (70.4) 5354 (69.6) 221 (70.8) 5245 (69.1) 254 (72.8)
Female 2390 (30.6) 81 (29.6) 2336 (30.4) 91 (29.2) 2340 (30.9) 92 (26.4)
OAT opioidsa
Methadone (included levomethadone) 3216 (41.1) 72 (26.3) 3066 (39.9) 74 (23.7) 2981 (39.3) 92 (26.4)
Buprenorphine (included combinations) 4604 (58.9) 202 (73.7) 4624 (60.1) 238 (76.3) 4604 (60.7) 257 (73.6)
ADHD Attention deficit hyperactivity disorder, AM ADHD medication (atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and
methylphenidate), NorPD Norwegian Prescription Database, SD standard deviation, and No Number of patients
a The last dispensed OAT opioid in the calendar year
b On all medical indications
The table displays the baseline characteristics of patients who were dispensed at least one OAT opioid per year in the period from 2015 to 2017
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study period were also dispensed benzodiazepines, z-
hypnotics, gabapentinoids, or non-OAT opioids in 2017.
Short- and intermediate-acting methylphenidate is the
most dispensed CAS throughout the study period. These
formulations, particularly the short-acting formulation,
are associated with euphoria and addiction compared to
long-acting formulation [18, 28]. However, the short-
and intermediate-acting methylphenidate might be pref-
erable in situations where more focus and concentration
is needed for shorter periods. In Norway, the reimburse-
ment for methylphenidate for adults is pre-approved for
intermediate-acting formulations as opposed to long-
acting formulations [29], which may explain that few
patients were dispensed long-acting formulations. A
study evaluating the dispensations of ADHD medica-
tions in the general population among the Nordic coun-
tries showed that Denmark and Norway, in contrast to
Finland, Iceland, and Sweden, were substantially dis-
pensed intermediate-acting rather than long-acting
methylphenidate in the treatment of ADHD [30]. The
Norwegian guidelines for treating ADHD do not
mention the formulation of methylphenidate to patients
on OAT in their recommendations [7]. However, a
European consensus report recommends long-acting
formulations of CAS to prevent misuse among patients
with drug use disorders and ADHD [18].
The proportion of patients who received ADHD medi-
cation increased in the inclusion period. Nevertheless,
the dispensation rates were still in the lower range of
what was expected. It is estimated that as much as a
third of patients with drug addictions in Norway have
comorbid ADHD [16], and the proportion of those with
opioid use disorder is supposed to be 11–33% [3–5]. As-
suming that 40–50% of patients with ADHD were dis-
pensed ADHD medication in the general population
[18], one would expect that about 4–16% of those with
opioid use disorder receive ADHD medication. Our find-
ings showed that only 4–5% of the patients on OAT also
were dispensed ADHD medication during the study
period. This might have several explanations. A consen-
sus report evaluating screening, diagnosis, and treatment
of patients with drug use disorders and ADHD, recom-
mends the use of CAS when potentially therapeutic pros
and cons are considered in advance [18]. In addition, the
Norwegian guidelines for ADHD discourage dispensa-
tions of ADHD medication to patients on OAT who
used other potentially addictive drugs concomitantly [7].
Furthermore, low dispensation rates of CAS may also be
explained by medical illnesses or psychosocial condi-
tions, and active illicit drug use, which may disturb the
diagnostic assessment of ADHD and delay pharmaco-
logical treatment.
Retention to treatment is generally challenging in the
treatment of drug addictions, particularly among pa-
tients with comorbid ADHD. Inadequate knowledge of
pharmacological properties of different ADHD medica-
tions may explain a low coverage. For example, unlike
CAS, the non-stimulant atomoxetine may need several
weeks to give optimal clinical response [18]. Late-onset
of the effect of atomoxetine or careful dose-escalation of
methylphenidates and amphetamines may conflict with
patient’s expectations on a quick reduction of ADHD
symptoms. In addition, removing factors leading to dis-
continuation of CAS treatment may play an essential
role in preventing relapse to illicit stimulant drug use
and sustained stimulant injections, as well as improving
the quality of life by keeping complications such as
Table 2 The proportion of patients on OAT were dispensed
ADHD medication categorized on medical diagnoses and types
of CAS
a)
Year 2015 2016 2017
All indications
Number of patients 274 312 349
ADHD medication No. %a No. %a No. %a
Methylphenidate 194 71 217 70 207 59
- short- and intermediate-actingb 182 66 206 66 193 55
- long-actingc 38 14 30 10 33 9
Dexamphetamine 63 23 64 21 60 17
Atomoxetine 23 8 26 8 21 6
Lisdexamphetamine 14 5 47 15 84 24
Racemic amphetamine < 5 0 < 5 1 8 2
b)
Year 2015 2016 2017
ADHD
Number of patients 223 270 312
ADHD medication No. %a No. %a No. %a
Methylphenidate 171 76 198 72 194 62
- short- and intermediate-actingb 163 73 190 70 182 58
- long-actingc 32 14 26 10 29 9
Dexamphetamine 45 20 55 20 53 17
Atomoxetine 12 5 19 7 16 5
Lisdexamphetamine 12 5 39 14 72 23
Racemic amphetamine < 5 < 5 < 5 < 5 7 2
ADHD Attention deficit hyperactivity disorder, ADHD medication =
atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine,
and methylphenidate, ICD-10 10th Revision of International Classification of
Diseases, ICPC2 International Classification of Primary Care 2, and OAT opioid
agonist therapy
a Per cent of patients who received OAT and CAS, b Include all tablets and
capsules with short- and intermediate-acting methylphenidate, c Include depot
formulations of methylphenidate (Concerta®, Delmosart®, Equasym Depot®, or
Methylphenidate Sandoz®)
The tables display patients on OAT who were dispensed an ADHD medication
in the period 2015 to 2017 categorized on a) all medical indications, and b)
ADHD (ICD-10 code: F90 or ICPC2 code: P81)
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hepatitis C infection low [31]. Integrating ADHD treat-
ment in OAT, or vice versa, maybe a way to facilitate
the diagnostics and treatment and improve follow-up
approaches among marginalized patients on OAT with
comorbid ADHD [32].
In this study, the mean doses of ADHD medications
were in the highest range of usual recommended doses.
The benefits of high-dose ADHD medication on the
treatment of ADHD in the OAT population are not
clear. Two placebo-controlled randomized trials, includ-
ing patients with ADHD and addictions to amphet-
amines or cocaine, have found a decrease of ADHD
symptoms by using doses up to 180 mg methylphenidate
[19] and 80mg racemic amphetamine daily compared to
placebo [20]. The former study [19] also found that
high-dose of methylphenidate reduced relapse to illicit
stimulant use and contributed to higher retention in
treatment. Previous research has also confirmed similar
findings [33]. The latter study [20], evaluating racemic
amphetamine to placebo, showed that doses of 60 mg
and 80mg racemic amphetamine per day, respectively,
inhibited cocaine-related craving. Although, a dose of
80 mg racemic amphetamine did not seem to reduce
ADHD symptoms more than a dose of 60 mg per day.
Overall, one can assume that using higher doses of me-
thylphenidate or racemic amphetamine may improve the
effect of these medications on ADHD by keeping pa-
tients in treatment, reducing the craving for illicit stimu-
lant drugs, as well as by alleviating ADHD symptoms.
The proportion of patients who were dispensed lisdex-
amphetamine increased significantly from 2015 to 2017.
In addition, the mean dose rose markedly in the same
period, although it was not statistically significant. A
meta-analysis evaluating the efficacy, acceptability, and
tolerability of ADHD medication among patients with
ADHD without drug addiction favored amphetamines as
Table 3 Logistic regression analyses of variables associated with dispensed ADHD medication and OAT
2015 2016 2017
Dispensed ADHD medication N = 274 N = 312 N = 349
Not dispensed ADHD medication N = 7546 N = 7378 N = 7236
Crude OR Adjusted OR
(95% CI)
Crude OR Adjusted OR
(95% CI)
Crude OR Adjusted OR
(95% CI)
Age
- ≤ 25 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
- 26–35 1.8 1.8 (0.7–4.5) 1.3 1.3 (0.6–2.9) 0.8 0.8 (0.4–1.7)
- 36–45 1.4 1.5 (0.6–2.7) 0.9 1.0 (0.5–2.2) 0.7 0.7 (0.4–1.5)
- 46–55 0.9 1.0 (0.4–2.6) 0.6 0.7 (0.3–1.6) 0.5 0.5 (0.2–1.0)
- ≥ 56 0.4 0.5 (0.2–1.4) 0.3 0.4 (0.2–0.9) 0.3 0.3 (0.1–0.6)
Gender
- Female 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
- Male 1.1 1.0 (0.8–1.4) 1.1 1.0 (0.8–1.3) 1.2 1.2 (1.0–1.6)
The number of dispensations of OAT opioids per calendar year
- ≥ 52 1.0 (ref.) 1.0 (ref.) 1.00 (ref.) 1.0 (ref.) 1.0 (ref.) 1.00 (ref.)
- 13–51 0.9 1.0 (0.7–1.4) 0.7 0.8 (0.6–1.2) 1.1 1.1 (0.8–1.7)
- 7–12 0.7 0.8 (0.5–1.3) 0.8 0.9 (0.6–1.3) 1.3 1.3 (0.9–2.0)
- 1–6 0.7 0.7 (0.4–1.2) 0.9 1.0 (0.7–1.6) 1.0 1.0 (0.6–1.7)
OAT opioidsa
- Methadone (incl. Levomethadone) 1.0 (ref.) 1.00 (ref.) 1.00 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
- Buprenorphine (incl. combinations) 2.0 1.7 (1.3–2.3) 2.2 1.9 (1.4–2.5) 1.9 1.6 (1.3–2.1)
Dispensed opioids (excl. OAT opioids) 1.0 1.1 (0.8–1.5) 1.0 1.1 (0.8–1.5) 1.4 1.5 (1.1–1.9)
Dispensed gabapentinoids 0.8 0.9 (0.5–1.4) 1.2 1.2 (0.8–1.7) 1.1 1.0 (0.7–1.4)
Dispensed benzodiazepines and/or z-hypnotics 0.8 1.0 (0.7–1.2) 0.8 0.9 (0.7–1.2) 1.0 1.0 (0.8–1.3)
Dispensed DAA 0.8 1.0 (0.5–2.1) 1.1 1.4 (0.9–2.3) 1.4 1.6 (1.2–2.2)
ADHD Attention deficit hyperactivity disorder, ADHD medication Atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and
methylphenidate, CI confidence interval, DAA direct-acting antivirals against hepatitis C infection, and OAT opioid agonist therapy
a The last OAT opioid was dispensed during a calendar year recorded in the Norwegian Prescription Database
The table displays odds ratios for each independent variable among patients who were dispensed ADHD medication (dependent variable) and OAT. For example,
the adjusted odds of being dispensed opioids in 2017 was 1.5 among patients who were dispensed ADHD medication. Each independent variable is stated as
crude (unadjusted) and adjusted for each calendar year. Italics display significant values
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Fig. 1 (See legend on next page.)
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the first drug group of choice in the short-term treat-
ment of ADHD in adults [25]. By comparing methyl-
phenidate and amphetamines, the latter was more
efficacious and showed higher acceptability (i.e., fewer
patients leaving the study). National Institute for Health
and Care Excellence (NICE) guidelines [9] and a consen-
sus report [18] evaluating patients with drug addictions
and ADHD recommend methylphenidate or lisdexam-
phetamine as the first drugs of choice in the treatment
of ADHD in adults. A risk assessment of the potential of
misuse of lisdexamphetamine and methylphenidate has
been completed by the WHO, which pointed towards
that methylphenidate and lisdexamphetamine still have
low harmful profiles compared to other stimulants such
as racemic amphetamine and methamphetamine in
treatment of ADHD [34]. The use of ADHD medication
in the Norwegian OAT population was in line with these
recommendations. In addition, it is essential to mention
that the lisdexamphetamine named Aduvanz® was
granted the Norwegian marketing authorization in
September 2017, and the upcoming facilitation in the
pre-approved reimbursement of lisdexamphetamine was
introduced in October 2018 [35]. These changes may
also explain some of the increasing dispensation rates
found in this study.
Eighty-five of 142 patients who were dispensed ADHD
medication and OAT opioids concomitantly received ei-
ther benzodiazepines, z-hypnotics, gabapentinoids, or
(See figure on previous page.)
Fig. 1 Doses of dispensed ADHD medication among patients who received OAT opioids from 2015 to 2017. Legends: ADHD = Attention deficit
hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate,
CI = confidence interval, and Df = degrees of freedom. 1) Paired-samples t-test, df = 87, 2) Paired-samples t-test, df = 79, 3) Paired-samples t-test,
df = 10, 4) Paired-samples t-test, df = 26, 5) Paired-samples t-test, df = 5, and 6) Paired-samples t-test, df = 4. * = Upper recommended doses
according to The European Medicines Agency (EMA) per July 2019, ** = Calculation of the differences in mean daily doses between 2015 and
2017, *** = Upper recommended daily dose of short- and intermediate-acting methylphenidate according to the EMA, and **** = Include short-
and intermediate-acting methylphenidate (tablets or capsules), not depot formulations. The figure displays the mean daily doses of each
dispensed ADHD medication among patients who were dispensed at least one dispensation ADHD medication and OAT opioid, respectively,
each calendar year in the study period from 2015 to 2017
Fig. 2 Patients on ADHD medication who were dispensed other potentially addictive drugs in 2017. Legends: ADHD = Attention deficit
hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate,
BZD = benzodiazepines, GAB = gabapentinoids, OAT = Opioid agonist therapy, OPI = non-OAT opioids, and z-HP = z-hypnotics. The figure displays
dispensations of BZD, GAB, OPI, and z-HYP in 2017 among patients who were dispensed at least one dispensation of ADHD medication and OAT
opioids each calendar year in the period from 2015 to 2017. Eighty-five patients were dispensed BZD or z-HP, GAB, or OPI in this population
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non-OAT opioids at least as frequent as in the
remaining OAT population not were dispensed ADHD
medications in 2017. Our findings confirm previous
studies on the OAT population, showing that about half
of patients on OAT were dispensed other potentially ad-
dictive drugs [11, 36]. The fact that a substantial propor-
tion of patients were dispensed CAS concomitant with
dispensations of other potentially addictive drugs may
point towards the need to improve the prescribing prac-
tice of addictive drugs in this comorbid population in
order to keep the risk of adverse interactions low [11,
12, 37]. On the other hand, the prevalence of psychiatric
and somatic comorbidities in OAT is high [38–40], and
it may predict the high dispensation rates of potentially
addictive drugs when these comorbidities are treated. In
some cases, prescribing potentially addictive drugs may
be used to keep the patients completely abstinent from
illicit potentially addictive drugs if health professionals
follow up strictly, and the prescribing practices are con-
sidered proper [14, 15].
Strengths and limitations
The use of national registry data has some clear
strengths, by capturing whole cohorts of the studied
populations. Pharmacy records are considered more
valid than both medical records and data collected from
questionnaires and interviews. Because practically all dis-
pensed drugs are registered in the NorPD database,
completeness, and precision of all received information
is high, and the potential for information biases is low.
This study also had some limitations. First, because
non-reimbursed dispensations of ADHD medication
were not received through the Norwegian Health
Economics Administration (HELFO), the medical indica-
tions for these dispensations are not available for the re-
searchers through NorPD. Further, gabapentinoids,
benzodiazepines, z-hypnotics, and non-OAT opioids
have different medical indications, and the indications
have not been evaluated in this study. Second, the num-
ber of dispensed OAT opioids may be incompletely reg-
istered by the pharmacies. The self-reporting survey of
OAT in Norway in 2017 showed that the mean fre-
quency of dispensations of OAT opioids was four times
a week [22]. This finding may indicate that the number
of dispensations is underestimated. Third, the NorPD
only receives information about dispensed drugs, and we
cannot know whether the drugs have been consumed.
All addictive drugs are coveted for illegal consumption,
and the drugs may be re-distributed. Illicit use is com-
mon in this population and cannot be covered using
register data. Fourth, slightly less than 10% of OAT opi-
oids are dispensed in addiction specialist outpatient
clinics, and those are not necessarily registered in the
NorPD. Some of these outpatient clinics order OAT
opioids directly from pharmacies without linking to a
personal identification number. These patients were
missed in this study, and those could have higher dis-
pensation rates of addictive drugs than patients included
in this study [22].
Conclusion
Co-prescribing of CAS and atomoxetine was low in the
OAT population in Norway, relative to the expected
prevalence of ADHD in this patient group. Considering
that up to a third of the OAT population is estimated to
have ADHD, only 3.5 to 4.6% of patients received both
ADHD medication and OAT opioids in Norway in the
period from 2015 to 2017. Furthermore, 85 of 142 OAT
patients who were dispensed ADHD medication each
year throughout the study period were dispensed at least
one dispensation of other potentially addictive drugs
concomitantly in 2017. Generally, the polydrug use, in-
cluding CAS, OAT, and other potentially addictive
drugs, may lead to adverse side effects; however, a treat-
ment combining several potentially addictive drugs in
OAT patients using CAS has only been scarcely studied.
Randomized-controlled trials evaluating ADHD medica-
tion in different doses are needed to improve the treat-
ment of ADHD in the OAT population.
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ABSTRACT
Objectives To compare the use of benzodiazepines, z- 
hypnotics, gabapentinoids, opioids and centrally acting 
stimulants (CAS) among patients who had received opioid 
agonist therapy (OAT) in Norway and Sweden during the 
period 2015 - 2017.
Design A register- based prospective cohort study using 
information about dispensed drugs from the Norwegian 
Prescription Database and Swedish Prescribed Drug 
Register.
Setting Patients who were dispensed OAT opioids from 
pharmacies.
Participants A total of 7176 Norwegian and 3591 
Swedish patients on OAT were included.
Outcome measures The number and frequency of 
potentially addictive drugs dispensed were calculated for 
the two countries. The mean daily doses of dispensed 
benzodiazepines and z- hypnotics were summarised by 
calculating benzodiazepines in diazepam equivalents and 
z- hypnotics in zopiclone equivalents.
Results In 2017, 46% of patients in Norway, and 15% 
in Sweden, were dispensed a benzodiazepine. Moreover, 
14% in Norway and 26% in Sweden received z- hypnotics. 
Gabapentinoids were dispensed to 10% of patients in 
Norway and 19% of patients in Sweden. In Norway, 6% 
and 12% of the patients received strong and weak non- 
OAT opioids, respectively, whereas in Sweden 10% were 
dispensed strong non- OAT opioids and 5% weak non- OAT 
opioids . CAS were dispensed to 4% in Norway and 18% 
in Sweden. The mean daily doses of benzodiazepines 
were 16 and 17 mg diazepam equivalents in Norway and 
Sweden, respectively. For z- hypnotics, the mean daily 
dose was 8 mg zopiclone equivalents in both countries. 
‘Benzodiazepines and z- hypnotics’ was the most 
dispensed drug combination in 2017. Similar results were 
found in 2015 and 2016.
Conclusions Nearly half of those patients who were 
dispensed an OAT opioid in Norway and Sweden were 
dispensed potentially addictive drugs. The differences 
identified between Norway and Sweden might be related 
to differences in eligibility guidelines and restrictions with 
respect to OAT.
INTRODUCTION
Several studies indicate that around 50% of 
those patients who receive opioid agonist 
therapy (OAT) are dispensed benzodiaz-
epines (e.g., diazepam and oxazepam), 
z- hypnotics (zolpidem and zopiclone), 
gabapentinoids (pregabalin and gabapentin), 
non- OAT opioids (e.g., morphine and 
oxycodone) or centrally acting stimulants 
(CAS) (e.g., methylphenidate and lisdexa-
mphetamine) yearly1–5, notwithstanding 
the use of any potentially addictive illicit 
drugs.1 6 7 Prescribing potentially addictive 
drugs to patients on OAT is controversial and 
comes with pros and cons.1 8 Combinations 
of several potentially addictive drugs may 
increase the risk of non- fatal or fatal over-
doses,1 as well as amplify negative complex 
medical and psychosocial challenges such 
as unemployment,9 criminal behaviour10 
and discontinuation of OAT.6 11–13 However, 
the majority of patients on OAT have psychi-
atric and physical comorbidities, including 
psychotic disorders, attention deficit 
Strengths and limitations of this study
 ► This study used national register- based data of 
drugs dispensed from pharmacies in Norway and 
Sweden.
 ► This study did not capture patients who were dis-
pensed opioid agonist therapy (OAT) opioids from 
entities other than pharmacies.
 ► There is potential for misclassification of patients if 
dispensed opioids were dispensed on medical indi-
cations other than OAT.
 ► About 40% and 10% of OAT patients in Sweden and 
Norway, respectively, were not identified by using 
these national register- based data.
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hyperactivity disorder (ADHD), personality disorders, 
depression, other substance use disorders besides opioid 
addiction or injection- related diseases such as hepatitis 
C virus infection.14–16 The wide range of high- prevalent 
comorbidities can require coprescriptions of potentially 
addictive drugs to obtain an optimal medical treatment 
in the OAT population. Examples such as prescriptions 
of CAS in order to improve ADHD symptoms17 and short- 
term prescriptions of benzodiazepines to treat psycho-
motor agitation caused by stimulant intoxications18 or 
seizure prophylaxis, as in cases of benzodiazepine or 
alcohol withdrawal,19 illustrate clinical indications for 
such coprescriptions.
The prevalence of potentially addictive drugs 
dispensed among patients on OAT varies between coun-
tries.1 5 20–23 In the USA, in 2013, between 22% and 
65% of patients on OAT were dispensed benzodiaze-
pines, and 42% and 20% were dispensed benzodiaze-
pines and z- hypnotics, respectively, in the UK between 
1998 and 2014.20 24 In Sweden, 41% of OAT patients 
were dispensed z- hypnotics in the period 2005–2012.1 
Furthermore, epidemiological studies have shown that 
a wide range of OAT patients, from 8% to 22%, were 
dispensed gabapentinoids in different countries,1 3 24 
while between 12% and 34% were dispensed non- OAT 
opioids.21 22 25 In contrast, no studies have evaluated CAS 
dispensing among patients on OAT. Overall, there are 
substantial intercountry differences regarding patients 
on OAT who were dispensed potentially addictive 
drugs; however, there is a gap in knowledge concerning 
whether these differences still persist.
OAT has in recent decades been increasingly applied 
as an effective and well- documented treatment for opioid 
addiction.26–29 In Norway, around 7500 patients currently 
receive OAT,28 while the corresponding number for 
Sweden is nearly 4400 patients.30 Research on differences 
and similarities in the dispensing practice of potentially 
addictive drugs in these countries needs to be investigated 
to optimise the use of these drugs in the OAT population. 
In addition, evaluating dispensed doses of benzodiaze-
pines, z- hypnotics, pregabalin, gabapentin and the CASs 
methylphenidate and lisdexamphetamine - the first hand 
of choice in the treatment of ADHD - are of particular 
interest due to the risk of overdoses and intoxications. It 
is also important for the study of possible variations in 
dispensed doses between the two countries.
Thus, this study aims to describe the rates and doses 
of potentially addictive drugs dispensed from Norwegian 
and Swedish pharmacies to patients receiving OAT in the 
period 2015–2017. We aim to describe the following:
1. The dispensing rates of benzodiazepines, z- hypnotics, 
gabapentinoids, non- OAT opioids and CAS per calen-
dar year.
2. The mean daily doses of dispensed benzodiazepines, 
z- hypnotics, pregabalin, gabapentin, lisdexamphet-
amine and methylphenidate per calendar year.
3. The most commonly dispensed combinations of po-
tentially addictive drug groups: benzodiazepines, 
z- hypnotics, gabapentinoids, non- OAT opioids and/or 
CAS among patients on OAT in 2017.
METHODS
Data sources
Data were retrieved from the Norwegian Prescription 
Database and Swedish Prescribed Drug Register. From 1 
January 2004 in Norway and 1 July 2005 in Sweden, all 
pharmacies are obliged to submit electronically all data 
regarding dispensed drugs to the Norwegian Prescrip-
tion Database and Swedish Prescribed Drug Register. 
The Norwegian Prescription Database and Swedish 
Prescribed Drug Register are administered and regu-
lated by the Norwegian Institute of Public Health and 
Swedish National Board of Health and Welfare, respec-
tively. Both registers contain information on all drugs 
dispensed from pharmacies, with unique patient identi-
fiers, except for drugs administered at hospitals, nursing 
homes and outpatient clinics.31 32 The Anatomical Ther-
apeutic Chemical (ATC) classification system was used in 
accordance with the WHO standards per 2018.33 A recent 
report evaluating OAT stated that the Swedish Prescribed 
Drug Register identifies about 60% of patients on OAT,27 
while the Norwegian Prescription Database is assumed to 
identify about 90% of the patients.28 Moreover, in 2016, 
Sweden changed the OAT eligibility criteria by including 
long- term use of opioids (not only opiates like heroin, 
opium and morphine) as analgesics for chronic, severe 
pain.26 27 Inclusion criteria in this study, therefore, identi-
fied patients with a high opiate tolerance who had a high 
degree of continuity in their OAT treatment.
Study population
All patients between 18 and 75 years of age who received 
at least one mean defined daily dose (DDD) of one or 
more defined OAT opioids per day during 2015, 2016 or 
2017 were included (see online supplementary table S1). 
A minimum of one mean DDD per day was set as a crite-
rion for inclusion to exclude patients who were dispensed 
low- dosed OAT opioids on medical indications other 
than OAT. The DDD of OAT opioids was calculated for 
each calendar year separately, which means that patients 
were only included in the calendar year when the mean 
dispensed DDD per day of OAT opioids, measured in 
DDD divided by 365.25 days, was one or more. The type 
of OAT opioids that were the latest dispensed (calculated 
in DDD) per year determined which type of OAT opioid 
category the patients belonged to in a calendar year. 
Dispensing methadone tablets or injections as well as 
buprenorphine formulations (ATC code: N02AE01) that 
have other medical indications besides OAT in Norway 
and Sweden, were excluded in the calculation of mean 
DDD of OAT opioids per day.
Patient and public involvement
Patients and the public were not involved in the devel-
opment of the study design, planning and recruitment. 
Study results were not distributed to the patients after 
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the study. All data were handled strictly confidentially 
and anonymously. The Strengthening the Reporting 
of Observational Studies in Epidemiology Guidance 
checklist was applied during the preparation of the 
study.
Definitions of OAT opioids, other potentially addictive drugs 
and drug groups
All the potentially addictive drugs in the drug groups 
of benzodiazepines, z- hypnotics, gabapentinoids, OAT 
opioids, non- OAT opioids and CAS, which had marketing 
authorisations in Norway or Sweden in the period from 
2015 to 2017, were included. All included drugs were 
defined according to their ATC codes. In addition, the 
non- OAT opioids were divided into two groups: ‘strong 
non- OAT opioids’ and ‘weak non- OAT opioids’ according 
to their analgesic potency.
Analysis strategy and statistical analyses
Data analysis
The age of included patients per year was calculated by 
subtracting the dispensing year from the birth year. The 
age of patients was categorised into four groups: 18–35, 
36–45, 46–55 and 56–75.
The dispensing rates per year were defined as all 
included patients who were dispensed at least one poten-
tially addictive drug during a calendar year divided by the 
number of included patients in the same year. The rates 
were calculated for each drug and the respective drug 
groups.
The mean daily doses per year of all dispensed benzo-
diazepines, z- hypnotics, pregabalin, gabapentin, lisdexa-
mphetamine and methylphenidate were calculated by 
summing all dispensed DDD of each potentially addictive 
drug per calendar year in the study period. The DDD 
of each drug was converted to milligrams by using the 
definitions of the WHO Collaboration Centre for Drug 
Statistics Methodology (see online supplementary table 
S2).33 The dispensed doses (in milligrams) of each drug 
were divided by 365.25 days to calculate the mean daily 
doses per year. Further, the mean daily dose per year of 
each dispensed benzodiazepine was converted to mean 
daily dispensed diazepam equivalents according to the 
equivalency table stated by the Norwegian Directorate 
of Health and a study evaluating the equipotency of 
lorazepam versus diazepam (see online supplementary 
figure S1).34 35 The dispensed diazepam equivalents per 
day were used to calculate the total sum of all dispensed 
benzodiazepines per day per year. The mean daily doses 
of dispensed z- hypnotics were calculated by converting 
mean dispensed zolpidem dose per day to zopiclone 
equivalents according to the guidelines of the Norwegian 
Directorate of Health.34 Furthermore, the total mean 
doses per day of zopiclone and zolpidem in zopiclone 
equivalents for a calendar year were summed.
Statistical analyses
Means, medians, percentiles and percentages were used 
to calculate dispensing rates, and the dispensed doses of 
benzodiazepines, z- hypnotics, pregabalin, gabapentin, 
lisdexamphetamine and methylphenidate. Stata SE V.16.0 
statistical software was used for all analyses.
RESULTS
Descriptive characteristics
A total of 7176 Norwegian and 3591 Swedish patients on 
OAT were included in the study period (table 1). In 2015, 
6007 patients in Norway, and 2640 in Sweden fulfilled 
the inclusion criteria (see online supplementary figure 
S2). A further 5542 OAT patients in Norway, and 2683 
OAT patients in Sweden were included in 2016, with 5556 
Norwegian OAT patients and 2739 Swedish OAT patients 
having fulfilled the eligibility criteria in 2017.
In 2017, 72% and 70% of the Norwegian and Swedish 
patients were male, respectively. The mean age of the 
patients included was 46 years in Norway and 45 years in 
Sweden. Buprenorphine/buprenorphine- naloxone was 
the most dispensed OAT opioid throughout the study 
period, having been dispensed to 55% of patients in 
Norway and 57% of patients in Sweden. The findings in 
2015 and 2016 were similar.
Dispensing rates of potentially addictive drugs
In Norway, 56% of patients on OAT were dispensed 
benzodiazepines, z- hypnotics, gabapentinoids, non- OAT 
opioids or CAS in 2015 (table 2). In 2017, the propor-
tion was 59%. In Sweden, the proportion of patients on 
OAT who received at least one dispensation of these 
potentially addictive drugs was 56% in 2015 and 55% 
in 2017 (figure 1). In 2017, the proportion of patients 
receiving benzodiazepines was 46% in Norway and 15% 
in Sweden. Furthermore, 14% in Norway and 26% in 
Sweden received z- hypnotics, and 10% of the Norwegian 
patients and 19% of the Swedish patients were dispensed 
gabapentinoids. CAS were dispensed to 4% of the Norwe-
gian patients and 18% of the Swedish patients on OAT. 
Similar results were also achieved in 2015 and 2016 (see 
online supplementary figure S3).
Dispensed doses of benzodiazepines, z-hypnotics, gabapentin, 
pregabalin, lisdexamphetamine, and methylphenidate
In 2017, the mean doses of dispensed benzodiazepines 
were 17 mg/day diazepam equivalents in Norway, with a 
corresponding 16 mg/day in Sweden (table 3). Further, 
the mean dose of dispensed z- hypnotics was 8 mg/day 
zopiclone equivalents in both countries in 2017. The 
mean daily doses of dispensed pregabalin, gabapentin 
and lisdexamphetamine were higher in Norway than 
in Sweden (pregabalin: 402 mg vs 345 mg, gabapentin: 
1021 mg vs 772 mg and lisdexamphetamine: 58 mg vs 
51 mg), while the mean dose of dispensed methylphe-
nidate per day was higher in Sweden compared with 
Norway (methylphenidate: 80 mg vs 57 mg). The results 
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were relatively similar in 2015 and 2016 except for the 
mean dose of dispensed lisdexamphetamine per day, 
which was higher (in mg) in Sweden than in Norway in 
2015 (lisdexamphetamine: 42 mg vs 13 mg).
Combinations of potentially addictive drugs in 2017
The proportion of patients on OAT being dispensed 
a single potentially addictive drug was 34% in Norway 
and 31% in Sweden. A quarter were dispensed poten-
tially addictive drugs from two or more drug groups (see 
online supplementary table S3). ‘Benzodiazepines and 
z- hypnotics’ was the most commonly dispensed combi-
nation of drugs, whereas ‘benzodiazepines and non- 
OAT opioids’ and ‘z- hypnotics and gabapentinoids’ were 
the second most common combinations in Norway and 
Sweden, respectively.
DISCUSSION
The proportion of patients on OAT who were dispensed 
a potentially addictive drug was unchanged during the 
study period, with about half of the patients in both coun-
tries. There were, however, substantial variations between 
the countries in all dispensed drug groups. Benzodiaze-
pines and weak non- OAT opioids were more commonly 
dispensed in Norway than in Sweden. In contrast, z- hyp-
notics, gabapentinoids, CAS and strong non- OAT opioids 
were more frequently dispensed in Sweden compared 
with Norway. Similar variations between Norway and 
Sweden have also been found regarding dispensing weak 
and strong non- OAT opioids in the general population.36 
The most frequent combinations of potentially addic-
tive drugs with OAT medications in 2017 were observed 
for benzodiazepines and z- hypnotics in both countries. 
The mean daily doses of dispensed benzodiazepines and 
z- hypnotics were also similar between the countries, while 
pregabalin, gabapentin and lisdexamphetamine doses 
were higher (in mg) in Norway. The mean daily dose of 
methylphenidate was higher (in mg) in Sweden compared 
with Norway. Similar results were found in 2015 and 2016.
The Swedish OAT guidelines recommend restrained 
practice in dispensing potentially addictive drugs,26 27 
while Norway goes further by downright discouraging 
benzodiazepine use in OAT. It was, therefore, particularly 
surprising that only 15% of the patients in Sweden were 
dispensed benzodiazepines, whereas, in Norway, benzo-
diazepines were dispensed to about half of the OAT 
patients. However, the dispensing rates of z- hypnotics and 
gabapentinoids were higher in Sweden than in Norway. 
The fact that the prevalence of mental and physical disor-
ders is high among patients on OAT - and that there is 
a broad spectrum of medical indications for the use of 
benzodiazepines, gabapentinoids and z- hypnotics - makes 
it challenging to determine whether our results point 
towards inappropriate dispensing practice in the OAT 
populations in each country.14 15 37–39 It is nevertheless 
noteworthy that the dispensing rates of these drugs devi-
ated considerably between the two countries.
Sweden had dispensing rates nearly four times higher 
for CAS compared with Norway, which indicates that 
coverage of ADHD treatment in patients on OAT is higher 
in Sweden. In both countries, guidelines for ADHD treat-
ment recommend abstinence from other potentially 
addictive drugs when CAS are dispensed to patients on 
OAT.40 In addition, the Norwegian guidelines recommend 
Table 1 Basic characteristics of patients receiving opioid agonist therapy in Norway and Sweden
Baseline characteristics
2015 2016 2017
Norway Sweden Norway Sweden Norway Sweden
No. % No. % No. % No. % No. % No. %
Patients 6007 2640 5542 2683 5556 2739
  Age
  ≥18–35 1132 19 648 25 958 17 649 24 881 16 647 24
  >35–45 2043 34 786 30 1815 33 806 30 1751 32 819 30
  >45–55 2096 35 737 28 1961 35 708 26 2000 36 713 26
  >55–≤75 736 12 469 18 808 15 520 19 924 17 560 20
  Mean (SD) 45 (9) 44 (11) 45 (9) 45 (11) 46 (9) 45 (11)
Gender
  Male 4225 70 1886 71 3897 70 1939 72 3878 70 1961 72
  Female 1782 30 754 29 1645 30 744 28 1678 30 778 28
OAT opioids*
  Methadone/levomethadone 2747 46 1229 47 2389 43 1209 45 2533 46 1191 43
  Buprenorphine/buprenorphine- naloxone 3260 54 1411 53 3153 57 1474 55 3023 54 1548 57
*Patients were categorised in the groups ‘Methadone/Levomethadone’ and ‘Buprenorphine/buprenorphine- naloxone’. The type of OAT 
opioids was calculated based on the most dispensed OAT opioid measured in DDD per calendar year.
DDD, defined daily dose; No., number of patients; OAT, opioid agonist therapy.
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documented abstinence from potentially addictive drugs 
at least 3 months prior to the initiation of CAS in OAT 
patients when indicated.41 This may partly explain a lower 
dispensing rate of CAS in Norway compared with Swedish 
OAT patients. Furthermore, unlike Norway, Sweden 
seems to terminate OAT in cases of repeated illicit drug 
use, which indicates that the coverage of OAT among 
patients with severe opioid addiction may be lower in 
Sweden.30 42 This can explain why the proportion of OAT 
patients who meet the criteria for codispensing CAS is 
higher in Sweden compared with Norway.
The differences in dispensing rates and mean daily 
doses of codispensed potentially addictive drugs between 
Norway and Sweden may also be explained by the compo-
sition and heterogeneity of OAT populations. The Euro-
pean Monitoring Centre for Drugs and Drug Addiction, 
evaluating OAT in 12 European countries,29 points out 
that restrictive policy, narrow inclusion criteria and costs 
are seen as substantial challenges limiting the coverage of 
OAT. In general, patients who repeatedly use illicit drugs 
in OAT have more psychiatric and somatic comorbidi-
ties.43–45 In Sweden, repeated use of illicit drugs in OAT 
may cause patients to be terminated from OAT against 
their will.42 This is to believe that Norway probably has 
a higher coverage of OAT, which also includes patients 
using illegal drugs and, accordingly, those with a higher 
burden of comorbid diseases. In addition, the divergent 
dispensing practices in the two countries could reflect 
the lack of consensus and evidence- bases concerning the 
treatment of underlying disorders in OAT patients.
Moreover, a tenth of the Norwegian OAT patients were 
dispensed a gabapentinoid in 2017, whereas nearly twice 
as many were dispensed this drug in Sweden. During 
the last decade, the dispensing of gabapentinoids has 
increased substantially in the general population in 
Norway and Sweden despite studies that point out that 
gabapentinoids are potentially addictive.7 24 31 32 46 System-
atic reviews evaluating the use of gabapentinoids indicate 
that patients with opioid addiction were at a particular risk 
of misusing pregabalin and gabapentin,7 46 and euphoria 
and sedative effects were described when combining with 
opioids. Therefore, it is worrying that dispensing rates of 
gabapentinoids were high and increasing among patients 
on OAT.
Overall, based on our data and existing knowledge, we 
are unable to sufficiently evaluate whether dispensing 
rates of potentially addictive drugs were disproportion-
ately high or even low among patients on OAT in Norway 
and Sweden during the study period. Some patients may 
have been undertreated considering their high burden 
of disease. On the other hand, a recent study has found 
that being dispensed gabapentinoids, z- hypnotics or 
benzodiazepines is associated with overdose death among 
patients on OAT.1 To stay on the safe side of this chal-
lenging matter, lower dispensing rates of these drugs may 
be preferable considering a high number of overdose 
deaths in Norway and Sweden during the last decade.30 47 
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indications, regular urine testing to prevent concomi-
tant street drug use, and close collaboration between 
prescribers of OAT opioids and those dispensing poten-
tially addictive drugs may be important measures to 
decrease future overdose deaths and ensure more reason-
able and safe treatment approaches among the highly 
morbid patients on OAT.
STRENGTHS AND LIMITATIONS
The use of national registry data has some advantages, 
as it can capture whole cohorts of the studied popula-
tions. The Norwegian Prescription Database and Swedish 
Prescribed Drug Register have advantages in that they 
receive all information concerning dispensed drugs from 
pharmacies in Norway and Sweden, except for those 
administered at hospitals, nursing homes and outpatient 
clinics. These registers are the most useful databases that 
identify reliable information regarding drug dispensing 
among patients on OAT.31 32
However, this study also has some limitations, mainly 
related to possible differences in selection bias between 
the studied populations. First, in both countries, patients 
may use methadone mixture for a medical indication 
other than OAT yet still be included in the OAT popu-
lation. To account for this, only patients who had been 
dispensed a mean dose of one or more DDD of meth-
adone mixture, levomethadone or buprenorphine/
buprenorphine- naloxone during a calendar year were 
included. Second, mean daily doses were calculated by 
summing all dispensed doses of the respective drugs 
during a calendar year divided by 365.25 days. Dividing 
the dispensed doses per year by 365.25 have some limita-
tions. Some patients may have been dispensed drugs in a 
higher mean daily dose within a shorter period than the 
calculations of mean daily doses per year indicate. Further, 
the drugs that were dispensed at the end of December 
for consumption in the following months were calculated 
as consumed in the year the drugs were dispensed. The 
latter could potentially signify that the mean daily doses 
were calculated higher than the dose recommended by 
the prescribers. Third, it is estimated that only about 60% 
of patients on OAT are identified through the Swedish 
Prescribed Drug Register; the remaining proportion may 
receive OAT opioids from specialised addiction outpa-
tient clinics within specialist healthcare.27 In Norway, it is 
estimated that 90% of patients who were dispensed OAT 
opioids were registered in the Norwegian Prescription 
Database.28 The fact that 40% of the Swedish patients 
were lacking could skew the results and affect the conclu-
sion. Patients who received OAT opioids from outpatient 
clinics may have more psychiatric and physical comor-
bidities and need more follow- ups than patients who 
were dispensed OAT opioids by pharmacies. Therefore, 
these comorbid patients who could not be captured by 
our study may have had higher dispensing rates of poten-
tially addictive drugs, meaning that the dispensing rates 
may have been underestimated in this study. Fourth, the 
Swedish Prescribed Drug Register does not provide data 
on patients who died during the study period. Due to this, 
patients were censored from the year with no dispensing 
Figure 1 The proportion of patients on OAT who were dispensed potentially addictive drugs in 2017. The figure displays 
the proportion of patients on OAT who were dispensed at least one potentially addictive drug, benzodiazepine, z- hypnotic, 
gabapentinoid, strong non- OAT opioid, weak non- OAT opioid and centrally acting stimulant in Norway and Sweden in 2017. 
Strong non- OAT opioids were defined as all opioid expect codeine, tramadol and tapentadol. Weak non- OAT opioids were 
defined as all drugs that contain codeine, tramadol or tapentadol. OAT, opioid agonist therapy.
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Table 3 Dispensed dose of potentially addictive drugs in the period from 2015 to 2017
Year 2015 2016 2017
Country Norway Sweden Norway Sweden Norway Sweden
Benzodiazepines
  Diazepam equivalents
   Number of patients 2622 438 2503 451 2556 421
   Mean (mg/year) 6920 6896 6585 6437 6216 5936
   Mean (mg/day/year) 19 19 18 18 17 16
   Median (mg/day/year) 10 10 10 9 10 9
   25 percentile (mg/day/year) 3 2 3 2 3 2
   75 percentile (mg/day/year) 21 22 21 21 20 21
Z- hypnotics
  Zopiclone equivalents
   Number of patients 912 750 834 760 798 721
   Mean (mg/year) 2867 3037 2904 2951 2942 3008
   Mean (mg/day/year) 8 8 8 8 8 8
   Median (mg/day/year) 5 7 6 6 6 7
   25 percentile (mg/day/year) 1 2 1 2 1 2
   75 percentile (mg/day/year) 10 12 10 12 11 12
Gabapentinoids
  Gabapentin
   Number of patients 192 164 183 203 207 213
   Mean (mg/year) 335 409 256 505 334 730 276 083 372 966 282 017
   Mean (mg/day/year) 918 702 916 755 1021 772
   Median (mg/day/year) 376 324 492 329 492 329
   25 percentile (mg/day/year) 82 82 82 82 164 82
   75 percentile (mg/day/year) 1287 992 1232 986 1203 986
  Pregabalin
   Number of patients 348 330 359 331 413 317
   Mean (mg/year) 134 777 123 510 144 551 119 335 146 684 126 122
   Mean (mg/day/year) 369 338 396 327 402 345
   Median (mg/day/year) 261 277 319 260 275 287
   25 percentile (mg/day/year) 66 138 92 117 82 149
   75 percentile (mg/day/year) 561 480 592 483 575 501
Centrally acting stimulants
  Methylphenidate
   Number of patients 143 400 151 392 143 346
   Mean (mg/year) 18 957 28 966 21 364 29 248 20 845 29 305
   Mean (mg/day/year) 52 79 58 80 57 80
   Median (mg/day/year) 48 69 52 71 57 70
   25 percentile (mg/day/year) 16 35 18 31 20 28
   75 percentile (mg/day/year) 75 109 85 112 85 114
  Lisdexamphetamine
   Number of patients 9 82 28 144 51 183
   Mean (mg/year) 4778 15 238 18 158 17 649 21 033 18 514
   Mean (mg/day/year) 13 42 50 48 58 51
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OAT opioids in both countries. The annual self- reported 
survey on the Norwegian OAT population indicated that 
the death rate is approximately 1.5% per 100 patient- 
year, which could constitute about 125 patients yearly in 
our Norwegian and Swedish population.28 Fifth, because 
no dispensed drugs in Sweden nor all non- reimbursed 
dispensations in Norway are necessarily linked to medical 
diagnostic codes, such as the International Statistical 
Classification of Diseases and Related Health Problems 
version 10, or the International Classification of Primary 
Care, the medical indications for the dispensations are 
not available to the researchers through the prescription 
register- based databases. Sixth, in 2016, Sweden changed 
the inclusion criteria to be granted OAT by including 
opioid- addicted patients with extensive opioid use caused 
by chronic severe pain.26 27 The proportion of patients 
receiving OAT opioids due to pain was not estimated in 
this study.
CONCLUSION
About half of patients who were dispensed an OAT opioid 
were codispensed potentially addictive drugs in Norway 
and Sweden. There were remarkable differences in the 
dispensing rates and dispensed doses of potentially addic-
tive drugs between OAT patients in these countries. This 
might be related to differences in national guidelines, 
a lack of evidence- based knowledge and international 
consensus on the treatment of comorbid conditions 
among patients on OAT or differences in the criteria 
required to be included and kept in OAT, which again 
may contribute to varying clinical practice and treatment 
approaches in OAT populations across the countries. We 
call for further research to investigate proper approaches 
for the treatment of comorbid conditions in patients 
undergoing OAT.
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Abstract
Background: The impact of clinical and sociodemographic factors on fatigue remains unknown among patients
with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item
fatigue severity scale (FSS-9) and identify the impact that clinical and sociodemographic factors – such as injecting
substance use, chronic infectious diseases, liver fibrosis, opioid agonist therapy (OAT), debt difficulties, and housing
situation – have on fatigue.
Methods: We used data from a cohort of patients with SUD in Norway with annual health assessments surveying
FSS-9 and some clinical and sociodemographic factors. A total of 915 FSS-9 measurements were collected from 654
patients during the period 2016–2020. We defined baseline as the first annual health assessment when the health
assessments were listed chronologically. Time was defined as years from baseline. We used a linear mixed model to
analyse whether the clinical and sociodemographic factors affected the FSS-9 sum score, presented with beta
coefficients (β) with 95% confidence intervals (CI).
Results: The mean sum score of the FSS-9 was 43 (standard deviation: 16) at baseline. Females compared with
males (adjusted mean difference of FSS-9 sum score: 4.1, 95% CI: 1.3–7.0), having debt difficulties compared with
having no debt difficulties (2.9;0.4–5.3), and frequent use of benzodiazepines (5.7;3.0–8.4) or amphetamines (-5.0;-
8.0– -2.0) compared to less frequent or no use of these substances changed the FSS-9 baseline sum score. The
other clinical and sociodemographic factors did not predict any clinically relevant change in the FSS-9 sum score
from baseline to the following health assessments.
Conclusion: Patients with SUD suffer from high levels of fatigue. Female patients, patients with debt difficulties,
and those with extensive use of benzodiazepines are at particular risk of being fatigued. This should be taken into
consideration when planning health services.
Keywords: Substance-related disorders, Fatigue, Fatigue severity scale, Quality of life, Comorbidities, Illicit drugs,
Viral human hepatitis, HIV, Kidney disease
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Background
Patients with Substance Use Disorders (SUD) suffer
from a broad range of health-related difficulties that may
contribute to fatigue [1–3]. Fatigue presents itself as a
persistent and overwhelming feeling of exhaustion and
loss of energy. The condition is mainly associated with
chronic diseases and may mitigate treatment adherence
and exacerbate comorbid disorders [4, 5]. In SUD popu-
lations, a myriad of external factors can interact with fa-
tigue and affect these patients’ general well-being [6–8].
Injecting substance use, internal organ dysfunctions
(predominantly kidney and liver diseases), mental disor-
ders, as well as low income, unemployment, and home-
lessness are some of the external factors that interact
with fatigue. Despite this, relatively little attention has
been paid to the extent of fatigue and how much various
external factors influence fatigue among patients with
SUD. Therefore, understanding the key factors affecting
fatigue is essential to improve treatment outcomes and
adherence in this population.
Fatigue is associated with several sociodemographic
and clinical factors. Among patients with the Hepatitis C
Virus (HCV) infection, 50–70% have reported fatigue
[9–11], while 33–88% of those with the Human Im-
munodeficiency Virus (HIV) infection have presented
the same symptom [12]. A more uncertain prevalence of
fatigue is seen among patients with the Hepatitis B Virus
(HBV) [13, 14]. In addition, females, patients with lower
educational levels, and those with opioid use disorders
undergoing Opioid Agonist Therapy (OAT) with metha-
done or buprenorphine generally have a greater risk of
fatigue [15, 16]. Disentangling the effects of the potential
factors influencing fatigue in patients with SUD is essen-
tial for individualised treatment and developing clinical
guidelines.
Fatigue is a subjective concept, and various definitions
and instruments are used in the literature to capture it,
which makes interpretations more complicated [17–19].
The nine-item fatigue severity scale (FSS-9) is a well-
known questionnaire used to quantify fatigue treatment
effects. It shows excellent validity and reliability across
various chronic neurological and infectious diseases,
such as multiple sclerosis [17], HCV infection [20],
stroke [5], and Parkinson’s disease [21]. The fact that
FSS-9 shows a high consistency across various chronic
diseases makes it particularly suitable to estimate fatigue
among patients suffering from SUD with complex and
challenging comorbidities.
Thus, this prospective cohort study aims to investigate
fatigue using the nine-item Fatigue severity scale (FSS-9)
among patients with substance use disorders (SUDs) and
predict the impact of sociodemographic and clinical fac-
tors on FSS-9, including educational level, housing situ-
ation, debt difficulties, chronic infectious diseases,
injecting substance use, substance use, liver fibrosis, and
kidney disease. Moreover, we estimate:
1) using annual health assessments, the FSS-9 sum
score and whether and to what extent the sociode-
mographic and clinical factors impact this score;
2) the impact of sociodemographic and clinical factors
on changes in the FSS-9 sum score from the first
health assessment to the following annual health
assessments;
3) for two separate subgroups – patients receiving
methadone as opioid agonist therapy (OAT) and
those receiving buprenorphine as OAT – the FSS-9
sum score, whether and to what extent the sociode-
mographic and clinical factors affect the FSS-9 sum
score at baseline, and any changes in the FSS-9 sum
score from the first health assessment to the follow-
ing annual health assessments.
Methods
Data source
We used data from a cohort nested to the INTRO-HCV
trial on patients with SUD in Bergen and Stavanger,
Norway [22]. We collected data from May 2016 to Janu-
ary 2020, and recruited patients on OAT from out-
patient clinics in Bergen and Stavanger, as well as
patients with various SUDs receiving primary healthcare
from the municipality clinics in the city of Bergen.
Data collections
All included patients were assessed yearly with a health
assessment, including FSS-9 measurements, sociodemo-
graphic data, and current substance use. Additionally,
blood samples and liver fibrosis measurements using
transient elastography were conducted. We collected all
data in a health register using electronic data collection
software (Checkware®) under research nurses’ supervi-
sion. All the clinical data, including information regard-
ing OAT, OAT medication, substance use, and possible
comorbid clinical conditions, were collected from the
electronic medical record.
Study sample
We included 915 FSS-9 measurements from 654 patients
in the study period. In total, 225 had follow-up data and
conducted the health assessment, including the FSS-9
questionnaire, twice (n = 188) or thrice (n = 37), provid-
ing 487 repeated measurements. The median time inter-
val between the baseline health assessments, and any
subsequent assessments in the same patients, including
FSS-9 measurements, was 11 months (interquartile range
(IQR): 9–14) (Additional file 1).
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Measuring fatigue
We measured fatigue during the last week using FSS-9,
including items considering: mental and physical func-
tioning, motivation, carrying out duties, and interference
with work, family, or social life. An FSS-9 measurement
was completed when all nine items in the questionnaires
were entirely conducted during an annual health assess-
ment. The FSS-9 items were answered on a Likert scale
– ranging from 1 (no fatigue) to 7 (worst fatigue) – that
demonstrates the fatigue level. A high score of FSS-9
items notes a high level of fatigue, while a mean FSS-9
item score greater than 4.0 revealed severe fatigue. The
data collection software only allowed valid responses to
each question and prompted empty questions before
submission to minimise missing data. The FSS-9 was
also translated and back-translated from the US-English
version into Norwegian by qualified native Norwegian-
speaking translators (Additional file 2) [23].
Measuring liver stiffness and assessing blood samples
We assessed liver stiffness using transient elastography
(Fibroscan®) to reveal liver fibrosis and cirrhosis. The
elastography was reported as a median score of 10 mea-
surements conducted by research nurses. A liver stiff-
ness above 10 kilopascals (kPa) was defined as liver
fibrosis, while a value above 12.5 kPa indicated liver cir-
rhosis [24]. We also collected blood samples, including
hemoglobin, thrombocytes, C - reactive protein, aspar-
tate aminotransferase, estimated glomerular filtration
rate, hepatitis B surface antigen, HIV antigen/antibodies,
HCV antibodies, and HCV polymerase chain reaction
(HCV PCR) during the annual health assessment. Liver
stiffness was estimated by calculating the AST to platelet
ratio index (APRI) score and using transient elastogra-
phy (Fibroscan®) (Additional file 3). Moreover, the
hematological and biochemical samples were analysed to
detect anemia (Hemoglobin), infection or inflammation
(C – reactive protein), kidney disease (estimated glom-
erular filtration rate), liver disease (APRI), or chronic in-
fectious diseases (HIV, HCV, and HBV), which could
affect the FSS-9 score. Both elastography and blood sam-
ples were examined annually and simultaneously when
conducting the annual health assessments. We analysed
the blood samples at the Department of Laboratory
Medicine, Haukeland University Hospital, Bergen,
Norway, and at the Department of Medical Biochemistry
and Microbiology, Stavanger University Hospital, Sta-
vanger, Norway (accredited by ISO-standard 15,189).
Definition of study variables, including sociodemographic
and clinical factors
We defined baseline for patients as the first annual
health assessment that included an FSS-9 measurement
when we listed the health assessments chronologically.
We dealt with each FSS-9 measurement as a sum score
by summarising the value (one to seven) from each item
and as a mean score calculated by dividing the sum
score by nine (nine items). We defined being on OAT
according to whether patients received buprenorphine
or methadone (OAT opioids) at baseline. Further, in ac-
cordance with the World Health Organization’s stan-
dards, we calculated the daily dose of received OAT
opioids as a ratio between the received dose per day di-
vided by the expected mean dose of OAT opioids
(buprenorphine 18mg, buprenorphine-naloxone 18/4.5
mg or methadone 90 mg) [25]. We categorised educa-
tional level into five groups: ‘not completed primary
school,’ ‘completed primary school (nine years),’ ‘com-
pleted high school (12 years),’ ‘three or fewer years of
college or university’ or ‘more than three years of college
or university.’ Patients’ housing situations in the 30 days
prior to the FSS-9 measurement were classified into two
groups: “stable” and “unstable.” The latter category in-
volved patients who had lived on the street, in a home-
less shelter, or with family and friends during the past
30 days. Others who had a more permanent residence
were classified as having a stable housing situation. Debt
difficulties were defined as striving with paying off legal
or illegal debt due to a constrained private economy. We
set ‘injecting substance use’ as having injected at any
time during the past 12 months, whereas frequent sub-
stance use was categorised as consuming at least one of
the substance groups, including ‘benzodiazepines or z-
hypnotics,’ ‘cannabis,’ ‘stimulants (amphetamines or co-
caine),’ ‘alcohol,’ and ‘heroin or other illicit opioids’,
more than weekly during the 12 months prior to a health
assessment. Patients who did not use substances or used
them less than weekly during the past 12 months were
categorised as having ‘no frequent use of substance’.
Having chronic infectious diseases was defined as detect-
ing HCV PCR (HCV), hepatitis B surface antigen (HBV),
or HIV antigen/antibodies (HIV) in the blood samples.
For HCV PCR, we used the Helmert contrast in order to
classify patients into two groups – transmitted and non-
transmitted – and further into two subgroups: whether
patients have a low viral load (< 800,000 IU/ml) or high
viral load (≥ 800,000 IU/ml). By this two-fold division,
we investigated whether the level of viral HCV load was
associated with changes in the fatigue level.
Statistical analyses
We used Stata/SE 16.0 (StataCorp, TX, USA) for de-
scriptive analysis and IBM SPSS version 26.0 for
expectation-maximisation imputation and linear mixed
model analyses. The threshold for statistical significance
was set to P < 0.05 for all analyses unless otherwise
stated. In all analyses, we defined time as years from
baseline.
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We dealt with any missing values concerning sociode-
mographic and clinical factors – such as educational
level, housing situation, debt difficulties, receiving OAT,
OAT opioid dose ratio, injecting substance use, sub-
stance use, and the results of defined blood samples and
transient elastography – as ‘missing at random’ when
running expectation-maximisation imputation. We iden-
tified missing values in 2.6% in these factors and all were
replaced with estimated values by imputation.
The FSS-9 sum score at baseline was calculated by
summarising the nine items’ points. Linear mixed model
analyses were used to investigate whether the sociode-
mographic and clinical factors affected the FSS-9 sum
score and to what extent they impacted any changes in
the score from baseline to following the health assess-
ments. First, the factor variables were analysed separately
as outcome variables as a function of the time (time
from baseline). We did not identify substantial signifi-
cant changes in the sociodemographic and clinical fac-
tors between the annual health assessments (data not
shown). Thus, baseline levels were used as stable predic-
tors in the prediction of the level and changes in FSS-9.
We specified the linear mixed models as a random inter-
cept fixed slope regression model. The estimator was set
to Restricted Maximum Likelihood. To explore whether
predictors predicted changes in outcome, the interac-
tions between these factors and time were added to the
model. The full information maximum likelihood en-
sured that all available FSS-9 sum score measurements
were used. Additionally, we presented sub-group ana-
lyses for OAT patients using methadone or buprenor-
phine, respectively. For these analyses, we added the
OAT opioid ratio as a predictor. The potential correla-
tions between sociodemographic and clinical factors and
fatigue are presented in Additional file 4. We performed
a sensitivity analysis by adding Bonferroni corrected p-
values to adjust for Type I errors in all analyses.
Ethics approval and consent to participate
The study is reviewed and approved by the Regional
Ethical Committee for Health Research West, Norway
(REK Vest 2017/51). Each patient provided written in-
formed consent prior to enrolling in the study.
Results
Patients characteristics at baseline
Seventy-one percent of patients were male, and the mean
age was 43 years (standard deviation (SD): 11 years) at base-
line (Table 1). Six percent had not completed primary school,
or 44% had primary school as their highest educational level.
82% received OAT, of which 60% received buprenorphine or
buprenorphine-naloxone as an OAT opioid. Further, 13%
had an unstable housing situation in the last 30 days leading
up to the FSS-9 measurement. 73% had used at least one
substance weekly during the past 12months.
FSS-9 sum scores at baseline
The mean sum score for the FSS-9 was 43 (SD: 16),
representing a mean score for the FSS-9 items of 4.8
(2.6) (Table 2). A total of 69% of patients had severe fa-
tigue. The mean FSS-9 sum score was slightly left-
skewed (skewness: − 0.7) and tended towards a flattened
distribution (kurtosis: 2.4).
The mean scores for the FSS-9 were 43 (SD: 16) for pa-
tients receiving methadone and 43 (17) for those using
buprenorphine (Additional file 5), corresponding to a mean
score for the FSS-9 items of 4.8 (1.8) for patients receiving
methadone and 4.7 (1.9) for those using buprenorphine. Se-
vere fatigue was identified in 77% of patients receiving
methadone and 67% of those using buprenorphine. In these
two sub-groups, the FSS-9 sum scores were slightly left-
skewed (skewness: − 1.0 (methadone group), − 0.6 (bupre-
norphine group)) and flattened distributed (kurtosis: 3.0
(methadone group), 2.2 (buprenorphine group)).
The sociodemographic and clinical factors’ impact on the
FSS-9 sum score at baseline and the factors’ influence on
changes in the FSS-9 sum score from baseline to the
following annual health assessments
At baseline, we found that the FSS-9 sum score was higher
for females than males (adjusted mean FSS-9 sum score dif-
ference: 4.1, CI 1.3;7.0, p= 0.005), for patients with debt diffi-
culties compared with those without debt difficulties (2.9, CI
0.4;5.3, p= 0.022), and for patients with frequent benzodi-
azepine use compared with those with less frequent or no
use (5.7, CI 3.0;8.4, p < 0.001) (Table 3). In contrast, the FSS-
9 sum score was lower for patients with frequent stimulant
use than those with less frequent or no use (− 5.0, CI -8.0;-
2.0, p= 0.001). Moreover, we saw a small non-clinical signifi-
cant reduction of the FSS-9 sum score from baseline to the
following annual health assessments for patients with fre-
quent benzodiazepine use compared to those with less fre-
quent or no use (− 4.4, CI -8.2;-0.7, p= 0.021) and for
patients having significant liver fibrosis or cirrhosis measured
by transient elastography compared with those with non-
significant fibrosis or normal liver stiffness (− 5.5, CI -9.9;-1.0,
p= 0.016). With Bonferroni corrected p-values, we only
found that patients with frequent benzodiazepine or stimu-
lant use compared with those with less frequent or no use of
these substances changed the fatigue levels at baseline.
The sociodemographic and clinical factors’ impact on
changes in the FSS-9 sum score from baseline to the
following annual health assessments among patients on
OAT
Among patients receiving methadone as an OAT opioid,
we found that the FSS-9 sum score was higher for
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Age (years), n (%)
18–29 81 (12) 23 (10)
30–39 185 (28) 63 (28)
40–49 205 (31) 75 (33)
50–59 148 (23) 53 (24)
≥ 60 35 (5) 11 (5)
Mean (SD) 43 (11) 44 (10)
Gender, n (%)
Male 461 (71) 170 (76)
Female 193 (29) 55 (24)
Highest educational level, n (%)
Not completed primary school 40 (6) 15 (7)
Completed primary school (9 years) 286 (44) 105 (47)
Completed high school (12 years) 259 (40) 81 (36)
≤ 3 years of college or university 57 (9) 20 (9)
> 3 years of college or university 12 (2) <5 (2)
Receiving opioid agonist therapy, n (%) 537 (82) 205 (91)
OAT opioid (%)
Methadone 209 (39) 96 (43)
Buprenorphine/Buprenorphine-naloxone 321 (60) 107 (48)
OAT opioid dose ratio (median (IQR))a 0.9 (0.8–1.1) 1.0 (0.9–1.1)
Housing situation the past 30 days, n (%)
Stableb 569 (87) 203 (90)
Unstablec 85 (13) 22 (10)
Injected substances the past 12 months, n (%) 338 (56) 116 (52)
Frequent substance use the past 12 months, n (%)d
Alcohol 154 (26) 56 (25)
Benzodiazepines 238 (39) 87 (39)
Cannabis 313 (52) 124 (55)
Opioids 97 (16) 27 (12)
Stimulants (amphetamines and cocaine) 176 (29) 60 (27)
Chronic infectious diseases, n (%)
Hepatitis C virus infection 315 (48) 184 (82)
Low virulent (< 800,000 IE/ml) 168 (25) 92 (41)
High virulent (≥ 800,000 IE/ml) 147 (22) 92 (41)
Hepatitis B virus infection 5 (0) < 5 (< 1)
Human immunodeficiency virus < 5 (< 1) < 5 (< 1)
Hematological and biochemical samples, median (IQR)
Hemoglobin (g/dl) 14 (13–15) 14 (13–15)
Estimated glomerulus filtration rate (ml/min/1.73 m2) 104 (89–122) 105 (91–124)
C-reactive protein (mg/L) 4 (1–9) 3 (1–8)
Aspartate transaminase (U/L) 31 (23–50) 40 (30–65)
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females than males (7.3, CI 2.5;12.2, p = 0.003), for pa-
tients having debt difficulties compared with those not
having debt difficulties (4.9, CI 0.7;9.1, p = 0.023), for pa-
tients having frequent benzodiazepine use compared
with those having less frequent or no use (6.0, CI 1.6;
10.5, p = 0.008), and for patients with a high HCV viral
load compared with those with a low HCV viral load
(31.5, CI 1.5;61.5, p = 0.040) at baseline (Additional file 6).
Among patients receiving buprenorphine as an OAT
opioid, we found that patients with frequent alcohol use
had higher the FSS-9 sum score (4.8, CI 0.2;9.3, p =
0.039), while patients with frequent stimulant use had
lower the FSS-9 score (− 5.0, CI -9.9;-0.1, p = 0.047)
compared with patients with less frequent or no use of
these substances at baseline (Additional file 7). For both
subgroups, no sociodemographic and clinical factors
were clinically associated with substantial changes in the
FSS-9 sum score from baseline to the following annual
health assessments. With Bonferroni corrected p-values,
we did not identify any predictors that changed the fa-
tigue score at baseline and between the annual health
assessments.
Discussion
This study showed that 69% of SUD patients had severe
fatigue symptoms. The sociodemographic and clinical
factors that substantially contributed to higher fatigue
scores at baseline were females compared with males
(four points), frequent benzodiazepine use compared
with less frequent or no use (six points), and debt diffi-
culties compared with no debt difficulties (three points).
However, the fatigue score was five points lower for pa-
tients with frequent stimulant use than those with less
frequent or no use. For patients using buprenorphine as
an OAT opioid, we found five points lower fatigue score
for patients with frequent stimulant use and five points
higher fatigue score for patients with frequent alcohol








Liver stiffness, median (IQR)
Transient elastography (kPa) 5 (4–7) 6 (5–8)
Aspartate transaminase to platelets ratio index 0.3 (0.2–0.6) 0.4 (0.3–0.8)
The table displays the sociodemographic and clinical characteristics for all included patients, and for patients with two or more health assessments, including FSS-
9 measurements at baseline
FSS-9 nine-item fatigue severity scale (Likert scale), IQR interquartile range, kPa kilopascal, OAT opioid agonist therapy, SD standard deviation
aOAT opioid ratio is a ratio between the received dose of OAT opioids per day and the expected median daily dose (18 mg buprenorphine, 18/4.5 mg
buprenorphine-naloxone or 90mg methadone). A ratio on 1.0 indicates that patients received the expected daily dose; bA stable housing situation was defined as
having owned or rented housing situation or being imprisoned; cUnstable housing situation was defined as living in a homeless shelter, with family or friends, or
on the street; dFrequent substance use was defined as using substance at least weekly during the past 12 months
Table 2 Mean (Standard deviation (SD)) item scores for single items on FSS-9 at baseline and follow-up
Baseline (N = 654) Follow-up (N = 225)
FSS-9
I1: My motivation is lower when I am fatigued 5.4 (2.0) 5.6 (2.0)
I2: Exercise brings on my fatigue 4.7 (2.1) 5.0 (2.0)
I3: I am easily fatigued 4.5 (2.1) 4.8 (2.1)
I4: Fatigue interferes with my physical functioning 4.9 (2.1) 5.1 (2.0)
I5: Fatigue causes frequent problems for me 4.4 (2.2) 4.5 (2.2)
I6: My fatigue prevents sustained physical functioning 4.6 (2.2) 4.4 (2.2)
I7: Fatigue interferes with carrying out certain duties and responsibilities 5.0 (2.1) 5.0 (2.1)
I8: Fatigue is among my three most disabling symptoms 4.6 (2.3) 4.8 (2.3)
I9: Fatigue interferes with my work, family, or social life 4.9 (2.2) 4.6 (2.3)
Mean score of all items 4.8 (1.8) 4.9 (1.7)
Sum score of all items 43.2 (15.9) 43.8 (15.2)
Follow-up: FSS-9 score on the last health assessment during the study period among patients with two or more annual health assessments; FSS-9 nine-item
fatigue severity scale (Likert scale ranging from 1 (no fatigue) to 7 (worst fatigue)), I Item, SD standard deviation
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use compared with those with less frequent or no use of
these substances at baseline. For patients receiving
methadone as an OAT opioid, the fatigue score was
higher for females than males (seven points), for patients
with frequent benzodiazepine use compared with those
with less frequent or no use (six points), for patients
with debt difficulties compared with those without diffi-
culties with debt (five points), and for patients with a
high versus a low viral load of HCV (32 points) at base-
line. The latter finding suggesting an extreme difference
between a high and a low viral load of HCV was surpris-
ing. Other studies assessing HCV viral load and correl-
ation based on clinical and histological features have
also not found HCV viral load to impact other related
outcomes [26–28]. This finding is likely related to ran-
dom variability within the data, and it should be inter-
preted with caution. Moreover, no sociodemographic
and clinical factors were associated with clinically signifi-
cant changes in the fatigue score from baseline to the
following health assessments.
Table 3 Linear mixed model of fatigue (FSS-9) adjusted for sociodemographic and clinical factors (N = 654)
Fixed effects
Effect estimate Time trend (per year)
Estimate (95% CI) p-value Slope (95% CI) p-value
FSS-9 sum score 42 (26–58) < .001 3.6 (−23.5–30.7) 0.792
Female 4.1 (1.3–7.0) 0.005 −0.3 (−4.5–3.8) 0.877
Age per 10 years1) 0.2 (−1.0–1.4) 0.755 −0.2 (− 2.1–1.7) 0.844
Educational level − 1.1 (− 2.6–0.3) 0.132 −0.3 (− 2.3–1.7) 0.754
Unstable housing situation 0.0 (−3.7–3.7) 0.992 2.6 (− 3.6–8.8) 0.408
Debt difficulties 2.9 (0.4–5.3) 0.022 −0.2 (− 3.8–3.3) 0.898
Injecting substance use −0.1 (− 2.9–2.7) 0.944 −0.7 (− 4.6–3.3) 0.740
Frequent use of substances
Benzodiazepines 5.7 (3.0–8.4) < .001a −4.4 (−8.2 – − 0.7) 0.021
Alcohol 1.8 (−1.1–4.6) 0.221 0.6 (−3.5–4.7) 0.776
Cannabis 1.2 (− 1.4–3.8) 0.356 1.8 (− 1.7–5.3) 0.309
Opioids 3.3 (− 0.3–6.9) 0.069 −4.6 (− 10.8–1.7) 0.149
Stimulants2) − 5.0 (− 8.0– − 2.0) 0.001 a 2.1 (− 2.1–6.3) 0.327
Chronic infectious diseases
Hepatitis B virus infection 3.3 (− 10.4–16.9) 0.638 −2.6 (− 16.8–11.5) 0.715
Hepatitis C virus infection
- Detected 3.0 (− 5.4–11.4) 0.484 0.7 (− 18.7–20.1) 0.941
- Low vs. high viral load − 0.4 (− 10.3–10.9) 0.948 − 7.0 (− 17.1–3.0) 0.169
HIV − 0.1 (− 15.3–15.5) 0.994 13.0 (− 6.8–32.7) 0.197
Liver stiffness
Transient elastography per 10 kPa 1.2 (−1.6–4.0) 0.391 −5.5 (− 9.9 – − 1.0) 0.016
APRI score per 1 unit 0.5 (− 0.6–1.5) 0.378 1.4 (− 0.9–3.6) 0.230
Hematologic and biochemical blood samples (continuous variables)
Hemoglobin per 1 unit (g/dL) −0.3 (− 1.1–0.6) 0.513 0.3 (− 0.9–1.5) 0.622
eGFR per 30 units (ml/min/1.73m2) 0.0 (− 2.0–0.9) 0.453 0.0 (− 2.0–1.9) 0.973
CRP per 10 units (ml/L) −0.1 (− 0.6–0.7) 0.848 0.0 (− 0.1–0.2) 0.682
The table displays a linear mixed model analysis (Restricted Maximum Likelihood regression) evaluating sociodemographic and clinical factors’ (predictors)
changes in the FSS-9 sum score at baseline and the predictors’ influence on changes in the FSS-9 sum score (time trend) per year from baseline. The predictors’
effect estimates and time trends estimate adjusted mean differences in the FSS-9 sum score
APRI aspartate transaminase to platelet ratio index, CI confidence interval, CRP C-reactive protein, FSS-9 nine-item fatigue severity scale, eGFR estimated glomerular
filtration rate, HIV human immunodeficiency virus, kPa Kilopascal, OAT opioid agonist therapy
1) Age per 10 years was centred according to mean age (43 years) in the study sample at baseline. 2) Includes amphetamine or cocaine use. The educational level:
highest level of education was coded 0–4 with 4 as the highest educational level. Unstable housing situation: living on the street, homeless shelter, or with family
and friends at any time during the past 30 days prior to the health assessment. Debt difficulties: struggling with repaying current illegal and legal debt. Injecting
substance use: Having injected substance during the past 12 months prior to the health assessment. Frequent use of substances: at least weekly during the past
12 months prior to the health assessment. Viral load of HCV: From − 0.5 to 0.5, where the range ≥ − 0.5 to < 0 represents the low viral load (HCV PCR < 800,000 IE/
ml), and the range ≤ 0.5 to > 0 identifies the high viral load (HCV PCR ≥ 800,000 IE/ml). Zero (0) defined patients without HCV infection
a) Statistically significant results when using Bonferroni corrected p-values (αaltered = 0.05 / 41 = 0.0012)
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In the present study, patients with SUD had a mean
fatigue score (4.8) comparable to some of the most se-
vere chronic diseases. In recent studies, patients infected
with HIV or HCV, or those co-infected with both of
them, have a mean FSS-9 score that ranged from 3.3 to
4.5 [10, 29, 30]. Patients with myasthenia gravis have re-
ported a comparable fatigue score of 4.7 [31], and simi-
larly, so have patients who have suffered from a stroke
at least 6 months after the stroke onset (4.8) [32]. One
can assume that a high prevalence of underlying mental
disorders, extensive polysubstance use, and lower social
status could have attributed to the high level of fatigue
in the SUD population.
We found that females were weakly more fatigued
than males. For both genders, patients with frequent
use of benzodiazepines were weakly more fatigued
than those with less frequent or no use. Recent stud-
ies evaluating fatigue in the general population and
patients with chronic disorders have demonstrated
similar gender differences in fatigue levels [15, 23, 31,
33]. Gender inequalities regarding household responsi-
bilities and caring for the family have generally been
highlighted as explanations for females’ fatigue levels
[34]. Additionally, females with SUD may be worse
off than males in many domains. They may have less
financial resources, experience more physical trauma
caused by exchanging sex for drugs and money, and
face more stigma related to family failures [34]. More-
over, in the general population and among patients
with SUDs, females are more likely to use benzodiaz-
epines than males, with a similar tendency found in
different countries [2, 35–38]. Females’ higher preva-
lence of anxiety disorders, sleeping disorders and the
fact that they are more likely to seek medical care
may contribute to more prescriptions of hypnotics
and anxiolytics, such as benzodiazepines and z-
hypnotics [39–41]. One can believe that these med-
ical, psychological, and social challenges may overall
explain the gender gap concerning a higher fatigue
level among females in the SUD population.
Our findings revealed that patients with frequent use
of benzodiazepines were weakly more fatigued than
those with less frequent or no use. Among patients with
frequent use of stimulants, we found that they were less
fatigued than those with less frequent or no use. These
group differences were overall small. In the general
population, previous studies assessing the effect of
benzodiazepine use have suggested that patients using
benzodiazepines have a lower quality of life, self-
reported physical health, and more disability than those
not using benzodiazepines [42, 43]. This is parallel with
the higher fatigue levels shown in the present study. Fur-
thermore, using stimulants, particularly illicit amphet-
amines, is generally associated with poor mental health
and stimulant withdrawal symptoms in the SUD popula-
tions [44, 45]. A temporary sense of better self-perceived
mental health and fewer withdrawal symptoms may arise
when consuming stimulant substances, which contrib-
utes to a temporary reduction of fatigue compared to
the experience without stimulants. However, our trend
analyses indicate that the fatigue levels remained stable
over time when the frequent use of stimulants is
persistent.
The present study showed no clear associations be-
tween fatigue and chronic infectious diseases or kidney
disease. For patients with HBV, HIV or end-stage kidney
disease, the low prevalence of HBV and HIV and a mean
renal function within the normal range could explain
why no associations with fatigue were detected. Further-
more, we are surprised that SUD patients with HCV in-
fections did not demonstrate a higher fatigue level
compared to patients with SUD without HCV infection,
considering that the prevalence of fatigue is up to 70%
in populations with HCV [9–11], which is considerably
higher than in general population [23]. However, the
large extent of polysubstance use in the present popula-
tion (75%) could have temporarily displaced the HCV in-
fection’s change on fatigue.
We found that 77% of patients using methadone as
an OAT opioid and 67% of those using buprenor-
phine had severe fatigue symptoms. Four sociodemo-
graphic and clinical factors significantly changed
fatigue levels among methadone users, while two fac-
tors influenced fatigue among those using buprenor-
phine. Methadone is a full opioid agonist associated
with more euphoria and analgesia than the partial
opioid agonist buprenorphine [46]. In a quantitative
study evaluating patients’ experience of using metha-
done and buprenorphine in OAT, unwanted physical
effects, for example, over-sedation, were particularly
pointed out in some methadone cases [47]. These ef-
fects might explain methadone users’ high prevalence
of severe fatigue symptoms and why more sociode-
mographic and clinical factors influenced methadone
users’ the fatigue levels than those using
buprenorphine.
Overall, no single sociodemographic and clinical factor
was associated with substantial changes in fatigue at
baseline or over time in the SUD population. This signi-
fies that fatigue was substantially constant between pa-
tients. However, the mean fatigue level significantly
exceeded the threshold for severe fatigue in the SUD
population, which underlies the importance of identify-
ing patients who simultaneously have several sociodemo-
graphic and clinical risk factors for severe fatigue.
Identifying these patients and treating the underlying
causes of fatigue should be the way to reduce the fatigue
in the population.
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Strengths and limitations
This study has several strengths. We have included 654
patients with SUD that usually are difficult to reach in
health care. Of those, 225 patients were followed up
by two or three annual health assessments, making
longitudinal analyses possible. This study does, how-
ever, have some limitations. First, the patients were
mainly recruited from outpatient clinics receiving
OAT. The majority had opioid dependence, although
this was often combined with other dependencies,
which could affect the generalisability of our results
to other SUD populations. Second, we had a pro-
spective follow-up of only a third of those patients re-
cruited at baseline. This also causes weakness in our
results and makes it necessary to carefully interpret
the longitudinal analyses. Third, due to clinical chal-
lenges, including systematic and patient delays, the
annual health assessments were not precisely con-
ducted one year after the previous health assessment.
This may affect the interpretation of the predicted fa-
tigue level changes from baseline. Fourth, due to data
imputation and inclusion of up to 42 predictors in
the linear mixed model analyses, there is a risk of
Type I error. We dealt with this by presenting the
Bonferroni corrections to all p-values in the analyses.
Conclusion
The present study shows a high symptom burden of fa-
tigue among patients with SUDs, particularly among fe-
males, patients with debt difficulties, and those with
extensive use of benzodiazepines. Identifying severe fa-
tigue and considering fatigue in the follow-ups could
help optimise SUD treatment for these patients. Policy-
makers could take this into consideration when planning
health services.
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Additional file 1. The number of months from baseline to the second
or third health assessment. No.: Number of patients; SD: Standard
deviation; ref.: Reference. The table displays the number of patients with
one, two, and three health assessments, including a nine-item Fatigue Se-
verity Scale score. The table displays the time between baseline and the
second and third health assessments.
Additional file 2. The US-English and the Norwegian versions of FSS-9.
Description: Legends: FSS-9; Nine-item Fatigue Severity Scale. All items in
the FSS-9 are ranged as a Likert scale from 1 to 7, where 1 indicates
“strongly disagree” and 7 “strongly agree”.
Additional file 3. Aspartate aminotransferase to platelet ratio index
(APRI). Description: APRI: Aspartate aminotransferase to platelet ratio
index. The figure displays the APRI score equation. The AST upper limit of
normal range was defined as 45 IU/L (male) and 35 IU/L (female).
Additional file 4. Potential correlations between sociodemographic and
clinical factors and fatigue. The figure shows that potential
sociodemographic and clinical comorbidities may affect fatigue among
patients with substance use disorders.
Additional file 5. Mean (SD) item scores for single items on the FSS-9
at baseline and follow-up. Legend: FSS-9: Nine-item Fatigue Severity
Scale; I: Item; OAT: Opioid agonist therapy; SD: Standard Deviation.
Follow-up: The FSS-9 score on the last health assessment during the
study period among patients with two or more annual health assess-
ments. Mean (SD) item scores for single items on the FSS-9 for patients
using methadone or buprenorphine as OAT opioid.
Additional file 6. Linear mixed model of fatigue (FSS-9) adjusted for
sociodemographic and clinical factors among patients receiving
methadone as an OAT opioid at baseline (N = 209). Legends: APRI:
Aspartate transaminase to platelet ratio index; CI: Confidence interval;
CRP: C-reactive protein; FSS-9: Nine-item Fatigue Severity Scale; eGFR: esti-
mated glomerular filtration rate; HIV: Human Immunodeficiency virus; kPa:
Kilopascal; OAT: Opioid Agonist Therapy. 1) Age per 10 years was centred
according to mean age (43 years) in the study sample at baseline. 2) In-
cludes amphetamine or cocaine use. The OAT opioid ratio: a ratio be-
tween the received dose of OAT opioids per day divided by the
expected mean dose of OAT opioids (buprenorphine 18 mg,
buprenorphine-naloxone 18/4.5 mg or methadone 90 mg). The educa-
tional level: highest level of education was coded 0–4 with 4 as the high-
est educational level. Unstable housing situation: living on the street,
homeless shelter, or with family and friends at any time in the past 30
days prior to the health assessment. Debt difficulties: struggling with re-
paying current illegal and legal debt. Injecting substance use: Having
injected a substance in the past 12 months prior to the health assess-
ment. Frequent use of substances: at least weekly during the past 12
months prior to the health assessment. Viral load of HCV: From − 0.5 to
0.5, where the range ≥ − 0.5 to < 0 represents the low viral load (HCV
PCR < 800,000 IE/ml), and the range from ≤0.5 to > 0 identifies the high
viral load (HCV PCR ≥ 800,000 IE/ml). Zero (0) defined patients without
HCV infection. When using the Bonferroni corrected p-values (αaltered =
0.05 / 43 = 0.0012), the predictors did not affect the FSS-9 sum score sig-
nificantly. The table displays a linear mixed model analysis (Restricted
Maximum Likelihood regression) evaluating sociodemographic and clin-
ical factors’ (predictors) changes in the FSS-9 sum score at baseline and
their influence on changes in the FSS-9 sum score (time trend) per year
from baseline among patients receiving methadone as an OAT opioid.
The predictors’ effect estimates and time trends estimate adjusted mean
differences in the FSS-9 sum score.
Additional file 7. Linear mixed model of fatigue (FSS-9) adjusted for
sociodemographic and clinical factors among patients receiving
buprenorphine as an OAT opioid at baseline (N = 321). Legends: APRI:
Aspartate transaminase to platelet ratio index; CI: Confidence interval;
CRP: C-reactive protein; FSS-9: Nine-item Fatigue Severity Scale; eGFR: esti-
mated glomerular filtration rate; HIV: Human Immunodeficiency virus; kPa:
Kilopascal; OAT: Opioid Agonist Therapy. 1) Age per 10 years was centred
according to mean age (43 years) in the study sample at baseline. 2) In-
cludes amphetamine or cocaine use. The OAT opioid ratio: a ratio be-
tween the received dose of OAT opioids per day divided by the
expected mean dose of OAT opioids (buprenorphine 18 mg,
buprenorphine-naloxone 18/4.5 mg or methadone 90 mg). The educa-
tional level: highest level of education was coded 0–4 with 4 as the high-
est educational level. Unstable housing situation: living on the street,
homeless shelter, or with family and friends at any time during the past
30 days prior to the health assessment. Debt difficulties: struggling with
repaying current illegal and legal debt. Injecting substance use: Having
injected a substance during the past 12 months prior to the health as-
sessment. Frequent use of substances: at least weekly during the past 12
months prior to the health assessment. Viral load of HCV: From − 0.5 to
0.5, where the range ≥ − 0.5 to < 0 represents the low viral load (HCV
PCR < 800,000 IE/ml), and the range ≤ 0.5 to > 0 identifies the high viral
load (HCV PCR ≥ 800,000 IE/ml). Zero (0) defined patients without HCV in-
fection. When using the Bonferroni corrected p-values (αaltered = 0.05 /
43 = 0.0012), the predictors did not affect the FSS-9 sum score signifi-
cantly. The table displays a linear mixed model analysis (Restricted Max-
imum Likelihood regression) evaluating sociodemographic and clinical
factors’ (predictors) changes in the FSS-9 sum score at baseline and their
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influence on changes in the FSS-9 sum score (time trend) per year from
baseline among patients receiving buprenorphine as an OAT opioid. The
predictors’ effect estimates and time trends estimate adjusted mean dif-
ferences in the FSS-9 sum score.
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